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1. SUMMARY 
Although important progresses have been achieved in the therapeutic management of 
transplant recipients, acute and chronic rejections remain the leading causes of premature 
graft loss after solid organ transplantation. This, together with the undesirable side effects of 
immunosuppressive drugs, has significant implications for the long-term outcome of 
transplant recipients. Thus, a better understanding of the immunological events occurring 
after transplantation is essential. 
The immune system plays an ambivalent role in the outcome of a graft. On one hand, some 
T lymphocytes with effector functions (called alloreactive T cells) can mediate a cascade of 
events eventually resulting in the rejection, either acute or chronic, of the grafted organ; on 
the other hand, a small subset of T lymphocytes, called regulatory T cells, has been shown to 
be implicated in the control of these harmful rejection responses, among other things. Thus, 
we focused our interest on the study of the balance between circulating effectors (alloreactive) 
and regulatory T lymphocytes, which seems to play an important role in the outcome of 
allografts, in the context of kidney transplantation. The results were correlated with various 
variables such as the clinical status of the patients, the immunosuppressive drugs used as 
induction or maintenance agents, and past or current episodes of rejection. We observed that 
the percentage of the alloreactive T lymphocyte population was correlated with the clinical 
status of the kidney transplant recipients. Indeed, the highest percentage was found in patients 
suffering from chronic humoral rejection, whilst patients on no or only minimal 
immunosuppressive treatment or on sirolimus-based immunosuppression displayed a 
percentage comparable to healthy non-transplanted individuals. During the first year after 
renal transplantation, the balance between effectors and regulatory T lymphocytes was tipped 
towards the detrimental effector immune response, with the two induction agents studied 
(thymoglobulin and basiliximab). 
Overall, these results indicate that monitoring these immunological parameters may be very 
useful for the clinical follow-up of transplant recipients; these tests may contribute to identify 
patients who are more likely to develop rejection or, on the contrary, who tolerate well their 
graft, in order to adapt the immunosuppressive treatment on an individual basis. 
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2. INTRODUCTION 
 
A short and non-exhaustive history… 
The first description of transplantation in humans is found in Chinese texts, as soon as in the 
4th century BC. Tsin Yue-Jen, a surgeon, switched the hearts of two soldiers and said that both 
patients survived, but gave no reason for the transplant… In the next centuries, great advances 
were made in the understanding of human anatomy, physiology and surgery. In 1900-1902, 
the German scientist Karl Landsteiner discovered the principle of the four blood groups. 
Figure 1. 
Sir Peter Medawar. 
Figure 2. 
The first successful kidney transplantation performed by 
Joseph E. Murray in 1954 in Boston. 
In the 1940's, Sir Peter Medawar (1915-1987) at the University of London experimented with 
the immunological basis of organ rejection [Figure 1]. He was awarded his Nobel Prize of 
Medicine in 1960 for his work on tissue grafting and his discovery of acquired immunological 
tolerance, a model that paved the way to successful organ and tissue transplantation (his first 
publication: Gibson T and Medawar PB, 1943). 
The first truly successful – defined as lasting more than 6 months – transplantation was 
performed in 1954 in Boston [Figure 2]. Joseph E. Murray transplanted a kidney from one 
identical twin to another without any immunosuppressive medication. The recipient died 8 
years later and the donor was still alive in 2005. Joseph E. Murray won the Nobel Prize of 
Medicine in 1990. 
In 1958, the French immunologist Jean Dausset published his results on the major 
histocompatibility complex (MHC) and its role in graft rejection. He received the Nobel Prize 
of Medicine in 1980. 
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The 1960's were marked by a lot of successes in the field of human organ transplantation: first 
successful cadaveric kidney transplant (1962), lung transplant (1963), pancreas transplant 
(1965), liver transplant (1967), and heart transplant (1967). At the same period, the first long-
term dialysis treatments were developed and a dialysis centre opened in Seattle. 
In the 1970's, the Swiss biologist Jean-François Borel discovered cyclosporine A, a compound 
produced by fungi; its unique immunosuppressive properties revolutionized the long-term 
management of transplant recipients (Rüegger A et al., 1976). Years of clinical studies 
revealed that given as part of a cocktail, primarily with steroids, it selectively suppresses T 
lymphocytes and prevents the rejection of transplanted organs; cyclosporine A was finally 
approved by the FDA in 1983. 
Until now, a lot of advances have been made in the field of transplantation. An end-stage 
disease is not anymore a death sentence. It is possible to replace many organs by a cadaveric 
or living one and to improve significantly the life expectancy and the quality of life of 
transplant recipients. This success is essentially due to the development of new 
immunosuppressive compounds, the improvement of surgical techniques and the better 
understanding of the immunological mechanisms involved in transplantation. However, the 
achievement of a state of tolerance to the transplant is the only approach that is likely to 
provide long-term graft survival without the problems associated with life-long global 
immunosuppression. 
There is accumulating evidence that T cell-mediated dominant control of self-reactive T cells 
contributes to the maintenance of immunological self-tolerance and that its alteration can 
cause autoimmune disease. Efforts to delineate such a regulatory T cell population have 
revealed that CD25high cells in the CD4+ population in normal naïve animals bear the ability to 
prevent autoimmune disease in vivo and, upon antigenic stimulation, that they suppress the 
activation and proliferation of other T cells in vitro. The CD4+ CD25high regulatory T cells, 
which are naturally anergic and suppressive, appear to be produced by the normal thymus as a 
functionally distinct subpopulation of T cells. They play critical roles not only in preventing 
autoimmunity but also in controlling tumor immunity and transplantation tolerance. 
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2.1. The human immune system 
2.1.1. Role of the immune system 
Historically, Edward Jenner (1749-1823) is considered as the "father of immunology", the 
science of our body's defense against foreign invaders. The immune system is a collection of 
immune processes within an organism that protect against disease by identifying and killing 
foreign invaders such as microorganisms, tumor cells and imported foreign tissues and 
organs. Components of the immune system include various cell types originating in the bone 
marrow [Figure 3], specialized organs and tissues, and immunomodulatory proteins, all 
interacting in an organized and dynamic network. 
Figure 3. Model of the hematopoietic developmental hierarchy (Bryder D et al., 2006). 
HSC: hematopoietic stem cell; CMP: common myeloid progenitor; 
MEP: megakaryocyte/erythrocyte progenitor; GMP: granulocyte/macrophage progenitor; 
CLP: common lymphoid progenitor; Pro-DC: dendritic cell progenitor; Pro-T: T cell progenitor; 
Pro-NK: NK cell progenitor; Pro-B: B cell progenitor. 
The immune system can be divided roughly into two distinct components, namely the innate 
and the adaptive immune system. 
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2.1.2. Innate immunity 
The innate immune system is an evolutionarily ancient form of host defense against 
infections, and can be found in nearly all forms of life, including plants and invertebrates. It is 
the first line of defense of the organism, after breakdown of the physical barriers offered by 
the skin and the mucosal surfaces of the airways, the intestines and the genital sphere. It is 
composed of various types of cells, derived from common myeloid progenitors in the bone 
marrow: natural killer (NK) cells, mast cells, eosinophils, basophils, dendritic cells (DCs), 
and phagocytic cells including macrophages (in tissues) and neutrophils (in the blood).  
Activation of the innate immune system results in the upregulation of co-stimulatory 
molecules and in the production of cytokines (proteins released by cells that affect the 
behavior of other cells that bear receptors for them) and chemokines (proteins released by 
cells that attract other cells). In turn, these inflammatory mediators initiate a local process of 
inflammation, and may also trigger the activation of the complement cascade, a system of 
plasma proteins that activates proteolytic reactions on microbial surfaces (but not on host 
cells), coating these surfaces with fragments that are recognized and bound by phagocytic 
receptors on macrophages. Responses elicited by the innate immune system are non-specific 
and do not lead to long-term immunological memory. Many infections are handled 
successfully by the innate immune system and cause no disease. 
Finally, the innate immune system plays a crucial part in the initiation and subsequent 
direction of adaptive immune responses by a process known as antigen presentation, and in 
the control of infections during the first 4-7 days, the delay required by the adaptive immune 
system to be set up efficiently. 
2.1.3. Adaptive immunity 
The adaptive immune system is evolutionarily more recent and is present only in jawed 
vertebrates. It develops as a more specific line of defense and is triggered by the innate 
immune system with a substantial lag time between exposure and maximal response. The 
adaptive immune response displays an improved recognition of the pathogen, which is 
retained after the elimination of the pathogen; this phenomenon is called "immunological 
memory" and allows the adaptive immune system to mount faster and stronger attacks each 
time this pathogen is encountered. 
Adaptive immune responses depend upon specialized antigen-presenting cells (APCs), called 
dendritic cells, and upon lymphocytes, which derive from common lymphoid progenitors in 
the bone marrow and are divided into B lymphocytes (B cells, mature in the bone marrow) 
and T lymphocytes (T cells, mature in the thymus) based on their sites of differentiation and 
on their antigen receptors. They also depend on other cellular mediators shared with the 
innate immune system, such as phagocytic cells and NK cells.  
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Lymphocytes are remarkable in being able to mount a specific immune response against 
virtually any foreign antigen. This is possible because each individual lymphocyte matures 
bearing a unique variant of a prototype antigen receptor, so that the population of T and B 
lymphocytes collectively expresses a huge repertoire of receptors that are highly diverse in 
their antigen-binding sites. In theory, there are lymphocytes of at least 108 different 
specificities in an individual at any one time. 
B cells are the mediators of the so-called "humoral immunity". They are generated and mature 
in the bone marrow and bear on their cell surface the B cell antigen receptor (BCR), which is 
a membrane-bound form of the antibody that the B cell will secrete after activation and 
differentiation to plasma cells. B cells protect the organism against extracellular pathogens 
and their toxic products, by producing antibodies, which are Y-molecules whose arms form 
two identical antigen-binding sites. Antibodies can protect from pathogens or their toxic 
products by binding to them, thereby preventing their access to cells that they might infect or 
destroy ("neutralization"); another way of antibody-mediated protection is that antibodies 
enable a phagocytic cell to ingest and destroy the bound pathogen ("opsonization"); finally, 
antibodies might activate the complement cascade, which leads to the formation of pores in 
the targeted pathogen and to its direct destruction. Eventually, neutralization, opsonization 
and complement activation all result in the scavenging and degradation of the pathogen or the 
toxic product by macrophages. 
On the other hand, T cells mediate the so-called "cellular immunity". They are also generated 
in the bone marrow, but mature and differentiate in the thymus. They exhibit on their cell 
surface a highly specific receptor, the T cell antigen receptor (TCR). T cells are needed to 
control intracellular pathogens (which are inaccessible to B cells and antibodies), such as 
some bacteria, parasites and all viruses. Through their TCR, they recognize pathogen-derived 
antigens presented by the major histocompatibility complex (MHC) of APCs. Since we 
focused our study on T cells, they will be discussed extensively in the next part. 
Although the immune system is mainly specialized to recognize foreign peptides derived from 
pathogens (infections), it might also be activated in the presence of non pathogen-derived 
antigens, such as antigens provided by an allograft (transplantation), tumor-derived peptides 
(cancer), environmental antigens (allergy) and even auto-antigens (autoimmunity). 
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2.2. T cells 
2.2.1. Generation and maturation of T cells 
Before birth, T lymphoid progenitor cells are generated in the bone marrow from 
hematopoietic stem cells, and subsequently migrate to the thymus where they will complete 
their maturation and differentiation to become T cells. After birth, the thymus is a continuous 
source of new lymphocytes, which migrate to populate the peripheral lymphoid tissues; 
however, after puberty, the thymus progressively shrinks and T cell numbers are maintained 
through division of mature T cells, outside of the central lymphoid organs. 
An extensive review of thymic development, anatomy and physiology can be found in 
Rezzani R et al. (2008). Briefly, the thymus provides a network of specialized nonlymphoid 
stromal cells that interact intimately with the developing lymphocytes, providing signals 
through secreted growth factors and cell surface molecules. It consists of two distinct 
anatomical regions – an outer cortical region, the cortex, and an inner medulla. The cortex 
contains only immature thymocytes and scattered macrophages, whereas more mature 
thymocytes, along with macrophages and dendritic cells, are found in the medulla. 
Developing thymocytes pass through a series of distinct phases that are marked by changes in 
the status of TCR genes and expression of the TCR molecules, and by changes in expression 
of cell surface proteins such as the CD3 complex and the co-receptor proteins CD4 and CD8 
[Figure 4]. Two distinct lineages of T cells – : and :, which have different types of 
TCR – are produced early in T cell development; later, : T cells develop into two distinct 
functional subsets, CD4 and CD8 T cells. When hematopoietic precursors first enter the 
thymus from the bone marrow, they lack most of the surface molecules characteristic of 
mature T cells (CD3, CD4, CD8), and their receptor genes are unrearranged; they are called 
"double negative" (DN) thymocytes. Afterwards, immature thymocytes undergo several 
transitions (DN1-DN4), leading to expression of both CD4 and CD8, and of a non-functional 
TCR complex called "pre-TCR" (Godfrey DI et al., 1993); they are called "double positive" 
(DP) thymocytes. After this stage, which takes place in the cortex of the thymus, thymocytes 
acquire a fully assembled TCR expressed at high levels, and subsequently undergo a crucial 
dual screening step, namely positive and negative selection (Robey E et al., 1994). During 
positive selection, thymocytes which bind with adequate affinity to self-antigen/self-MHC 
complexes on thymic cortical stromal cells are rescued from death by receiving survival 
signals, whilst those thymocytes that bind with too low affinity die by apoptosis; the fate of 
thymocytes is also determined during positive selection: they are committed to become either 
CD4+ cells (if they were positively selected by MHC class II molecules) or CD8+ cells (if they 
were positively selected by MHC class I molecules). Negative selection is mediated by 
thymic medullary epithelial cells and DCs and occurs during and after the double-positive 
stage: thymocytes that react with a too high avidity with self-antigens are deleted by 
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apoptosis, thus eliminating potentially harmful autoreactive T cells ("central tolerance"). 
About 98% of thymocytes die during the development process by failing either positive 
selection or negative selection, whereas the only 2% that survive exit the thymus as single 
positive, CD4+ or CD8+, mature naïve T cells.  
Figure 4. Thymus structure and function (Rezzani R et al., 2008). 
DN: double negative; DP: double positive; SP: single positive; cTEC: cortical thymic epithelial 
cell; mTEC: medullary thymic epithelial cell; DC: dendritic cell; 
NK: natural killer. 
Once T cells have left the central lymphoid tissues, they are carried in the blood to the 
peripheral lymphoid tissues. If they do not encounter their specific antigen and become 
activated within a peripheral lymphoid tissue, they leave the tissue and recirculate via lymph 
and blood, continually reentering lymphoid tissues until either antigen is encountered or the T 
cell dies. 
2.2.2. Organization of the mature T cell pool 
Mature recirculating T cells that have not yet encountered their antigens are known as naïve 
T cells. In order to be activated, naïve T cells must recognize a foreign peptide bound to a self 
MHC molecule in addition to the concomitant delivery of a co-stimulatory signal by 
specialized APCs, driving the clonal expansion of naïve T cells and their differentiation into 
effector cells. 
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2.2.2.1. Antigen processing and presentation 
The development of an adaptive immune response is not initiated directly at the site of 
infection, but instead in secondary lymphoid tissues such as lymph nodes, Peyer's patches of 
the gut, tonsils and the spleen. Pathogen-derived antigens (or other "foreign" antigens and 
even auto-antigens in the case of autoimmunity) are transported to these secondary lymphoid 
tissues by the lymph or, more rarely, by the blood. These antigens are ingested by 
professional APCs (DCs, macrophages and B cells), processed into peptides and delivered at 
their cell surface by their MHC molecules, along with co-stimulatory molecules, for 
presentation to T cells. 
MHC molecules are divided into two classes, class I and class II, based upon their structure, 
tissue distribution and source of peptide antigen, as well as upon their interactions with T cell 
subsets. In humans, they are called "HLA", for "Human Leucocyte Antigen" and are encoded 
on chromosome 6. There are six major HLA loci encoded within the MHC.  
The class I HLA molecules are encoded by three distinct genetic loci known as HLA-A, -B,
and -C. Class I molecules comprise a single heavy chain, non covalently complexed to a 
smaller molecule known as 2-microglobulin (Parham P et al., 1987; Natarajan K et al., 
1999). The heavy chain has three domains, 1, 2, and 3. The 1 and 2 domains create the 
antigen-binding cleft, the floor of which is formed by a -pleated sheet that is overlaid by two 
-helical walls. The 3 domain and 2-microglobulin form a membrane-proximal scaffold 
that interacts with CD8 on T cells [Figure 5A]. Class I molecules are expressed on most 
nucleated cell types as well as on platelets, and all three locus products are expressed in a 
co-dominant fashion. 
Figure 5A. Structure of the 
MHC class I molecule. 
Figure 5B. Structure of the 
MHC class II molecule. 
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The class II molecules include HLA-DR, -DQ, and -DP, encoded by distinct genetic loci 
clustered in the class II region of the MHC. The overall protein structure adopted by class II 
molecules is similar to that of class I, but it is achieved by the association of two membrane-
bound chains known as  and  (Madden DR, 1995). The  and  chains assemble 
non-covalently to create an antigen-binding cleft located above a conserved 
membrane-proximal structure that can interact with CD4 on T cells [Figure 5B]. Class II 
molecules are constitutively expressed only on DCs, macrophages and B cells, and all three 
locus products are expressed in a co-dominant fashion. 
It is generally admitted that MHC class I molecules present peptides of 8-11 amino acids of 
length, obtained after degradation of cytoplasmic proteins, to CD8 T cells, whereas MHC 
class II molecules present longer peptides (11-25 amino acids), originating from extracellular 
proteins taken up by the APCs, to CD4 T cells. 
2.2.2.2. Naïve T cell activation and clonal expansion 
There are mainly three mandatory requirements for the optimal antigen-specific activation and 
subsequent clonal expansion of naïve T cells, preventing unspecific activation as well as 
expansion of inefficient T cells; it is known as the "three-signal model". 
First, as already explained, activation of naïve T cells is triggered when TCR and either CD4 
or CD8 co-receptors bind to peptide/MHC complexes presented by professional APCs 
("signal 1"). The strength of the TCR signal has a quantitative influence on T cell activation 
and differentiation (Sloan-Lancaster J et al., 1993; Viola A et al., 1996). Second, a 
co-stimulatory signal is required, provided by both the cell surface molecules displayed on 
APCs and the soluble factors ("signal 2"). The absence of a second signal promotes T cell 
anergy, which is a state of antigen-specific nonresponsiveness, or apoptosis (DeSilva DR et 
al., 1991; Jenkins MK et al., 1991; Norton SD et al., 1991; Harding FA et al., 1992). Several 
co-stimulatory signaling molecules have been described, and they generally belong to two 
families: the B7 family (reviewed in Greenwald RJ et al., 2005) [Figure 6] and the 
tumor-necrosis factor (TNF) family of receptors (reviewed in Watts TH, 2005). 
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Figure 6. Structures of the B7-1/B7-2 – CD28/CTLA-4 superfamily members (Sharpe AH et 
al., 2002).
CTLA-4: cytotoxic T lymphocyte antigen 4; ICOS: inducible T cell co-stimulator; 
ICOSL: ICOS ligand; MHC: major histocompatibility complex; PD-1: programmed death 1; 
PD-L1, PD-L2: PD-1 ligands 1 and 2; TCR: T cell receptor. 
The combination of both TCR–peptide/MHC complex and co-stimulatory molecules 
interactions provides optimal signal to naïve T cells, initiating a complex intracellular 
signaling cascade leading to the activation of transcription factors such as NF-B, NFAT and 
AP-1 (Mustelin T et al., 2003) [Figure 7]. Ultimately, T cell activation leads to the induction 
of new gene synthesis that results in the differentiation, proliferation and effector actions of T 
cells. 
Figure 7. Intracellular signaling pathways and kinases involved in T cell activation (Mustelin T 
et al., 2003). 
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Among others, T cell activation induces the synthesis of IL-2 along with the  chain of the 
IL-2 receptor (CD25). The IL-2 receptor has three chains: , , and  (Minami Y et al., 1993). 
Resting T cells express a form of this receptor composed of  and  chains that binds IL-2 
with moderate affinity, allowing resting T cells to respond to very high concentrations of 
IL-2. Association of the  chain with the  and  chains creates a receptor with a much higher 
affinity for IL-2, allowing the cell to respond to very low concentrations of IL-2. Binding of 
IL-2 to the high-affinity receptor then triggers progression through the rest of the cell cycle 
(Hatakeyama M et al., 1989), by activating the "target of rapamycin" pathway to provide 
"signal 3". IL-2 also promotes the differentiation of these cells into armed effector T cells. 
2.2.2.3. Memory T cell subsets and effector functions 
Once activated, T cells acquire new functions and properties that render them able to fight 
efficiently the triggering stimulus. We have already seen that T cells generated in the thymus 
can be divided into two main classes, depending on the co-receptor expressed on their cell 
surface and the class of MHC molecules recognized, namely CD4 and CD8 T cells, which 
display distinct functions. 
CD4 T cells, display a broad range of effector functions [Figure 8]. Historically, two different 
subsets were first identified in 1986, T helper 1 cells (TH1) and T helper 2 cells (TH2) 
(Mosmann TR et al., 1986). However, in 1995, a new subset with particular functional 
properties was identified, called regulatory T cells (Treg) (Sakaguchi S et al., 1995). Finally, 
in 2005, a fourth lineage of effector CD4 T cells was identified, which were able to produce 
IL-17; they are known as TH17 cells (Park H et al., 2005). CD4 T cells subsets fates and 
functions will be discussed in more detail in the next parts. 
Figure 8. Summary of the four CD4 T helper cell fates: their functions, their unique products, 
their characteristic transcription factors, and cytokines critical for their fate determination 
(Zhu J and Paul WE, 2008). 
2. INTRODUCTION 
20 
On the other hand, CD8 T cells, also called cytotoxic T cells (CTLs), have the ability to kill 
target cells that display peptide fragments of cytoplasmic pathogens, most notably viruses, but 
also of tumor cells and allogeneic cells, bound to MHC class I molecules at the cell surface. 
CD8+ T lymphocytes cause lysis of target cells by two mechanisms: membranolysis, in which 
secreted molecules such as perforin and granzymes form pores in the membrane of target cells 
(Berke G, 1994), and apoptosis, mediated through the triggering of apoptosis-inducing 
(Fas-like) surface molecules on the target cell (Hashimoto S et al., 2000). 
2.3. CD4 T cells 
2.3.1. TH1 cells 
TH1 cells have been shown to be responsible for cell-mediated immunity. They mediate 
immune responses against intracellular pathogens (Mosmann TR et al., 1989; Paul WE and 
Seder RA, 1994). In humans, TH1 cells play a particularly important role in resistance to 
mycobacterial infections, and are also responsible for the induction of some autoimmune 
pathologies and of delayed-type hypersensitivity. They mainly produce interferon  (IFN), 
tumor necrosis factor  (TNF), lymphotoxin  (LT), interleukin-12 (IL-12) and IL-2. IFN
is important in activating macrophages to increase their microbicidal activity. 
The presence of IL-12, produced by maturing DCs, as well as of type I and II IFN, produced 
by NK cells and DCs, drives the polarization of naïve T cells towards a TH1 phenotype, by 
activating specific transcription factors. The transcription factor T-bet is the master regulator 
of TH1 differentiation (Szabo SJ et al., 2000). In addition, Stat1 plays a major role in the 
IFN-mediated induction of T-bet (Lighvani AA et al., 2001) and Stat4, an IL-12 signal 
transducer, is important for amplifying TH1 responses (Kaplan MH et al., Nature, 1996) and 
for inducing direct IFN production in activated CD4 T cells. TH1 cells express IL-12R2
upon TCR activation and then maintain its expression thanks to IL-12 and IFN stimulation 
(Szabo SJ et al., 1997). Among chemokine receptors, CxCR3 (Sallusto F et al., 1998) and 
CCR5 (Loetscher P et al., 1998) show a striking preferential expression on TH1 cells. 
2.3.2. TH2 cells 
TH2 cells are responsible for humoral immunity, through secretion of specific cytokines that 
induce B cell proliferation and differentiation into antibody-secreting plasma cells. They 
mediate host defense against extracellular pathogens including bacteria and parasites such as 
helminthes (Mosmann TR et al., 1989; Paul WE and Seder RA, 1994). They are also 
important in the induction and persistence of asthma and other allergic diseases. They mainly 
produce IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25. 
The presence of IL-4 in the environment drives the polarization of naïve T cells towards a 
TH2 phenotype and represses the expression of TH1 cytokines, by inducing the expression of 
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the master regulator GATA-3 (Pai SY et al., 2004) through activation of Stat6 (Kaplan MH et
al., Immunity, 1996). IL-4R expression is up-regulated during TH2 differentiation. Among 
chemokine receptors, CCR3 (Sallusto F et al., 1997), CCR4 (Bonecchi R et al., 1998) and 
CCR8 (D'Ambrosio D et al., 1998) are preferentially expressed in TH2 cells. 
2.3.3. TH17 cells 
The recently identified TH17 lineage is responsible for, or participates in, the induction of 
many organ-specific autoimmune diseases such as experimental autoimmune encephalitis 
(Komiyama Y et al., 2006), collagen-induced arthritis (Murphy CA et al., 2003) and 
inflammatory bowel disease (Yen D et al., 2006), as well as for the protection against 
extracellular bacteria in mice (Rudner XL et al., 2007) and against fungi in humans 
(Palm NW and Medzhitov R, 2007). They have been termed TH17 because of their ability to 
secrete high amounts of the pro-inflammatory cytokine IL-17 (Park H et al., 2005), which 
mediates inflammation through the ubiquitously expressed IL-17 receptor (Spriggs MK, 
1997). 
RORt is the transcription factor responsible for the differentiation of TH17 cells (Ivanov II et
al., 2006), as demonstrated by the fact that overexpression of RORt induces IL-17 
production and that RORt-deficient cells produce very little IL-17. Recently, it was also 
shown that ROR is up-regulated in TH17 cells (Yang XO et al., 2008) and that deficiency in 
both RORt and ROR completely abolishes IL-17 production. Finally, Stat3, which is the 
main signal transducer for IL-6, IL-21 and IL-23, is indispensable for IL-17 production 
(Harris TJ et al., 2007). In mice, IL-6 and TGF act synergistically to drive the differentiation 
of TH17 cells, whilst the absence of IL-6 triggers the differentiation of regulatory T cells 
(Chen W et al., 2003). The apparent link between these two populations suggests that 
differentiation of one or the other lineage critically depends on the encountered cytokine 
milieu. 
In addition to the three above-described effector lineages, CD4 T cells in the thymus can 
differentiate into a fourth subset, namely regulatory T cells (Treg), which has the unique 
property to repress immune responses (so-called suppressive capacity). We will discuss the 
phenotypic and functional properties of regulatory T cells in the next part. 
2.4. Treg cells 
T cells able to suppress immune responses have been described in the early 1970s under the 
term of "suppressor T cells" by Gershon RK et al., who concluded that: "[in mice, some] 
thymocytes are capable of suppressing the antigen-induced response of other thymocytes 
without the mediation of B cells or their product (i.e., antibody)" (Gershon RK and Kondo K, 
1970). In 1982, it was demonstrated that the development of autoimmune oophoritis induced 
by neonatal thymectomy could be prevented by a single injection of spleen cells or 
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thymocytes from normal adult female mice (Sakaguchi S et al., 1982). The subject regained 
interest in the mid-1990s when Sakaguchi S et al. showed that a minor population (5-10% in 
mice) of CD4+ T cells, which co-expresses the IL-2 receptor (IL-2R)  chain (CD25), is 
crucial for the control of autoreactive T cells in vivo. They demonstrated that when CD4+ cell 
suspensions prepared from mice lymph nodes and spleens were depleted of CD25+ cells by 
specific monoclonal antibodies, and then inoculated into athymic mice, all recipients 
spontaneously developed evident autoimmune diseases (such as thyroiditis, gastritis, insulitis, 
sialoadenitis, adrenalitis, oophoritis, glomerulonephritis, and polyarthritis); reconstitution of 
CD4+ CD25+ cells within a limited period after transfer of CD4+ CD25- cells prevented these 
autoimmune developments in a dose-dependent fashion (Sakaguchi S et al., 1995). They were 
also the first to demonstrate that CD25 could be used as a marker for the so-called suppressor 
cells. Subsequent in vitro studies by several groups showed that CD4+ CD25+ T cells are both 
hyporesponsive and suppressive (Thornton AM and Shevach EM, 1998; Takahashi T et al., 
1998). CD4+ CD25+ regulatory T cells were discovered originally in mice, but a population 
with identical phenotypic and functional properties has also been defined in humans 
(Levings MK et al., 2001; Dieckmann D et al., 2001; Jonuleit H et al., 2001; Taams LS et al., 
2001). 
Regulatory T cells can be divided into "natural" Treg, which develop in the thymus as a 
specific T cell lineage, and "adaptive" Treg, which differentiate in the periphery from naïve T 
cells under specific conditions. Initially, regulatory T cells were thought to mediate tolerance 
to self antigens, thus preventing the development of autoimmune diseases; however, 
experimental evidences strongly suggest that they also play a central role in immune 
responses in the context of microbial infections (Suvas S and Rouse BT, 2006), allergic 
disorders (Xystrakis E et al., 2007), cancers (Wang HY and Wang RF, 2007), materno-fœtal 
tolerance (Aluvihare VR et al., 2004), and transplantation (Yong Z et al., 2007). 
2.4.1. Phenotypic characteristics of Treg 
Regulatory T cells display several cell surface as well as intracellular markers that permit to 
identify them among CD4+ T cells. For a purpose of clarity, we will focus our description on 
the so-called "natural" Treg (nTreg). 
2.4.1.1. CD25 
CD25, as mentioned previously, was the historical marker of Treg cells. It corresponds to the 
IL-2R  chain. However, it is not exclusively expressed by Treg cells, but also by CD4 and 
CD8 T cells upon activation. Furthermore, the expression profile of CD25 on peripheral CD4 
T cells is not easy to interpret, particularly in humans, since there is not a clear distinction 
between cells which do not express CD25 (CD25neg) and those expressing CD25 (CD25pos), 
but rather a continuous spread from CD25 negative cells to cells expressing high levels of 
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CD25 (CD25high); three populations can be distinguished based on the CD25 expression level: 
CD4+ CD25neg T cells (no or very low expression of CD25), CD4+ CD25int T cells 
(intermediate expression of CD25), and CD4+ CD25high T cells (high expression of CD25) 
[Figures 9A and 9B]. 
Figure 9A. Representative cytometric 
expression profile of CD4+ CD25+ T cells, in 
mice (Sakaguchi S et al., 1995). 
In mice, there is a clear distinction between 
CD4+ CD25neg and CD4+ CD25pos T cells. 
Figure 9B. Representative cytometric 
expression profile of CD4+ CD25+ T cells, in 
humans (Baecher-Allan C et al., 2001). 
In humans, three populations can be 
distinguished: CD4+ CD25neg, CD4+ CD25int
and CD4+ CD25high T cells. 
This distinction is important, since only CD4+ CD25high T cells display the characteristic 
suppressive capacity of regulatory T cells (this point will be discussed in more details later) 
[Figure 10]. 
Figure 10. Proliferative and suppressive capacity of CD4+ CD25neg, of CD4+ CD25int, and of 
CD4+ CD25high T cells (Baecher-Allan C et al., 2001). 
Upper panel: upon polyclonal stimulation (plate-bound anti-CD3), both CD4+ CD25neg and 
CD4+ CD25int T cells proliferated vigorously; co-culture of these two populations did not display 
inhibition of proliferation. 
Lower panel: upon polyclonal stimulation (plate-bound anti-CD3), only CD4+ CD25neg T cells 
proliferated whilst CD4+ CD25high T cells were hyporesponsive; in co-culture, CD4+ CD25high T cells 
strongly inhibited the proliferation of CD4+ CD25neg responder T cells. 
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Traditionally, mouse and human Treg cells have been characterized as CD4+ CD25+ cells. 
Indeed, mouse Treg cells can be effectively isolated based on staining for 
CD4+ CD25+ CD45RBlow expression. By contrast, the purity of isolated human Treg cells has 
always been an issue because T cells upregulate CD25 expression upon activation (Fontenot 
JD et al., Immunity, 2005). Consequently, the search for Treg-cell-specific cell surface 
markers, particularly in humans, has continued with a growing number of candidates 
proposed. 
2.4.1.2. FoxP3 
The transcription factor FoxP3 ("forkhead box P3") is considered to date as the most reliable 
marker for identification of regulatory T cells and is critically implicated in their 
development, maintenance and function (Fontenot JD et al., 2003; Hori S et al., 2003). It 
belongs to the forkhead/winged-helix family of transcription factors [Figure 11]. 
Figure 11. Functional structure of the FoxP3 protein (Campbell DJ and Ziegler SF, 2007). 
The FoxP3 transcription factor protein is composed of at least four functionally distinct 
domains (Gajiwala KS and Burley SK, 2000): beginning at the N-terminus, a transcriptional 
repression domain containing a proline-rich region (amino acids (aa) 1-193), a zinc-finger 
motif of uncertain function (aa 200-223), a dimerization domain containing a 
leucine-zipper-like motif (aa 240-261), and a forkhead DNA binding domain (aa 338-421) at 
the C-terminus. 
The critical role of FoxP3 on the development and function of regulatory T cells was first 
suggested in 2001 when the autoimmune Scurfy mice (Brunkow ME et al., 2001) and a 
human immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) patient 
(Bennett CL et al., 2001; Wildin RS et al., 2001) were found to have mutations in the FoxP3 
gene. Both Scurfy mice and IPEX patients present mutations in the FoxP3 gene leading to a 
dysfunctional or truncated protein. Scurfy mice completely lack natural regulatory T cells 
(Fontenot JD et al., 2003; Khattri R et al., 2003) and suffer from an aggressive 
lymphoproliferative disorder, with prominently activated CD4 T cells infiltrating many 
organs such as the lymph nodes, spleen, liver, skin and lungs (Godfrey VL et al., 1991). The 
development of this lymphoproliferative disorder could be prevented by the neonatal transfer 
of CD4+ CD25+ T cells (Smyk-Pearson SK et al., 2003). In IPEX patients, the FoxP3 protein 
is usually present but dysfunctional, permitting the generation of regulatory T cells, which are 
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normal in number and phenotype but display an altered suppressive capacity (Bacchetta R et 
al., 2006). In mice, FoxP3 expression is strictly restricted to regulatory T cells. By contrast, in 
humans, it is possible that FoxP3 expression can be induced following activation of naïve 
CD4 T cells, although it is still controversial if de novo FoxP3 expression is correlated with 
stable acquisition of Treg features or not (Walker MR et al., 2003; Roncador G et al., 2005; 
Gavin MA et al., 2006; Wang J et al., 2007). Recent studies have demonstrated the presence 
of epigenetic modifications of several regions in the FoxP3 locus exclusively occurring in 
natural regulatory T cells, both in mice (Floess S et al., 2007) and humans (Baron U et al.,
2007). An evolutionarily conserved region within the 5' non-coding part of the gene, named 
TSDR (Treg-specific demethylated region), was shown to contain CpG motifs, which are 
completely demethylated in regulatory T cells, but methylated in naïve and effector T cells; 
regulatory T cells induced in vitro display only incomplete DNA demethylation despite high 
FoxP3 expression, suggesting that expression of FoxP3 must be stabilized by epigenetic 
modification to result in a permanent suppressor cell lineage commitment. These 
modifications may be useful in discriminating natural regulatory T cells from transiently 
FoxP3-expressing activated T cells (Janson PC et al., 2008). 
FoxP3 acts mainly as a transcriptional repressor (through its N-terminal proline-rich repressor 
domain), by binding to NFAT and NF-B and therefore inhibiting the expression of their 
target genes (among others, genes coding for the cytokines IL-2, IL-4 and IFN)
(Schubert LA et al., 2001; Bettelli E et al., 2005; Wu Y et al., 2006). Recently, it was also 
shown that FoxP3 could directly interact with AML1/Runx1, suppressing IL-2 and IFN
production (Ono M et al., 2007). On the other hand, FoxP3 is responsible for the transcription 
of several genes specifically associated with the Treg phenotype, among which CD25, 
CTLA-4 and GITR (Williams LM and Rudensky AY, 2007) [Figure 12]. 
Figure 12. Control of Treg function by FoxP3 
(Sakaguchi S et al., 2008). 
(A) Structure of the FoxP3 protein. Bars 
indicate the binding sites for other 
transcription factors (AML1/Runx1, NFAT) or 
chromatin-remodeling enzymes (HDAC7, 
Tip60). 
Pro: proline-rich region; ZnF: zinc-finger 
domain; LZ: leucine-zipper domain; 
FHD: forkhead box domain. 
(B) The transcriptional complexes involving 
NFAT and AML1/Runx1 activate or repress 
the genes encoding cytokines and several cell 
surface molecules in Treg and non-Treg, 
depending on the presence of FoxP3. 
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In conclusion, FoxP3 is the master regulator of regulatory T cells, by inhibiting the expression 
TH1-, TH2- and TH17-associated genes, by stimulating the expression of Treg-associated 
genes, and by stabilizing Treg characteristic features. 
Although FoxP3 seems to be the "ideal" marker for identifying regulatory T cells, it has the 
drawback to be localized in the nucleus, which implies permeabilization of the cell membrane 
for its detection and is incompatible with the further use of the isolated cells in culture 
experiments. This has prompted efforts to identify other specific markers of Treg that are 
expressed on the cell surface, in addition to CD25. 
2.4.1.3. CTLA-4 
The CD28/CTLA-4 interacts with their ligands, the B7 family, to provide a second signal for 
T cell activation/anergy. In contrast to CD28, which provides an activatory co-stimulation 
signal, CTLA-4 (CD152) mediates down-regulation of immune responses by interacting with 
B7.1 (CD80)/B7.2 (CD86) on target cells (Thompson CB and Allison JP, 1997). CTLA-4 is 
constitutively expressed only by Treg cells (Takahashi T et al., 2000), and upregulated upon 
activation in conventional T cells (Walunas TL et al., 1994). The interaction between 
CTLA-4 and B7 molecules offers co-stimulation signal and results in Treg activation (Read S 
et al., 2000). This suggests that CTLA-4 is involved in the regulatory activity of Treg cells, 
although CTLA-4-deficient mice display Treg that are able to mediate suppression (Read S et 
al., 2006). 
2.4.1.4. GITR 
GITR belongs to the tumor necrosis factor receptor (TNFR) superfamily, which also includes 
4-1BB, OX40 (CD134) and CD95 (Nocentini G et al., 1997). It is expressed on various 
lymphocytes at various levels, but high surface expression of GITR is restricted to resting 
Treg cells in the periphery and the thymus (Shimizu J et al., 2002). However, like CD25, 
GITR expression is upregulated on CD25- T cells following activation, rendering it not as a 
specific marker of Treg. 
2.4.1.5. CD39 
CD39, also known as ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1 
[NTPDase 1]), is the most prominent ectoenzyme of the immune system. The function of 
CD39 is to effectively remove toxic extracellular ATP by converting it to ADP or AMP; 
CD39 is thought to work together with CD73, which catalyzes the conversion of AMP to 
adenosine. In the immune system, extracellular ATP functions as a "natural adjuvant" that 
exhibits multiple proinflammatory effects: it is released by damaged cells as an indicator of 
trauma and cell death. It was recently shown that CD39 is expressed primarily by FoxP3+
regulatory T cells and that its expression is driven by the Treg-specific transcription factor 
FoxP3 (Borsellino G et al., 2007). Subsequently, Deaglio S et al. (2007) demonstrated that 
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the concomitant expression of CD39 and CD73 on regulatory T cells contributes to the 
generation of the immunosuppressive factor adenosine, which is known to exert an inhibitory 
effect on T cell responses. 
2.4.1.6. CD127 
CD127, the  chain of the IL-7 receptor, has been recently reported to be very useful in 
discriminating regulatory and activated cells among CD4+ CD25high T cells in healthy 
individuals (Seddiki N et al., 2006; Liu W et al., 2006). In addition, the study conducted by 
Liu et al. suggests a link between CD127 and FoxP3: indeed they could show that FoxP3 
physically interacts with the promoter region of CD127, which could explain the 
down-regulation of CD127 observed in Treg cells. The absence of CD127 on the surface of 
Treg cells is also in accordance with the observation that Treg survival critically depends on 
the presence of IL-2 (secreted by other T cells), but not on the presence of IL-7, which is 
essential for the survival of conventional T cells (Von Freeden-Jeffry U et al., 1995). To date, 
the combination of CD4, CD25 and CD127 surface markers should allow for quantitative 
studies of regulatory T cells as well as for enrichment of live regulatory T cells for functional 
analyses and/or expansion in vitro (Hartigan-O'Connor DJ et al., 2007). 
2.4.1.7. Other markers 
Besides the aforementioned markers, additional molecules have been shown to be more or 
less associated with the Treg lineage, but none of them has been described as really specific 
of regulatory T cells. Among others, we can mention: programmed cell death-1 (PD-1, down-
regulated on Treg in mice and humans; Raimondi G et al., 2006), lymphocyte activation 
gene-3 (LAG-3, the mRNA of which is upregulated in Treg cells; Huang CT et al., 2004), 
neuropilin-1 (Nrp1, constitutively expressed on Treg cells; Bruder D et al., 2004), 
membrane-bound TGF (expressed on Treg cells; Nakamura K et al., 2001), and folate 
receptor 4 (FR4, upregulated on Treg cells; Yamaguchi T et al., 2007). 
2.4.2. Functional characteristics of Treg 
2.4.2.1. Suppressive function 
In vivo and in vitro, regulatory T cells are characterized by an anergic state (that can be 
partially reversed by high-doses of IL-2) and by a suppressive function. They inhibit multiple 
stages of target cell activity [Figure 13]. Indeed, natural Treg cells are able to suppress the 
proliferation of naïve T cells and their differentiation into effector T cells. They can also 
suppress effector activities of differentiated CD4+ and CD8+ T cells, and the function of NK 
cells, NK T cells, B cells, macrophages, osteoclasts, and DCs (reviewed in Von Boehmer H, 
2005; Shevach EM et al., 2006; Miyara M and Sakaguchi S, 2007; Tang Q and Bluestone JA, 
2008). 
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Figure 13. Regulatory T cells may exert their suppressive activity at different stages during the 
development of an immune response, from activation of a T cell to its effector function (Sojka DK et 
al., 2008). 
The mechanisms of Treg action remain poorly understood and contentious. Differences 
between in vitro and in vivo requirements, particularly with regard to the inhibitory cytokines 
IL-10 and TGF, have fuelled the controversy. In vitro, Treg cells suppress the proliferation 
and cytokine production (in particular of IL-2) of responder T cells when the two populations 
are co-cultured and stimulated by antigen in the presence of APCs (Takahashi T et al., 1998; 
Thornton AM and Shevach EM, 1998). Once activated by a particular antigen, Treg cells can 
suppress responder T cells irrespective of whether they share antigen specificity (Takahashi T 
et al., 1998). 
Three mechanisms of Treg-mediated suppression have been proposed; they include 
cell-contact-dependent suppression, secretion of immunosuppressive cytokines, and local 
competition for growth factors [Figure 14]. More than one mechanism of Treg-mediated 
suppression may operate for the control of a particular immune response, in a synergistic and 
sequential manner. All these mechanisms require close spatial proximity between the 
suppressor and suppressed cells, either in the target tissue or the regional lymph nodes. 
Figure 14. 
Proposed 
mechanisms of 
regulatory T cell 
suppression 
(Sojka DK et al., 
2008).
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(a) The cell-contact-dependent mechanism of suppression is still controversial. Transwell 
experiments have shown that direct cell-cell contact is indispensable for effective suppression. 
Several cell surface molecules on Treg have been proposed for this direct interaction, among 
which GITR (Shimizu J et al., 2002), CTLA-4 (Paust S et al., 2004), membrane-bound TGF
(Nakamura K et al., 2001), LAG-3 (Huang CT et al., 2004) and the cytolytic molecules Fas 
and granzyme B (Janssens W et al., 2003; Cao X et al., 2007; Zhao DM et al., 2006). Another 
pathway is the modulation of cyclic adenosine monophosphate (cAMP) levels in the target 
cells; indeed, elevation of cAMP levels is associated with inhibition of cellular proliferation, 
differentiation and cytokine gene expression, including IL-2 and IFN (Minguet S et al.,
2005). 
(b) Treg cells have been shown to produce immunoregulatory molecules such as TGF and 
IL-10, which directly affect the activity of cytotoxic T cells and APCs. TGF1 reduces 
cytokine secretion by activated CD4+ T cells (Zheng SG et al., 2004), without limiting their 
capacity to expand and without inducing their apoptosis, whilst IL-10 enhances the response 
of activated T cells to TGF1 through regulation of TGF receptor expression (Cottrez F and 
Groux H, 2001). Thus, combined effects of TGF and IL-10 inhibit the activity of effector T 
cells with minor effect on their expansion. Recently, a study in mice has shown that natural 
Treg cells predominantly produce immunosuppressive IL-35, a new member of the IL-12 
family (Collison LW et al., 2007). 
 (c) The constitutive expression of CD25 by Treg cells gives them an initial competitive 
advantage for the consumption of IL-2 over naïve T cells, which express CD25 only after 
TCR stimulation. It was recently shown that Treg-mediated competition for growth factors 
leads to cytokine deprivation-induced apoptosis in the target effector cells, both in vitro and 
in vivo (Pandiyan P et al., 2007). However, Treg-mediated suppression cannot be entirely 
explained by the competitive consumption of IL-2; indeed, Treg cells can suppress the 
autoimmune response of IL-2R-deficient T cells (Fontenot JD et al., Nat Immunol, 2005), and 
provision of exogenous IL-2 in in vitro co-cultures enables target T cells to proliferate in the 
presence of Treg whilst endogenous target T cell production of IL-2 remains suppressed 
(Thornton AM et al., 2004; Sojka DK et al., 2005). 
Many of the suppressive mechanisms that have been discussed here are not essential for Treg 
activity and may play a supportive role to an unidentified master regulatory function. To 
accommodate the variety of immune functions regulated by Treg cells [Figure 13], they may 
use a suppressive mechanism that targets an essential and common step in lymphocyte 
activation. 
The suppressive activity of Treg cells has to be counterbalanced in cases where mounting an 
effective immune response is required, such as in the case of microbial infections. This 
inhibition of Treg activity can be either achieved by negatively regulating the Treg cells 
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themselves or by positively arming the target cells against Treg suppressive activity. A variety 
of proinflammatory signals, such as Toll-like receptor triggering (Liu G and Zhao Y, 2007) 
and direct inhibition by TNF (Valencia X et al., 2006), can modulate Treg function. On the 
other hand, elevating the strength of target T cells activation level, through increasing antigen 
dose or provision of costimulatory signals (by upregulation of CD80 and CD86), has been 
shown to abrogate Treg-mediated suppression (George TC et al., 2003). 
2.4.3. Adaptive regulatory T cells 
Besides naturally-occurring regulatory T cells which develop in the thymus and display a 
diverse TCR repertoire that is specific for self antigens (Fontenot JD, J Exp Med, 2005; 
Hsieh CS et al., 2004), other subsets of regulatory T cells can also be "induced", "adapted" or 
"converted" from effector T cells during inflammatory processes in peripheral tissues, or 
experimentally generated for therapeutic purposes (Hawrylowicz CM and O'Garra A, 2005; 
Izcue A et al., 2006; Roncarolo MG et al., 2006). These regulatory cells do not always 
express FoxP3, are induced in the periphery much like TH1 or TH2 cells, and are generated to 
self and foreign antigens. Adaptive Treg cells appear to rely primarily on immunosuppressive 
cytokines to mediate suppression both in vivo and in vitro, although they have also been 
reported to suppress in a cell-contact dependent manner similar to natural Treg cells. It is 
likely that these different populations of Treg cells work together in a coordinated manner to 
regulate immune responses. To date, two subsets of adaptive Treg cells have been well 
characterized, T regulatory 1 (Tr1) and T helper 3 (TH3) cells. 
2.4.3.1. Tr1 cells 
Tr1 cells are a predominantly IL-10-expressing population that have been shown to cure 
models of inflammatory bowel disease in mice (Groux H et al., 1997; Vieira PL et al., 2004).
Unlike natural Treg, Tr1 cells are able to produce IL-10 and TGF and do not express FoxP3, 
yet their properties in vitro are very similar to those of FoxP3+ Treg cells. For example, they 
exhibit diminished proliferation in response to antigenic stimulation, exert cell 
contact-dependent suppression, scarcely produce IL-2, and display an activated cell surface 
phenotype (Vieira PL et al., 2004). These cells can be generated in several manners, such as 
by activating CD4 cells in the presence of IL-10, by culturing CD4 cells in the presence of 
dexamethasone and vitamin D3, by activating naïve CD4 cells through the TCR and the 
complement regulatory protein CD46, or by culturing them with IFN (Groux H et al., 1997; 
Allan SE et al., 2005; Barrat FJ et al., 2002). Interestingly, Tr1 cells generated in vivo by 
combined IL-10 and rapamycin treatment in the presence of antigen were able to transfer 
antigen-specific tolerance to naïve untreated mice (Battaglia M et al., Diabetes, 2006). 
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2.4.3.2. TH3 cells 
TH3 cells are also a suppressive CD4 population that secrete TGF and are able to inhibit 
immune responses in vivo (Chen Y et al., 1994). They were initially identified in Peyer's 
patches and in the mesenteric lymph nodes. These cells have been implicated in models of 
oral tolerance and can be generated in vitro by culture in the presence of TGF (Verbsky JW, 
2007). 
2.4.4. Regulatory T cells in clinical situations 
Naturally arising regulatory T cells have been initially shown to actively maintain 
immunological self-tolerance. Deficiency in or dysfunction of these cells may be a cause of 
autoimmune disease. However, it was subsequently appreciated that a reduction in their 
number or function can also elicit tumor immunity, whereas their antigen-specific population 
expansion can establish transplantation tolerance. The other clinical situations in which 
tolerance mediated by regulatory T cells has been implicated are allergy, microbial infections, 
and fœto-maternal tolerance [Figure 15]. 
Increasing Treg numbers and/or enhancing their suppressive function may be beneficial for 
treating autoimmune diseases and for preventing allograft rejection. On the other hand, 
depletion of Treg cells and/or inhibition of their function could enhance immunity against 
tumors and chronic infectious agents. As said previously, we focused our interest on 
CD4+ CD25+ T cells in the context of human solid organ transplantation. 
Figure 15. Clinical situations in which Treg-mediated tolerance is implicated (Sakaguchi S, 2005). 
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2.5. Transplantation immunology
Transplantation immunology refers to an extensive sequence of events that occurs after an 
allograft or a xenograft is removed from a donor and then transplanted into a recipient. Tissue 
is damaged at both the graft and the transplantation sites. An inflammatory reaction follows 
immediately, and innate immune responses are initiated. Cellular components of the immune 
system are believed to produce mediators that perpetuate the inflammation and promote 
maturation of adaptive immune responses. Innate immunity is triggered when highly 
conserved molecules on the surface of injured cells engage receptors expressed by cells of the 
innate immune system. Eventually, damage is controlled through tissue repair and 
reinforcement; if damage is nonpathologic, the graft survives. 
Antigen-independent causes of tissue damage (i.e., ischemia, hypothermia, reperfusion injury) 
are the result of mechanical trauma as well as of disruption of the blood supply when the graft 
is harvested. In contrast, antigen-dependent causes of tissue damage involve immune-
mediated damage, which can eventually lead to graft rejection and organ loss. 
2.5.1. Basic rules of graft rejection 
Graft rejection is an immunological response mediated primarily by T cells. It results from a 
complex process involving both innate and acquired immune systems. The basic rules of 
tissue grafting were first elucidated by skin transplantation between inbred strains of mice 
(Billingham RE et al., 1954), leading to the following definitions: 
- autograft: graft between different sites on the same animal or person;  
- syngeneic graft: graft between genetically identical animals or people (e.g., identical 
twins); 
- allograft: graft between genetically unrelated individuals of a same species; 
- xenograf: graft between individuals of different species. 
Only autograft and syngeneic graft are accepted without immunosuppressive treatments, 
whilst allograft and xenograft are rapidly rejected. Another observation that was made at that 
time is that when a mouse is grafted for a second time with skin from the same donor, it 
rejects the second graft faster (within 4-6 days instead of 10-13 days). This is called a 
second-set rejection and this accelerated response is MHC-specific; skin from a second-donor 
of the same MHC type is rejected equally fast, whereas skin from a MHC-different donor is 
rejected in a first-set pattern. Furthermore, naïve mice that are given T cells from a sensitized 
donor behave as if they had already been grafted [Figure 16]. 
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Figure 16. Skin graft rejection is the result of a T cell-mediated anti-graft response (Janeway CA et 
al., 2001). 
First panel: skin graft to syngeneic recipient, leading to indefinite acceptance. 
Second and third panels: skin graft to allogeneic recipient; first-set rejection (second panel) and 
second-set rejection (third panel). 
Fourth panel: T cell transfer from sensitized donor to naïve recipient, leading to second-set 
rejection. 
Graft rejection is the result of an alloreactive response, which can be defined as an immune 
response directed against nonself allogeneic antigens (alloantigens), developing in a 
transplant recipient. The alloreactive response can be divided into three successive stages, 
similarly to the “three-signal model”: first, the recognition of alloantigens by naïve host T 
cells; second, the activation and the expansion of alloreactive T cells; and third, the effector 
phase, which consists in the destruction process itself.  
2.5.2. Nature of alloantigens 
Transplants can express two types of alloantigens, defined as major and minor based on the 
speed with which skin grafts were rejected between species before the molecular nature of 
alloantigens was discovered. Major alloantigens consist in allogeneic MHC class I and class II 
molecules borne by donor APCs or present on the graft and processed by recipient APCs. 
They represent the major barrier to successful transplantation. Minor alloantigens are 
constituted by allopeptides that are presented by either class I or class II MHC molecules 
shared by both donor and recipient (Simpson E, 1998); they derive from proteins that are 
either only present in the donor, such as the male antigen H-Y, or present in both but 
displaying differences in amino-acid sequence between donor and recipient (Zelenika D et al., 
1998). In the context of transplantation, host T cells can recognize MHC antigens through two 
non-mutually exclusive different pathways: the direct and indirect pathways of alloantigens 
recognition. 
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2.5.3. Pathways of MHC alloantigens recognition 
Before they can cause rejection, naïve alloreactive T cells must be activated by APCs (of 
donor or recipient origin) with adequate co-stimulation [Figure 17].  
In the direct pathway of allorecognition, APCs of donor origin carried by the graft migrate via 
the lymph to regional lymph nodes, where their intact allo-MHC can activate those host 
T cells that bear the corresponding TCR (Sherman LA and Chattopadhyay S, 1993). The 
activated alloreactive effector T cells are then carried back to the graft, which they attack 
directly. The allo-MHC class I antigens are recognized by the TCR of CD8+ T cells, whereas 
the allo-MHC class II antigens are recognized by the TCR of CD4+ lymphocytes. 
In the indirect pathway of allorecognition, allogeneic proteins borne by the graft are taken up 
and processed by the recipient's own APCs, and presented to T cells by self-MHC molecules. 
Among the graft-derived peptides are the minor H antigens and also peptides from the foreign 
MHC molecules themselves, either class I or class II, which are a major source of the 
polymorphic peptides recognized by the recipient's T cells (Simpson E et al., 2002). CD4+ T 
cells specific for allogeneic peptides presented by self class II MHC molecules dominate the 
indirect pathway of T cell allorecognition (Fangmann J et al., 1992; Liu Z et al., 1992); 
actually, this corresponds to the physiological processing of soluble extracellular proteins that 
APCs are performing continuously. 
Figure 17. Direct and indirect pathways of T cell allorecognition (Whitelegg A and Barber LD, 
2004). 
The vast majority of T cells that respond to allogeneic MHC molecules do so via the direct 
recognition pathway. T cells with direct allospecificity account for more than 90% of the total 
alloimmune repertoire (Benichou G et al., 1999). Direct T cell allorecognition is the principle 
player in the initial vigorous immune response to allogeneic cells that causes acute rejection 
(Pietra BA et al., 2000) and is unique to transplantation. With time, the direct alloresponse 
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declines (Baker RJ et al., 2001). This may reflect gradual loss by natural cell death of the 
allogeneic DCs that activate the direct alloresponse (Lechler RI and Batchelor JR, 1982). 
Self-APCs, however, continue to acquire allogeneic MHC from foreign cells for processing 
and presentation by self class II MHC molecules. Indirect T cell allorecognition therefore 
comes to the fore and plays an important role in late onset chronic rejection (Vella JP et al.,
1997; SivaSai KS et al., 1999). 
2.5.4. Role of professional APCs 
In the context of transplantation, both direct and indirect pathways of T cell allorecognition 
can provide the first step in the activation of naïve T cells ("signal 1"). During priming by 
professional APCs, naïve alloreactive T cells also receive costimulatory signals ("signal 2"), 
allowing transduction of several intracellular signals, which lead to transcription of numerous 
genes involved in immune activation, such as chemokines and cytokines genes, and also of 
costimulatory molecules themselves ("signal 3"). 
In the setting of the direct pathway of alloantigens recognition, naïve alloreactive T cells first 
encounter donor APCs in the T cell area of lymph nodes or spleen. As a consequence of 
ischemia/reperfusion injuries due to the transplantation, donor APCs residing in the graft 
become rapidly activated and migrate out of the graft to recipient lymphoid tissues. At the 
same time, they undergo a maturation process consisting in the increased expression of MHC 
and costimulatory molecules. Both activation and maturation of donor APCs make them fully 
suitable for subsequent T cell activation. 
In the setting of the indirect pathway, immature circulating recipient APCs migrate from the 
blood into the graft through the combined effects of the chemokines released by the graft 
itself and the increased expression of adhesion molecules on graft endothelial cells. There, 
they ingest and process donor MHC molecules before they return to the lymph nodes or 
spleen where they initiate the priming of T cells (Lechler R et al., 2001). Of note, mice 
lacking lymph nodes and spleen are able to accept cardiac allografts indefinitely (Lakkis FG 
et al., 2000). 
As a consequence of T cell activation, effector elements are generated that mediate graft 
injury and are responsible for the clinical manifestations of allograft rejection. They include 
cellular (T cell cytotoxicity) and/or humoral (alloantibodies) components, as described 
hereafter. 
2.5.5. Alloreactive T cell cytotoxicity 
Once activated, T cells acquire cytotoxic properties that enable them to kill their targets. The 
two main cytotoxic mechanisms are the perforin/granzyme and the Fas/Fas-ligand (FasL) 
systems [Figure 18]. 
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The perforin/granzyme pathway is mainly used by CD8 T cells and NK cells. Perforin and 
granzymes are rapidly synthesized after CD8 T cell activation, and stocked as intracellular 
granules (Shresta S et al., 1998). Upon CD8/TCR-allo-MHC molecule recognition, a tight 
junction is formed, allowing intracellular cytotoxic granules to fuse with the target cell 
membrane. Perforin molecules are able to form pores in the target cell membrane, through 
which granzyme molecules penetrate in the cytoplasm and the nucleus, leading to DNA 
fragmentation and apoptosis of the target cell (Russell JH and Ley TJ, 2002). This chain of 
events is known as the granzyme exocytosis pathway. Both perforin and granzymes 
molecules are needed for maximal cytotoxicity of CD8 T cells; indeed, perforin-deficient 
mice display impaired in vitro target cell lysis, whilst granzymes A and B knockout mice are 
able to make cell membrane pores but do not induce target cell apoptosis (Simon MM et al., 
1997). 
Along with the granzyme exocytosis pathway, CD8 CTLs can also utilize the Fas-dependent 
pathway to induce cytolysis and apoptosis (Ju ST et al., 1994). In the Fas-dependent pathway, 
FasL is either packaged into cytotoxic granules with perforins and granzymes or is trafficked 
directly to the activated effector cell surface for binding to the target cell. Whereas Fas is 
constitutively expressed on most cell surfaces (Peter ME and Krammer PH, 1998), FasL is 
essentially inducible. Binding of FasL on the effector cell to Fas on the target cell membrane 
triggers apoptosis ultimately through the same effector mechanisms as in the granzyme 
exocytosis pathway. 
Figure 18. Mechanisms of cytotoxic 
T lymphocyte-induced graft 
damage (Rocha PN et al., 2003). 
FasL: Fas ligand; GE: granzyme 
exocytosis pathway; MHC: major 
histocompatibility complex; TCR: 
T cell receptor. 
CD4 T cells may also eliminate cells expressing MHC class II antigen through a Fas-
dependent or Fas-independent mechanism (Williams NS and Engelhard VH, 1996). In 
addition, CD4 TH1 cells can mediate delayed-type hypersensitivity (DTH) responses via the 
production of soluble mediators, such as IFN and TNF, that function to activate and guide 
immune cells, including monocytes and macrophages, to the site of injury. This activation 
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causes a further amplification of cytokine and chemokine production, along with generation 
of proteolytic enzymes, nitric oxide, and other soluble factors that perpetuate the local 
inflammatory response. These mediators may also directly alter graft function by modulating 
vascular tone, permeability and integrity, or by promoting platelet aggregation. 
2.5.6. Alloantibodies 
Alloreactive CD4 T cells also promote B cell maturation and differentiation into 
antibody-secreting plasma cells via CD40-CD40 ligand interactions. Alloantibodies that are 
produced by these B cells exert most of their detrimental effects on the graft by activating the 
complement and coagulation cascades (Brauer RB et al., 1995). Alternatively, antibodies can 
bind Fc receptors on NK cells or macrophages and cause target cell lysis via 
antibody-dependent cell-mediated cytotoxicity (ADCC) [Figure 19]. Alloantibodies may be 
present already before transplantation, through transfusions, pregnancy, or previous 
transplantation, or may develop de novo (Brändle D et al., 1998). Preformed alloantibodies 
(anti-HLA or anti-blood group A or B) are able to immediately bind to graft endothelial cells 
after revascularization, activating the complement and coagulation cascades and leading to 
hyperacute rejection and transplant loss from graft infarction (Baldwin WM 3rd et al., 2001). 
Figure 19. Mechanisms of antibody-mediated graft damage (Rocha PN et al., 2003). 
ADCC: antibody-dependent cell-mediated cytotoxicity; MCP-1: monocyte chemotactic protein-1; 
vWF: von Willebrand factor. 
In conclusion, there are many distinct effector pathways that can by themselves lead to the 
same outcome, namely allograft rejection. One consequence of this redundancy of the 
alloimmune effector response may be the difficulty to set up a reliable in vitro assay that may 
help to monitor the tolerance state of allograft recipients. 
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2.5.7. Types of allograft rejection 
The following discussion will be focused on what happens in the context of renal 
transplantation since our study considered almost exclusively renal transplant recipients. On a 
temporal point of view, one can distinguish three different types of allograft rejection: 
hyperacute, acute, and chronic rejection. The past two decades have seen 1-year renal 
allograft survival increase from 50% to nearly 90% in cadaveric donors and 95% in living 
related donors (Cecka JM, 2002), this increase being largely due to the use of calcineurin 
inhibitor (CNI)-based immunosuppression (Starzl TE et al., 1981), the better treatment of 
acute rejection episodes, and the improvement in tissue typing and organ preservation 
techniques. However, 10-year survival rates fall dramatically to 51% and 68% respectively, of 
which 50-80% are attributable to chronic rejection. 
2.5.7.1. Hyperacute rejection 
As mentioned earlier, hyperacute rejection (HAR) is the consequence of the presence of large 
quantities of preformed circulating alloantibodies against ABO or MHC proteins that bind 
these antigens on graft endothelial cells and activate the classic complement pathway. The 
actions of complement and inflammatory mediators transform the endothelium from a 
protective barrier between the blood and extravascular tissues into a procoagulant, 
chemoattractive and adhesive interface that promotes inflammation. Once endothelial cells are 
damaged, the underlying matrix is exposed, activating the extrinsic coagulation pathway. The 
end result of these processes is widespread intravascular thrombosis, haemorrhage and tissue 
injury. Pathological examination reveals obstruction of small vessels by platelet thrombi, 
interstitial haemorrhage and severe injury to endothelial cells, with immunoglobulin and 
complement deposits. HAR remains a major barrier to xenotransplantation. Given the lack of 
effective treatment, it almost invariably leads to allograft loss within minutes to few hours 
after transplantation, at least in the case of renal transplantation, since heart and liver 
transplants seem relatively resistant to HAR. However, thanks to the advent in blood typing 
and T cell cross-match testing, hyperacute rejection has become a very rare event in the 
clinical practice. 
2.5.7.2. Acute rejection 
The precise pathogenesis of acute rejection (AR) is still controversial. It was historically 
considered as a pure cell-mediated process, since experiments had shown that mice lacking T 
cells were unable to reject fully mismatched allografts and that reconstitution of these mice 
with T cells restored the rejection process (Mombaerts P et al., 1992). However, it is now 
clear that acute rejection may also be antibody-mediated and represents a distinct 
clinicopathologic entity (Colvin RB, 2007). The gold standard for diagnosis of acute rejection 
(cellular or humoral) remains the histopathologic examination of a renal allograft biopsy 
(90% sensitivity). Standardization of interpretation of rejection-related histopathology has 
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evolved over the past decade, primarily due to the introduction of the Banff criteria in 1993 
(Solez K et al., 1993), which were regularly revised since then [see Appendix I for the latest 
update (Solez K et al., 2007)]. Acute rejection may occur days, weeks, or even years after 
transplantation. 
2.5.7.2.1. Acute T cell-mediated rejection 
Clinically, patients with acute T cell-mediated rejection (TCMR) present with a sudden rise in 
serum creatinine, fluid retention, and sometimes fever and graft tenderness. With current 
induction regimens and immunosuppressive therapies (both largely directed at T cells), 
TCMR incidence has dropped to 5-10% in the first year after renal transplantation in 
unsensitized patients. On pathological examination, it is manifested by a massive infiltration 
of mononuclear cells, essentially T cells, in the interstitium, tubules ("tubulitis") and 
sometimes arteries ("endarteritis") [Figure 20]. 
Figure 20. Pathological 
examination of a renal 
biopsy with acute 
T cell-mediated rejection 
(Cornell LD et al., 2008). 
Multiple mononuclear 
cells infiltrate the tubules 
("tubulitis", arrow). 
Both tubulitis and endarteritis lesions are T cell-dependent and may occur in the absence of B 
cells and alloantibodies (Jabs WJ et al., 2003; Russell PS et al., 1997). During acute rejection, 
a variety of chemokines are produced in the graft, including CxCL10, CCL2, CCL3, CCL4, 
CCL5 and lymphotactin (Segerer S et al., 2001). Tubules are also a source of chemokines 
CCL2, CCL3, CCL4, CCL5, CxCL8 (IL-8) and Cx3CL1, and cytokines TNF, TGF and 
IL-6 (Robertson H et al., 2000; Cockwell P et al., 2002; Ali S et al., 2005; Al-Lamki RS et 
al., 2001). 
2.5.7.2.2. Acute antibody-mediated rejection 
Acute humoral rejection (AHR) accounts for approximately 25% of all acute rejection 
episodes, but may be mixed with a component of T cell-mediated rejection. Risk factors for 
developing AHR include presensitization (i.e., presence of anti-donor HLA antibodies before 
transplantation) and decreased immunosuppression (e.g., due to non-compliance). Besides 
HLA molecules, other proteins can serve as targets if expressed on graft endothelial cells, 
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including ABO blood group antigens, putative endothelial alloantigens (Collins AB et al.,
2006) and even auto-antibodies (e.g., those to angiotensin II type 1 receptors (Dragun D et al.,
2005)). Like patients with TCMR, those with AHR present with an abrupt rise in serum 
creatinine. A renal biopsy is required to distinguish both entities. Pathologically, the kidney 
usually shows an accumulation of neutrophils and monocytes in peritubular and glomerular 
capillaries (Tinckam KJ et al., 2005; Fahim T et al., 2007). Recognition of AHR has become 
easier with the advent of C4d staining (Feucht HE et al., 1993), an inactive fragment of C4b 
of the classic complement pathway [Figure 21]. 
Figure 21. Pathological 
examination of a renal 
biopsy with acute 
antibody-mediated 
rejection (Cornell LD et al.,
2008). 
Peritubular capillaries show 
margination of neutrophils. 
C4d is detected in these 
capillaries by immuno-
fluorescence (inset). 
C4d per se has no known functional role, but remains bound in the tissue for several days 
after immunoglobulin and C1 have been released. C4d deposits in the majority of the 
peritubular capillaries as an intense ring pattern, detectable using immunofluorescence 
microscopy (Regele H et al., 2002). Circulating donor-specific alloantibodies (DSAs; to 
donor HLA class I or II antigens) are present in 88-95% of the patients who have C4d 
deposition (Colvin RB, 2007). However, AHR can occur in the absence of demonstrable 
circulating antibodies, which is probably due to the absorption of alloantibodies by the graft 
(Martin L et al., 2005). 
2.5.7.3. Chronic rejection 
Clinically, chronic rejection (CR) manifests as a progressive deterioration in renal function, 
usually associated with hypertension and proteinuria, in the absence of another specific 
pathology. It is the most important cause of renal graft failure after the first year following 
transplantation. At five years, CR affects 30% to 40% of renal transplants, whilst it generally 
admitted that at 10 years more than 50% of kidney transplant recipients suffer from CR. The 
diagnosis of CR is made purely upon histological findings. It may occur by cellular or 
humoral mechanisms, or both. Chronic changes can be seen in the glomeruli, vessels, tubules, 
and interstitium. Histological features of chronic rejection include transplant glomerulopathy, 
peritubular capillaropathy, transplant arteriopathy, and, less specifically, interstitial fibrosis 
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and tubular atrophy. The pathogenesis of CR depends on multiple immunological as well as 
non-immunological factors. 
Immunological factors that contribute to the development of CR include acute rejection 
episodes, especially those arising more than three months after transplantation (Nankivell BJ 
et al., 2001). In addition, there is increasing evidence that subclinical rejection, defined as 
histologically proven acute rejection in the absence of functional graft deterioration, is an 
important factor in predicting the subsequent development of CR (Veronese FV et al., 2004). 
HLA mismatching (Kasiske BL, 1997) as well as presensitization and production of anti-HLA 
antibodies after transplantation (Davenport A et al., 1994) correlate both with increased risk 
of CR. In this regard, detection of C4d deposits in peritubular capillaries may be a useful 
diagnostic marker (Mauiyyedi S et al., 2001). 
Non-immunological risk factors for CR development include delayed-graft function (DGF; 
Cosio FG et al., 1997), ischemic-reperfusion injury (Szabo A and Heemann U, 1998), 
increasing donor age (Halloran PF et al., 1999), cytomegalovirus (CMV) infection (Humar A 
et al., 1999), cadaveric donor with brain death (Koo DD et al., 1999), toxicity of CNIs 
(cyclosporine or tacrolimus; Nankivell BJ et al., 2004), and donor/recipient comorbidities 
such as hypertension and hypercholesterolemia (Paul LC and Benediktsson H, 1995; 
Fernandez-Miranda C et al., 1997). 
Although the risk factors are well recognized, the precise pathogenesis of CR remains 
incompletely understood. Both immunological and non-immunological factors seem to result 
in activation of the transplant vascular endothelium, which sets in motion a cascade of events 
leading to vascular dysfunction, and, ultimately, organ dysfunction. These events include 
induction of a procoagulant state, release of proinflammatory cytokines, expression of 
adhesion molecules, leucocyte activation, vasoconstriction, and capillary leakage 
(Karimova A and Pinsky DJ, 2001). The efflux of proinflammatory cytokines enhances the 
migration and localization of neutrophils, monocytes, macrophages and T lymphocytes to the 
site of endothelial injury. Additionally, there is increased expression of adhesion molecules 
(E-selectin, ICAM-1, VCAM-1) and of MHC class I and II molecules (Fuggle SV et al.,
1993). Experimental models have shown the importance of macrophages and T cells in the 
generation of fibrosis in CR (Pilmore HL et al., 2000). There is some evidence that the nature 
of infiltrating T cells (TH1 or TH2) may contribute to the progression of CR; unfortunately, at 
present, there is contradictory evidence as which subset is associated with the generation of 
CR or which is protective (Uboldi de Capei M et al., 2004; Nocera A et al., 2004). 
Macrophages secrete a wide range of profibrotic cytokines (TNF, IL-1, PDGF, bFGF, 
TGF) and matrix proteins, resulting in the characteristic accumulation of extracellular matrix 
seen in CR. One putative mechanism of fibrosis is by epithelial-mesenchymal transition 
(EMT) of tubular cells to an activated myofibroblast that migrates into the interstitium 
(Robertson H et al., 2004). 
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Despite a better understanding of the physiopathology of CR, there are to date no known drug 
regimens that inhibit or reverse its progression. Efforts should be made to prevent CR, with 
measures directed to the controllable risk factors such as presensitization and HLA 
histocompatibility. But efforts should also be made to detect subclinical rejection and 
insufficient immunosuppression beyond the early phase after transplantation, since 
sub-detectable immune activation is for sure the major immunological cause of CR. Detection 
strategies should be able to identify and predict immunological events prior to the 
manifestation of clinical parameters indicating graft failure. The available methods of immune 
monitoring as well as the future directions will be briefly discussed in the next section. 
2.5.8. Tools for immune monitoring 
A major challenge in the follow-up of transplant recipients is in the adequate "tuning" of the 
patients' immune function. The anti-allograft immune response must be suppressed in order to 
prevent the occurrence of rejection; on the other hand, over-immunosuppression is associated 
with undesirable side effects, such as opportunistic infections and development of 
malignancies, and must be avoided. 
In order to be useful, the candidate tests need to be accurate, specific and widely adoptable 
with a rapidity of data interpretation. To fulfill these criteria, they need to be tested in large 
patient cohorts, over adequate observation periods and over a range of disease severities and 
types. Ideally, they should be detectable in a noninvasive manner, for example in the blood or 
urine in the case of renal transplantation. 
To date, the most obvious but most basic tests are measurement of serum creatinine, 
creatinine clearance and proteinuria, that are used to monitor graft function. However, both 
are biomarkers of clinical function and cannot provide specific information concerning the 
state of the recipient's immune system. Indeed, histological biomarkers of graft biopsies 
according to the Banff classification system are currently the gold standard for diagnosing the 
status of organ transplants, indirectly reflecting immune reactivity towards the organ 
transplant (Rush D, 2006). Protocol biopsies (and treatment of subclinical acute rejection 
episodes with corticosteroids when indicated) have been shown to lead to better outcome 
(Shishido S et al., 2003). Nevertheless, the invasive (and therefore risky) and expensive 
nature of biopsies are major constraints to their repetitive use as would be required for 
immune monitoring. Currently, the measurement of immunosuppressive drugs levels in blood 
is the sole method to monitor transplant immunosuppression. However, it has become clear 
that even strict compliance to prescribed dosage and drug therapeutic window levels prevent 
neither over-immunosuppression nor under-immunosuppression and their associated side 
effects. The analysis of circulating anti-HLA antibodies, including DSAs, by enzyme-linked 
immunosorbent assay (ELISA) and more recently by the Luminex technology, has also 
become a routine method of monitoring renal transplant recipients. Indeed, it has been shown 
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that presence of circulating anti-HLA antibodies (donor-specific or not) has a negative impact 
on graft outcome (Terasaki PI and Ozawa M, 2004; Langan LL et al., 2007). However, they 
are not highly accurate predictors of graft failure given that they can persist for years before 
any apparent deterioration of graft function (Lee PC et al., 2002), they appear late following 
transplantation (up to several years) (Hourmant M et al., 2005) and they can also be present in 
patients displaying operational tolerance (Roussey-Kesler G et al., 2006). Various cellular 
assays have been used in the past, such as the mixed leucocyte reaction (MLR) assay, 
cytotoxic T lymphocyte (CTL) assay and the limiting dilution assay (LDA). Although they 
can be informative in certain settings (Weimar W et al., 2004), they have generally proved too 
time-consuming for routine use. Subsequently, novel techniques have been developed, 
including the transvivo delayed-type hypersensitivity (DTH) test (VanBuskirk AM et al., 
2000; Xu Q et al., 2007), the enzyme-linked immunospot (ELISPOT) assay (Gebauer BS et
al., 2002; Hricik DE et al., 2003; Poggio ED et al., 2004), and blood phenotyping by 
multicolor flow cytometry and intracellular staining of cytokines (Martínez-Llordella M et al.,
2007; Louis S et al., 2006), among others. Their respective principles, advantages and 
disadvantages are listed in Table 1 (adapted from Hernandez-Fuentes MP et al., 2003, and 
Ashton-Chess J et al., 2009). 
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Assay Technique / detection Advantages Disadvantages 
MLR assay Bulk proliferation of 
recipient cells stimulated 
by donor cells, measured 
by 3H-thymidine 
incorporation 
Direct alloreactivity Low sensitivity,  
little reproducibility,  
little predictive value 
(Segall M et al., 1996) 
CTL assay Cytolytic activity of in 
vivo primed recipient T 
cells, measured by 51Cr 
release 
Reproducibility, large 
experience in the clinical 
setting 
Assessment of CD8 T 
cell activity only,  
long incubation period, 
use of radioactivity 
LDA Number of responding 
cells in a given 
population 
Measures function and 
frequency 
Requires in vitro
expansion,  
labor intensive, 
mathematically 
complex 
DTH assay Index of reactivity of 
T cells to antigens, 
measured by 
quantification of resultant 
swelling in mouse 
footpad 
Direct and indirect 
alloreactivity, uncover 
regulation, only assay 
used to study tolerant 
patients 
Requires mice, 
cumbersome,  
large numbers of cells 
required, measurement 
of swelling subjective 
ELISPOT 
assay 
Frequency of 
effector/memory T cells, 
measured by detection of 
cytokine production 
High sensitivity, 
relatively easy to use, 
measures frequency and 
function, short in vitro
culture 
Counting of cells/spots 
somewhat subjective 
Flow 
cytometry 
Frequency of specific 
cells, detected by flow 
cytometry 
Phenotype and function 
of cells, easy to perform, 
requires very few cells, 
multiparametric staining 
possible 
Limited sensitivity,  
limited experience in 
clinical transplantation 
Table 1. Comparison of cellular assays for immunological monitoring (adapted from Hernandez-Fuentes MP 
et al., 2003, and Ashton-Chess J et al., 2008). 
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Furthermore, there is a real expectation that these tests may be used to identify tolerance as 
much as to predict rejection. In some cases, the identification of immunological tolerance 
would allow the partial or even complete cessation of immunosuppression, a highly desirable 
goal, given the morbidity and mortality associated with long-term administration of these 
drugs. However, given the complexity and the redundancy of the immune system, multiple 
mechanisms may contribute to tolerance, and these mechanisms may change over time and 
differ depending on the tissues involved. Therefore, it is likely that a battery of tests is needed 
to define the phenotype of tolerance and/or its absence. In the next section, we will review the 
current state of knowledge in the field of tolerance in solid organ transplantation. 
2.5.9. Tolerance in solid organ transplantation 
In the context of solid organ transplantation, "tolerance" can be defined as a state of 
antigen-specific unresponsiveness that is sustained in the absence of chronic 
immunosuppression. Indeed, it is the ultimate goal in transplantation to be able to get rid of 
lifelong immunosuppression and its associated complications such as increased susceptibility 
to infections, development of tumors, and cardiovascular and metabolic complications. As 
soon as in 1953, Billingham, Brent and Medawar conceptualized transplantation tolerance and 
proved it is possible in laboratory animals (Billingham RE et al., 1953). Since then, numbers 
of publications have demonstrated that tolerance to allografts can be induced in experimental 
animal models and in human adult recipients, mainly by exploiting the natural mechanisms 
that maintain immune homeostasis and tolerance to self-antigens. It is now well recognized 
that immunological tolerance involves central as well as peripheral mechanisms. 
Central tolerance is achieved in the thymus during the process of negative selection: 
thymocytes that react with a too high avidity with self-antigens are deleted by apoptosis 
(clonal deletion). This mechanism has been exploited by the delivery of donor antigens to the 
thymus of adult recipients leading to the intrathymic elimination of harmful alloreactive T cell 
clones. The delivery of donor antigens to the thymus can be achieved either experimentally by 
the intrathymic injection of donor-derived peptides (Markmann JF et al., 1993) or by the 
induction in the recipient of hematopoietic mixed chimerism with co-existence of cells of 
both recipient and donor origin (Ildstad ST and Sachs DH, 1984; Sayegh MH et al., 1991). 
Peripheral tolerance is indispensable to control the few autoreactive cells that escape the 
negative selection process, as well as the autoreactive cells specific for self-antigens that are 
not expressed in the thymus. Peripheral tolerance includes schematically four distinct 
mechanisms: immunological ignorance, anergy induction, apoptosis/deletion, and active 
regulation. 
Immunological ignorance is an uncommon mechanism of tolerance, but can be achieved 
either because the target antigens are present in too low concentration to trigger an immune 
response, or because they are sequestrated in locations which are not freely exposed to the 
2. INTRODUCTION 
46 
surveillance of the immune system (so-called "immunologically privileged sites", such as the 
eye, the central nervous system and the testis). In the context of transplantation, it is difficult 
to introduce donor cells or tissue without alerting the recipient immune system to their 
presence; however, attempts have been made in this direction by encapsulating cells such as 
islets of Langerhans before implantation (O'Shea GM and Sun AM, 1986). 
T cells can be made non-responsive (anergic) to presented antigens if the T cell engages an 
MHC molecule without co-stimulatory molecules. Anergy will occur if there is no acute 
inflammation, leading to no co-stimulatory molecules upregulation due to the low 
concentration of cytokines. It has been described both in vitro and in vivo. Some forms of 
T cell anergy may also result in the development of regulatory activity (Lombardi G et al., 
1994). In the context of transplantation, T cell anergy can be achieved by blockade of 
costimulatory signals (Sayegh MH and Turka LA, 1998). Various costimulatory molecules 
have been targeted in rodent models; the most successful results were obtained with the 
CD154:CD40 pathway blockade using an anti-CD40L monoclonal antibody (Graca L et al.,
2000). Unfortunately, the humanized anti-CD40L antibody did not meet the expectations in 
transplant recipients (Kawai T et al., 2000). Another promising target is the CD28:CD80/86 
pathway. Excellent results have been obtained with CTLA-4Ig, a fusion protein with 
specificity to CD80/86 expressed on APCs (Judge TA et al., 1999). A modified compound, 
LEA29Y (balatacept), was tested in phase II clinical trials in kidney transplant recipients, and 
was shown to be as effective as cyclosporine A (Vincenti F et al., 2005), although it did not 
induce transplantation tolerance. 
Apoptosis or deletion of T cells occurs either passively by deprivation of growth factors, such 
as IL-2, IL-4, IL-9, IL-15 and IL-21, which do no longer stimulate the expression of 
anti-apoptotic genes (Bcl-2, Bcl-xl), or actively by activation-induced cell death (AICD) 
when IL-2 binds its receptor and stimulate the expression of the death ligand FasL. The 
importance of apoptosis in tolerance induction has been demonstrated in transgenic mice 
expressing constitutively the anti-apoptotic molecule Bcl-xl in T lymphocytes, as well as in 
IL-2-deficient mice; in both mice strains, T cells were shown to be resistant to apoptosis, and 
tolerance could not be achieved (Wells AD et al., 1999). 
Finally, immunoregulation is an active process, whereby one population of cells controls or 
regulates the activity of another population. Various populations of leucocytes have been 
described as having the ability to control immune responsiveness to alloantigen stimulation in 
both the innate and adaptive immunity, among others CD4+ CD25+ regulatory T cells 
(Hall BM et al., 1990; Hara M et al., 2001), in vitro induced Tr1 cells (Groux H et al., 1997), 
TGF-producing TH3 cells (Faria AM and Weiner HL, 2005), CD8+ CD28- cells (Chang CC 
et al., 2002), CD3+ CD4- CD8- T cells (Zhang ZX et al., 2000), and innate NKT cells 
(Kronenberg M, 2005). The involvement of regulatory T cells in transplantation tolerance was 
formally established in 1990 by Hall BM et al. in adoptive transfer studies in rats where 
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transplantation tolerance could be achieved with cyclosporine A. Subsequently, it was 
established that the suppression was mediated by CD4+ T cells and that regulation could 
spread to, and recruit, further naïve cohorts of T cells over time as long as donor antigen 
remained in the system (so-called "infectious tolerance"), allowing the suppression to be 
sustained life-long (Qin S et al., 1993). Another important phenomenon in transplantation 
tolerance is the so-called phenomenon of "linked suppression»: strain A recipients tolerating 
grafts from strain B show a capacity to accept grafts from (BxC)F1 donors; in time, some 
animals accepting (BxC)F1 grafts become tolerant of C. This demonstrates that once 
regulators have been induced to a limited set of alloantigens, they can spread tolerance to 
other antigens in the same tissue (Davies JD et al., 1996). Treg cells can be found inside the 
tolerized graft (Graca L et al., 2002), and these cells can have indirect allospecificity for 
donor antigens (Hara M et al., 2001). In patients transplanted with lung (Meloni F et al., 
2004), liver (Demirkiran A et al., 2006), or kidney grafts (Salama AD et al., 2003), a positive 
correlation between graft survival and the number of circulating Treg cells has been shown. 
Based on all these observations, it is now widely accepted that Treg cells play a pivotal role 
for the induction of transplantation tolerance in rodents as well as in human beings. Therefore, 
this has led to an increasing interest in the possibility of using Treg cells as a biological 
therapy to induce tolerance to alloantigens. Several immunotherapeutic strategies implicating 
the use of Treg cells have been developed, some of which being already tested in human 
clinical trials. 
2.5.10. Potential therapeutic use of regulatory T cells in 
transplantation 
Experimental studies in the past and in recent years have demonstrated the proof-of-principle 
that the adoptive transfer of Treg cells isolated from animals subject to different tolerizing 
protocols (costimulation blockade, donor-specific transfusion, CD4 T cell depleting or 
nondepleting antibodies) can prolong allograft survival in different transplantation models 
(reviewed by Kang SM et al., 2007). The advantages of Treg-based immunotherapy over 
conventional treatments are numerous, including the potential for antigen specificity with the 
lack of general immunosuppression, the possibility of inducing physiological long-lasting 
regulation in vivo, and the fact that the Treg-based immunotherapy can be individualized for 
each patient, with very limited side effects. 
In mice, adoptive transfer of freshly isolated Treg cells together with a bone marrow allograft 
has been shown to ameliorate graft-versus-host disease (GVHD) and facilitate engraftment of 
the bone marrow (Joffre O et al., 2004). The same results were obtained with adoptive 
transfer of ex vivo polyclonally expanded donor Treg cells (Hoffmann P et al., 2002). Thanks 
to these promising results generated in animal models and to the lack of antigen-specific 
requirement for the transferred Treg cells, bone marrow transplantation is the setting for the 
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first human clinical trial, either with ex vivo generated Treg cells (group of B. Blazar and 
C. June, University of Minnesota, USA; unpublished data), or with freshly isolated 
unmanipulated Treg cells (group of M. Edinger, Regensburg, Germany; unpublished data). 
Another approach using Tr1 cells generated ex vivo upon stimulation with alloantigens in the 
presence of IL-10 and TGF has been shown to be effective in reducing the incidence of 
GVHD after bone marrow transplantation (Zeller JC et al., 1999). Again, this has led to the 
initiation of a clinical trial in humans (group of M.-G. Roncarolo, San Raffaele Scientific 
Institute, Milan, Italy; unpublished data). 
In contrast to what has been reported in GVHD, there are to date no reports showing that the 
transfer of freshly isolated Treg cells can prevent the rejection of allogeneic solid organ 
transplantation. Several studies have demonstrated that Treg cells generated in vivo in 
transplanted animals by various approaches (such as by treatment with vitamin D3 and 
mycophenolate mofetil (Gregori S et al., 2001)) do transfer tolerance in secondary transplant 
recipients. It is likely that the lack of data proving efficacy after transfer of freshly isolated 
Treg cells may be due to unreported unsuccessful experiments and to the requirement of 
antigen-specific Treg cells for protection (Lee MK 4th et al., 2004). On the other hand, it has 
been shown that Tr1 cells generated in vivo, in mice transplanted with allogeneic pancreatic 
islets and treated with rapamycin and IL-10, transfer antigen-specific tolerance to secondary 
transplant recipients (Battaglia M et al., Diabetes, 2006). However, at present, the lack of data 
clearly showing that transferred Treg cells protect from allograft rejection in several 
preclinical animal models represents a major hurdle to the use of Treg-based immunotherapy 
in solid organ transplantation in humans. 
Despite these encouraging results, it is necessary to continue research in the field of detection 
of immunological "tolerance signature", in order to detect operational tolerance and to adapt 
immunosuppressive therapies to individual characteristics, as well as in the field of induction 
regimens and maintenance immunosuppressive drugs, in order to understand their effects on 
survival and proliferation of immune cells, including Treg cells. 
2.5.11. Immunosuppressive agents 
Immunosuppressive agents are used for induction (intense immunosuppression in the initial 
days after transplantation), maintenance, and reversal of established rejection. 
Immunosuppression can be achieved by depleting lymphocytes, diverting lymphocyte traffic, 
or blocking lymphocyte response pathways [Figure 22].  
Immunosuppression has three effects: the therapeutic effect of suppressing rejection, the 
undesired consequences of immunodeficiency, with development of malignancies and 
infections, and the nonimmune toxicity to other tissues. Immunodeficiency leads to 
characteristic infections, such as cytomegalovirus (CMV), Epstein-Barr virus (EBV) and BK 
polyomavirus infections, and cancers, such as post-transplantation lymphoproliferative 
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disease (PTLD), which are directly correlated with the intensity of immunosuppression. 
Nonimmune toxicity is agent-specific and is often related to the mechanism that is used, 
because each agent or class of drugs targets molecules with physiologic roles in nonimmune 
tissues. 
Immunosuppressive drugs can be classified into small-molecule drugs, depleting and 
nondepleting protein drugs (polyclonal and monoclonal antibodies), fusion proteins, 
intravenous immune globulins (IVIg), and corticosteroids [Table 2]. 
Figure 22. Individual immunosuppressive drugs and sites of action in the three-signal model of 
alloimmune response (Halloran PF, 2004). 
MPA: mycophenolic acid (active principle of MMF); FTY720: fingolimod. 
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Small-molecule drugs 
Immunophilin-binding drugs 
Calcineurin inhibitors 
Cyclophilin binding drugs: cyclosporine A (Sandimmun®)
FKBP12-binding drugs: tacrolimus (Prograf®)
mTOR inhibitors: sirolimus (Rapamune®), everolimus (Certican®)
Inhibitors of nucleotide synthesis 
Purine synthesis inhibitors: mycophenolate mofetil (CellCept®, Myfortic®)
Antimetabolites: azathioprine (Imurek®)
Sphingosine-1-phosphate-receptor antagonists: FTY720 (fingolimod)
Protein drugs 
Depleting antibodies (against T cells, B cells, or both) 
Polyclonal antibody: horse or rabbit antithymocyte globulin (Atgam® resp. 
Thymoglobulin®, ATG-Fresenius®)
Mouse monoclonal anti-CD3 antibody (muromonab-CD3; Orthoclone OKT® 3) 
Humanized monoclonal anti-CD52 antibody (alemtuzumab; MabCampath®)
B-cell-depleting monoclonal anti-CD20 antibody (rituximab; MabThera®)
Nondepleting antibodies and fusion proteins 
Humanized or chimeric monoclonal anti-CD25 antibody (daclizumab resp. 
basiliximab; Zenapax® resp. Simulect®)
Fusion protein with natural binding properties: CTLA-4Ig (LEA29Y, i.e. 
belatacept) 
Intravenous immune globulins 
Corticosteroids (prednisone, prednisolone, methylprednisolone)
Table 2. Classification of immunosuppressive agents used in solid organ transplantation (adapted 
from Halloran PF, 2004). 
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2.5.11.1. Small-molecule drugs 
Most small-molecule immunosuppressive agents are derived from microbial products and 
target proteins that have been highly conserved in evolution.  
Azathioprine (aza) was the first immunosuppressive agent to achieve widespread use in organ 
transplantation. It is thought to act by releasing 6-mercaptopurine, which interferes with DNA 
synthesis. Since the introduction of cyclosporine A and mycophenolate mofetil, azathioprine 
has become a second-line drug. 
Cyclosporine A (CsA) is in effect a prodrug that engages cyclophilin, an intracellular protein, 
forming a complex that then engages calcineurin (Clipstone NA and Crabtree GR, 1992). 
Calcineurin is normally implicated in the transduction of the signaling pathways in T cells 
upon MHC/TCR interaction. Its engagement by CsA inhibits the transcription of specific 
transcription factors implicated in T cell activation, such as NFAT. CsA was the first 
immunosuppressant to target T cells without inducing myelotoxicity, inflammation, or 
immune cell depletion, and the use of CsA led to a significant increase in graft and patient 
survival rates (Kahan BD, 1989; Calne R, 2004). 
Tacrolimus (TAC) uses a similar mechanism of action. It engages another immunophilin, 
FK506-binding protein 12 (FKBP12), to create a complex that inhibits calcineurin with 
greater potency than does CsA. Recent analyses have not shown a better efficacy of TAC over 
CsA in terms of rejection prevention (Woodward RS et al., 2005). However, TAC is less 
likely to cause hyperlipidemia, hypertension and cosmetic problems, but more likely to induce 
post-transplantation diabetes (Vincenti F et al., 2007). The use of TAC has increased steadily, 
and it is now the dominant CNI. 
Few in vitro studies have described the effect of CNIs on Treg cells. However, it was shown 
that the induction of FoxP3 mRNA was inhibited in MLR assay (Baan CC et al., 2005); this 
observation was subsequently confirmed at the protein level (Zeiser R et al., 2006). In vivo,
treatment of mice with CsA was shown to compromise the thymic output of Treg cells, 
resulting in a sharp decrease of Treg cells in peripheral immune compartments (Coenen JJ et 
al., 2007). Together, these data suggest that CNIs are rather detrimental to the generation, 
survival and function of Treg cells. 
Mycophenolate mofetil (MMF) is a prodrug that releases mycophenolic acid (MPA), which 
inhibits inosine monophosphate dehydrogenase, a key enzyme in purine synthesis. It was 
shown to be superior to azathioprine in preventing rejection of kidney transplants 
(Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, 1996). This drug 
has largely replaced azathioprine and is widely used in combination with other 
immunosuppressive agents, because it is simple to use (no monitoring required) and free from 
organ toxicity and cardiovascular risk. Only one study described the in vitro effect of MMF 
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on Treg cells, showing that this drug did not affect the expression of FoxP3 or the suppressive 
capacity of these cells (Zeiser R et al., 2006). 
Sirolimus and everolimus are both target-of-rapamycin (mTOR) inhibitors engaging FKBP12 
to create complexes that inhibit mTOR but cannot inhibit calcineurin. These drugs block the 
signal 3 of the alloimmune response model by preventing cytokine receptors from activating 
the cell cycle. In addition, mTOR inhibitors are associated with antiproliferative actions 
(Chapman JR et al., 2007). Reported side effects include hyperlipidemia, thrombocytopenia, 
impaired wound healing, aggravation of proteinuria, mouth ulcers and skin lesions. 
Furthermore, sirolimus cannot be used in combination with CsA because it increases its 
nephrotoxicity (Cheng CH et al., 2008). Experimental in vitro evidences show that mTOR 
inhibitors do not interfere with the suppressive activity of Treg cells (Game DS et al., 2005; 
Coenen JJ et al., 2006), by contrast to CNIs. In vivo, mTOR inhibitors were shown to induce 
de novo expression of FoxP3 in murine alloantigen-specific T cells, in a TGF1-dependent 
manner (Gao W et al., 2007). Also Treg cells expanded ex vivo in the presence of sirolimus 
were able to prevent rejection of -islet transplants in mice (Battaglia M et al., 2005). These 
results clearly show that mTOR inhibitors favor Treg cells survival and function, maybe 
tipping the balance from an aggressive towards a more protective type of alloimmune 
response. 
FTY720 (fingolimod) engages lymphocyte sphingosine-1-phosphate receptors after 
phosphorylation and acts primarily by confining lymphocytes within peripheral lymphoid 
organs, rendering them incapable of migrating to the sites of inflammation, such as the graft. 
FTY720 is still under clinical trial in solid organ transplantation (Mansoor M and 
Melendez AJ, 2008) as well as in multiple sclerosis, although it seems to be associated with 
more adverse events compared with current standard immunosuppressive regimens 
(Tedesco-Silva H et al., 2005). 
2.5.11.2. Depleting antibodies 
Polyclonal antithymocyte globulins (ATGs) are produced by immunizing horses or rabbits 
with human lymphoid cells, harvesting the IgG, and absorbing out toxic antibodies, such as 
those against platelets and erythrocytes. The obtained antibodies block several T cell 
surface-associated proteins (such as CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, 
CD45, HLA-DR, HLA class I and 2-microglobulin), causing altered function, lysis, and 
prolonged T cell depletion that lasts beyond one year (Brennan DC et al., 1999). Rabbit 
preparations are favored over horse polyclonal ATGs because of greater potency. Initially 
approved for the treatment of corticosteroid-resistant acute cellular rejection, polyclonal 
ATGs are also used as induction agents, usually for 3 to 10 days after transplantation, in high 
immunological risk recipients (pre-sensitized, high donor/recipient MHC mismatches, 
Africans Americans). It has been suggested that these agents may favor the development of 
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transplantation tolerance. Indeed, in vitro treatment of human CD4 T cells by thymoglobulin 
induces the upregulation of Treg-associated genes and proteins such as CD25, CTLA-4, 
OX40 and FoxP3 (Liu Z et al., 2008). 
Muromonab-CD3 (OKT3) is an anti-CD3 monoclonal antibody that has been successfully 
used for more than 20 years as induction agent for patients at high immunological risk, as 
well as for the treatment of corticosteroid-resistant acute rejection episodes (Opelz G, 1995). 
However, due to its important side effects (among others the cytokine-release syndrome), 
ATGs are now usually preferred. 
Alemtuzumab is a humanized anti-CD52 monoclonal antibody that was first developed for 
use in lymphoproliferative diseases, such as refractory B cell chronic lymphocytic leukemia; 
CD52 is expressed on T cells, B cells, monocytes, macrophages, NK cells and granulocytes 
(Waldmann H and Hale G, 2005). Alemtuzumab also induces profound and durable 
lymphopenia. Used as off-label induction agent, there are only three prospective, randomized, 
but small, studies with one year or less follow-up, and most published series utilize historical 
control groups with relatively short follow-up. None demonstrated a real advantage of 
alemtuzumab over other induction agents. 
Rituximab is an anti-CD20 chimeric antibody that eliminates most B cells from the 
circulation. It has been first developed for the treatment of PTLD after solid organ 
transplantation; subsequently, rituximab has been used off-label for treatment of 
antibody-mediated rejection and for suppression of preformed alloantibodies in sensitized 
patients before transplantation (Becker YT et al., 2006). 
2.5.11.3. Nondepleting antibodies and fusion proteins 
Daclizumab (humanized) and basiliximab (chimeric) are both anti-CD25 monoclonal 
antibodies inhibiting signal 3 of the alloimmune response model. They preferentially target 
alloreactive T cells activated in the early post-transplantation period, and inhibit the 
IL-2-mediated proliferation and effector function. They are now commonly used as induction 
agents in patients at low immunological risk (Vincenti F et al., 2006). They do not cause 
significant lymphocyte depletion and have minimal toxic effects. One in vitro study showed 
inhibition of FoxP3 mRNA induction by daclizumab in allostimulated peripheral blood 
mononuclear cells (PBMC) (Baan CC et al., 2005), whilst another study demonstrated 
down-regulation of FoxP3 protein expression (Kreijveld E et al., 2007). However, in direct 
co-cultures of Treg cells and effector T cells, basiliximab did not interfere in the suppressive 
capacity of Treg cells (Game DS et al., 2005). 
Belatacept (LEA29Y) is a second-generation CTLA-4 immune globulin that is a fusion 
protein combining CTLA-4 (which engages CD80 and CD86) with the Fc portion of IgG1. It 
is currently undergoing phase III clinical trials in renal transplantation, and has shown 
promise as a safe and effective alternative immunosuppression regimen to CNIs and 
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steroid-based therapies. Phase II trials demonstrated similar efficacy to CsA, with greatly 
improved renal function. Although its side effects are not yet well characterized, belatacept 
has shown a decrease of the renal, cardiovascular, and metabolic side effects associated with 
CNIs (Vincenti F et al., 2005). Longer follow-up data have to establish whether belatacept 
can favor the induction of transplantation tolerance, as was suggested in animal models 
(Kirk AD et al., 1997). 
2.5.11.4. Intravenous immune globulins 
Intravenous immune globulins (IVIg) are commercial preparations derived from pooled 
plasma from more than 100'000 screened donors. It is likely that they contain the entire 
compilation of human antibodies. IVIg products were initially developed for treatment of 
immune deficiency disorders. More recently, they have been used in kidney transplantation
for decreasing panel reactive antibodies in highly sensitized patients (Gloor JM et al., 2003) 
and for the treatment of antibody-mediated rejection (Moger V et al., 2004). Their multiple 
mechanisms of action are the subject of various studies, but they are not entirely clear. They 
reduce alloantibodies, inhibit inflammatory cytokine production, block antibody production, 
and may inhibit complement activation. In desensitization protocols, IVIg are used either 
alone at high dose or in combination with plasmapheresis at lower dose. 
2.5.11.5. Corticosteroids 
Corticosteroids, which include prednisone, prednisolone and methylprednisolone, are 
pleiotropic hormones acting as agonists of glucocorticoids receptors. They are used fort their 
potent anti-inflammatory and immunomodulatory action. Their effects are mainly 
transcriptional through DNA-binding and protein-protein interactions of the steroid-receptors 
complex, targeting transcription factors such as AP-1 and NF-B, which are involved in 
transcription of pro-inflammatory cytokine and chemokine genes such as IL-2, TNF and 
IFN.
As discussed for the respective drugs, there are evidences that that some of the most widely 
used immunosuppressive drugs have clear and distinct effects on Treg cells, among other 
immune cell populations. However, it is not clear yet how immunosuppression affects the 
balance between regulatory (protolerogenic) and effector (pathogenic) T cells in vivo. Overall, 
the results from in vitro, animal, and clinical studies show that immunosuppressive drugs can 
have detrimental but also beneficial effects on Treg cells. Together, these data indicate that 
the use of specific immunosuppression as well as their timing and dosing have to be taken 
into account when elaborating strategies to induce and maintain transplantation tolerance. 
However, by contrast to the clear results obtained in vitro, the impact of immunosuppressive 
drugs in patients is much less clear and requires more clinical research before firm 
conclusions can be drawn. 
3. AIMS OF THE PROJECT
55 
3. AIMS OF THE PROJECT 
3.1. Characterization of CD4+ CD25+ T cells in healthy individuals 
and solid organ transplant recipients 
As emphasized in the Introduction part, there is now no doubt that CD4+ CD25+ regulatory T 
cells (Treg) can play a positive role in the acceptance of a transplanted organ, since it has 
been demonstrated that they are able to effectively suppress allograft rejection in vivo
(reviewed by Jiang S et al., 2006). However, when this project was designed five years ago, a 
lot of controversial data were published on the phenotype and functionality of Treg cells in 
human transplant patients. One limitation in the study of Treg cells, especially in humans, was 
the lack of a really specific phenotypic marker of this lineage of lymphocytes. The 
combination of CD4 and CD25, with a gating strategy on the cells positive for CD4 and 
expressing the highest level of CD25, was widely accepted as identifying the Treg population, 
by analogy with experiments made in mice. Recently, two additional markers have been 
identified that help in the isolation of the Treg population: FoxP3 and IL-7R (CD127). 
Indeed, using one or both of these markers, it was found that the majority of CD4+ CD25high T 
cells, but not all , have the typical suppressive properties of the Treg population, in healthy 
human volunteers (Seddiki N et al., 2006; Liu W et al., 2006). 
The aim of the project was to study by flow cytometry the phenotypic and functional 
characteristics of subsets of CD4+ CD25high T cells, namely regulatory T cells and activated 
T cells, in healthy humans as well as in solid organ transplant recipients. Parts of the 
following results were published in the Journal of Experimental Medicine in July 2007 
(Codarri L et al., 2007). 
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4.1. Characterization of CD4+ CD25+ T cells in healthy individuals 
Before studying CD4+ CD25+ T cells subsets in solid organ transplant recipients, it was of 
interest to analyze the control situation found in healthy donors. For this purpose, we analyzed 
the phenotype and frequency of these cells using flow cytometry, and their function by a 
mixed lymphocyte reaction (MLR) assay. 
4.1.1. Phenotype of CD4+ CD25+ T cells in healthy individuals 
The analysis of CD4+ CD25+ T cells by flow cytometry requires the use of monoclonal 
fluorescent antibodies and a thorough gating strategy. Monoclonal antibodies that we use to 
identify CD4+ CD25+ T cells and their subsets are directed against CD4, CD25, CD45RO, 
CD127 and FoxP3, among others. The first step is to gate on the lymphocyte population on a 
FSC / SSC dot plot [Figure 23]. Then, on a dot plot displaying CD4 and CD25, the CD4 
positive T cell population can be divided roughly into three distinct populations, based on the 
CD25 expression level: a CD25 negative population (CD25neg), a population expressing 
intermediate levels of CD25 (CD25int), and a population expressing the highest level of CD25 
(CD25high) [Figure 24]. 
Figure 23. FSC/SSC dot plot. 
The lymphocyte population is defined as a compact 
population of cells of relatively small size (FSC, 
forward scatter) and of weak granularity (SSC, side 
scatter). 
Figure 24. CD4/CD25 dot plot, gated on lymphocytes. 
CD4 positive T cells can be divided into three distinct 
populations based on the CD25 expression level: CD25neg,
CD25int, and CD25high.
As discussed in the Introduction part, only the CD25high population of CD4+ T cells displays 
regulatory features, and for this reason, the rest of our observations were focused on this 
subset of CD4+ T cells, that we will name CD4+ CD25high T cells. 
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In a first step to characterize the CD4+ CD25high T cells, we tested several healthy volunteers 
to see whether a correlation with the gender or the age exists. Overall, we found a mean of 
1.62% of CD25high cells within CD4+ T cells (range: 0.20-4.09%; median: 1.46%); there was 
no statistical difference between female and male healthy volunteers (females, mean: 1.45%, 
range: 0.20-2.50%; males, mean: 1.86%, range: 0.21-4.09%) [Figure 25].  
Figure 25. Percentage of CD4+ CD25high T cells in 14 male and 
19 female healthy volunteers. 
Minimal value, 25th percentile, median (—), mean (),
75th percentile and maximal value are depicted. 
It was also of interest to investigate the stability of the percentage of CD4+ CD25high T cells 
over time in healthy donors. For this purpose, we assessed the frequency of these cells in 3 
healthy subjects over a 1-year period, at 0, 1, 3, 6, and 12 months. We found that in fact the 
percentage of CD4+ CD25high T cells showed significant variations in a single individual; the 
coefficient of variation (CV) was found to be 32.2% in average (range: 19.0-50.4%) [Figure 
26A]. By contrast, the percentage of CD4+ T cells remained quite stable over the 1-year 
period, with a mean CV of 6.9% (range: 5.4-8.7%) [Figure 26B]. 
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Figure 26A. Kinetic of CD4+ CD25high T cells over a 1-year period in 3 healthy subjects. 
Figure 26B. Kinetic of CD4+ T cells over a 1-year period in 3 healthy subjects. 
4.1.2. Function of CD4+ CD25+ T cells in healthy individuals 
We also assessed the in vitro suppressive capacity of CD4+ CD25high T cells in four healthy 
volunteers. To do so, we sorted the CD4+ CD25high (regulatory cells) and CD4+ CD25neg
(responder cells) populations by flow cytometry and irradiated allogeneic PBMC (stimulator 
cells); stimulator and responder cells were put in culture either alone (positive control) or in 
the presence of regulatory cells, at a ratio of 2:1:1 respectively. The proliferation of the 
responder cells was assessed at day 7 by 3H-thymidine incorporation. The mean percentage of 
inhibition exerted by regulatory cells was calculated on the basis of triplicates, as follows: 
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We found a mean percentage of suppressive capacity of CD4+ CD25high T cells of 86.5% 
(range: 70.2-99.1%) [Figure 27], which is consistent with values reported in the literature. 
Figure 27. Suppressive capacity of CD4+ CD25high T cells in four healthy volunteers. 
The mean percentage of inhibition was 70.2% in healthy donor 1, 89.5% in healthy donor 2, 99.1% in 
healthy donor 3, and 87.2% in healthy donor 4. 
4.1.3. Definition of functionally different subsets among CD4+ CD25high
T cells 
During the past years, it has become increasingly clear that the population of CD4+ CD25high
T cells is not a homogeneous population in terms of phenotype and function. Indeed, CD25 is 
not a specific marker expressed only by regulatory T cells, but is also a marker of recent 
activation of both CD4 and CD8 T lymphocytes (Waldmann TA, 1989). For this reason, the 
identification of other markers to distinguish regulatory and recently activated T cells is 
mandatory, especially in settings of immune activation such as autoimmune inflammatory 
disorders and organ transplantation. 
As emphasized in the Introduction part, several markers have been shown to be more or less 
specific to regulatory T cells, and among them, the transcription factor FoxP3 and the 
interleukin-7 receptor  chain (IL-7R, CD127) seem to have the highest specificity. We will 
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not come back to FoxP3, which was already extensively described in the Introduction part as 
well as in the literature since its discovery in 2003 (Hori S et al., 2003; Fontenot JD et al., 
2003; Ramsdell F, 2003). On the other hand, the use of CD127 as a discriminatory marker is 
more recent, the first descriptions having been published in 2006 (Seddiki N et al., 2006; 
Liu W et al., 2006). Interestingly, at the same period (2005-2006), we were also working on 
the possible usefulness of CD127, based on a publication showing infiltration of mononuclear 
cells expressing both CD25 and CD127 in idiopathic dilated cardiomyopathy, an autoimmune 
disease (Holzinger C et al., 1995). Our observations in healthy individuals were consistent 
with the above-mentioned two publications, and we will summarize them below. 
4.1.3.1. Phenotype 
Using CD127 staining, in addition to CD4 and CD25, permits to reveal two well-defined 
populations, a CD127low one and a CD127high one, among CD4+ CD25high T cells. In addition, 
we found it helpful to add a fourth marker, CD45RO, which is expressed on cells with a 
memory phenotype: it permits to discriminate between naïve and memory regulatory T cells, 
and is useful for defining populations in sorting experiments. The first step in the gating 
strategy is to gate on CD4+ CD25high T cells and then to display a dot plot CD127 / CD45RO: 
three distinct populations can then be clearly identified [Figure 28]. 
Figure 28. CD127 / CD45RO dot plot, gated on CD4+ CD25high
T cells, of one representative healthy volunteer. 
We performed these analyses in 73 healthy donors. Overall, the vast majority of CD4+
CD25high T cells were found to be CD127low (mean ± std deviation: 91.55 ± 4.37%), whilst the 
CD127high population represented only 8.45% of CD4+ CD25high T cells. When using 
CD45RO as an additional marker, the CD45RO+ CD127low sub-population represented 
74.93% of CD4+ CD25high T cells, the CD45RO- CD127low sub-population 16.62%, and the 
CD45RO+ CD127high sub-population 5.97% [Figure 29]. 
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4.1.3.2. Function 
It was important to confirm the respective function of these subsets, and for this purpose we 
assessed the in vitro suppressive capacity of the CD45RO+ CD127low and CD45RO+
CD127high sorted CD4+ CD25high sub populations, as described elsewhere. This assay using 
thymidine incorporation as read-out showed that only the CD127low sub-population was able 
to mediate in vitro suppression (mean percentage of inhibition: 86.2%), whilst the presence of 
the CD127high sub-population did not affect the proliferation of the responder cells 
[Figure 30]. This result confirms that the regulatory T cells are contained within the 
CD127low sub-population of CD4+ CD25high CD45RO+ T cells and that CD127 can be safely 
used as a discrimination marker to distinguish regulatory T cells from activated T cells, at 
least in healthy donors, in accordance with previously published data (Seddiki N et al., 2006; 
Liu W et al., 2006). 
Figure 30. Respective suppressive capacity of the CD127high and CD127low sub-populations of 
CD4+ CD25high CD45RO+ T cells, in one representative healthy volunteer. 
The mean percentage of inhibition was 72.2% in this representative healthy volunteer. 
CD4+ CD25high  mean ± std deviation
CD45RO+ CD127low 74.93 ± 12.10% 
CD45RO+ CD127high 5.97 ± 3.11% 
CD45RO- CD127low 16.62 ± 10.96% 
CD45RO- CD127high 2.49 ± 2.32% 
Figure 29. Repartition of the four CD4+ CD25high T cell sub-populations based on the 
expression of CD45RO and CD127. 
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4.1.3.3. FoxP3 
Since the transcription factor FoxP3 is now widely accepted as a reliable marker of regulatory 
T cells, we were interested in assessing the relationship between the respective expression of 
CD127 and FoxP3 in the above-described CD4+ CD25high T cells sub-populations in healthy 
volunteers. Of note, the staining of FoxP3 requires permeabilization and fixation of the cells, 
what precludes their future use in suppression assays for example. In co-stainings with CD4, 
CD25 and FoxP3, more than 90% of FoxP3+ cells were found among CD4+ T cells 
[Figure 31A]. In CD4+ T cells, the expression level (mean fluorescence intensity, MFI) of 
FoxP3 was proportional to the one of CD25: the highest the CD25 MFI, the highest the FoxP3 
MFI; however, a significant percentage of FoxP3+ cells were found among CD25- cells 
[Figure 31B].  
Co-staining with CD127 and FoxP3, in addition to CD4, CD25 and CD45RO, confirmed an 
inverse correlation between CD127 and FoxP3 expression in CD4+ CD25high T cells (P=0.01); 
the CD127low cells were contained within the FoxP3 positive cell population, whereas 
CD127high cells were contained within the FoxP3 negative cell population [Figure 32]. 
Figure 31A. CD4 and FoxP3 staining, gated on 
lymphocytes. 
In this healthy volunteer, the CD4+ FoxP3+ T cell 
population represents 2.80% of the total lymphocytes. 
Figure 31B. CD25 and FoxP3 staining, gated on CD4+
T lymphocytes. 
FoxP3+ cells are found mainly among CD25+ CD4+
T cells. 
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Figure 32. Correlation 
between CD127 and FoxP3 
expression in CD4+ CD25high T 
cells, in 49 healthy volunteers. 
The correlation was found to 
be statistically significant 
(P=0.01).
Overall, among the 49 healthy volunteers tested, a majority of CD4+ CD25high T cells were 
FoxP3+ (mean ± std deviation: 70.86 ± 17.50%), whilst FoxP3- cells represented only 29.14% 
of CD4+ CD25high T cells. 
Collectively, these results indicate that CD127 is a valuable marker to discriminate between 
the regulatory and activated T cell sub-populations of CD4+ CD25high T cells, in healthy 
donors, and are in total accordance with the above mentioned publications (Seddiki N et al., 
2006; Liu W et al., 2006). 
4.1.4. Discussion 
Based on the results of our preliminary study on healthy volunteers, we next decided to 
perform the same kind of analyses in the clinical setting of solid organ transplantation. As 
mentioned in the Introduction part, there are evidences that regulatory T cells play a major 
role in the outcome of a graft. However, at the time we began this project, results in humans 
were quite controversial, probably due to the lack of reliable markers of regulatory T cells. 
Fortunately, as described in the healthy volunteers, new tools, such as FoxP3 and CD127, 
became available, and we decided to take advantage of them to study CD4+ CD25high T cells 
sub-populations in solid organ transplant recipients, especially liver and kidney recipients. 
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4.2. CD4+ CD25high T cells in solid organ transplant recipients 
Initial observations that regulatory CD4+ CD25high T cells play a pivotal role in 
transplantation tolerance were performed in mice: Sakaguchi S et al. showed that removal of 
CD4+ CD25high T cells from normal mice enhanced graft rejection (Sakaguchi S et al., 2001), 
and, conversely, they also showed that when regulatory CD4+ CD25high T cells enriched from 
normal syngeneic mice were inoculated, together with naïve T cells, to syngeneic T-cell-
deficient mice with allografts, the graft survival was significantly prolonged, and even 
permanent graft tolerance was established at large doses of these cells (Nishimura E et al., 
2004). Studies in human organ transplantation have investigated the number and functional 
properties of regulatory CD4+ CD25high T cells in relation to immunological quiescence 
(stable transplant recipients on immunosuppression), tolerance (stable transplant recipients off 
immunosuppression), and acute or chronic rejection. However, until recently, the obtained 
results were quite contradictory, most probably because of the lack of regulatory T cells 
specific markers. As mentioned above, FoxP3 and CD127 have been recently identified and 
became commercially available few years ago, prompting us to perform a complete study of 
the phenotype and function of CD4+ CD25high T cells and their sub-populations in solid organ 
transplant recipients. 
For this purpose, we decided to study a cohort of liver and kidney transplant recipients, 
treated at the Transplantation Centre at the Centre Hospitalier Universitaire Vaudois (CHUV) 
in Lausanne, as well as at the Divisions of Nephrology and Transplantation at the Hôpitaux 
Universitaires de Genève (HUG) in Geneva. 
Our initial results were published in the Journal of Experimental Medicine in July 2007 
(Codarri L et al., 2007); a copy of this publication is enclosed in the following pages. 
4.2.1. Expansion and tissue infiltration of an allospecific CD4+ CD25+
CD45RO+ IL-7Rhigh cell population in solid organ transplant 
recipients (J Exp Med 2007) 
In this publication, we analyzed 45 healthy subjects, 7 patients under immunosuppressive 
drugs for various autoimmune diseases, as well as a cohort of 21 liver and 26 kidney 
transplant recipients, divided in groups based on their clinical status, as follows: 
(a) 21 liver transplant recipients, who were all clinically stable, and had received a first 
cadaveric graft more than 12 months prior to the study; 
(b) 11 kidney transplant recipients, who were clinically stable (as defined by a stable 
serum creatinine < 150 mol/l, 24h-proteinuria < 0.5 g/day, no circulating anti-HLA 
antibodies), and had received a first graft (8 cadaveric, 3 living-donor) more than 12 
months prior to the study; 
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(c) 4 kidney transplant recipients, who had a biopsy-proven diagnosis of chronic humoral 
rejection (based on the criteria of the Banff'05 classification (Solez K et al., 2007), 
presence of circulating donor-specific anti-HLA antibodies, capillary C4d deposits, 
deteriorating graft function), and had received a first graft (3 cadaveric, 1 living-
donor) more than 12 months prior to the study; 
(d) 11 kidney transplant recipients, who were enrolled in a prospective study conducted at 
the HUG: they all received a first living-donor graft, an induction regimen which was 
composed of a 3-4d course of thymoglobulin (1.5mg/kg) and a long-term steroid-free 
immunosuppression which was composed of tacrolimus and mycophenolate mofetil. 
In summary, we could show that CD127 can also be used in liver and kidney transplant 
recipients as a discriminatory marker of CD4+ CD25high regulatory (CD127low) versus 
activated (CD127high) T cells. According to a previous study (Demirkiran A et al., 2005), we 
found that the percentage of the CD4+ CD25high CD45RO+ CD127low regulatory T cells was 
significantly decreased in transplant recipients as compared to healthy controls; furthermore, 
the percentage of the CD4+ CD25high CD45RO+ CD127high activated T cells was 
concomitantly increased in stable transplant recipients, and the expansion of this sub-
population was even greater among kidney transplant recipients with a biopsy-proven 
diagnosis of chronic humoral rejection. By functional experiments, we could demonstrate that 
the CD127high activated CD4+ CD25high T cell sub-population contained alloreactive T cells, 
which secreted the pro-inflammatory cytokines IFN and TNF upon polyclonal stimulation. 
Finally, we could demonstrate the presence of CD4+ CD127+ cells and of CD25+ CD127+
cells in the cellular infiltrate of renal biopsies with chronic humoral rejection. We also 
monitored prospectively the changes in these T cell populations during the first year after 
kidney transplantation; we observed that the percentage of the activated IL-7Rhigh T cell 
population increased as soon as 1 month after transplantation and remained expanded during 
the year of observation. Our results suggest that monitoring the CD4+ CD25high T cell sub-
populations could become a useful tool in the long-term follow-up of transplant recipients. 
Because the perspectives opened by these initial results were interesting, we decided to 
continue with an in-depth analysis of CD4+ CD25high T cell sub-populations, in particular of 
the activated CD127high and regulatory CD127low sub-populations, in the clinical setting of 
kidney transplantation.  
As demonstrated in our initial publication, the percentage of the activated T cell sub-
population was increased in stable transplant recipients as compared to healthy subjects, and 
this increase was even greater in kidney recipients with chronic humoral rejection. Based on 
these observations, we decided to expand our study to various clinical situations. We opted to 
include more stable transplant recipients having received various induction and 
immunosuppressive regimens, more transplant recipients with chronic renal dysfunction, and 
transplant recipients on no or minimal immunosuppression. This part of the project was felt to 
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be important to assess the actual usefulness of monitoring this parameter in the routine 
follow-up of transplant recipients. 
We were also interested in the phenotypic characteristics of these sub-populations, and in 
particular in the panel of homing receptors expressed; indeed, chemokines and their receptors 
are essential to control leucocyte migration and homing throughout the body in both 
physiological and pathological situations. In the context of the adaptive immune system, both 
chemokines and chemokine receptors orchestrate the immune response by providing the 
spatio-temporal guidance for T cell development, priming and effector functions (Viola A et 
al., 2008). In the context of renal transplantation, acute allograft rejection is characterized by 
the expression of chemokine receptors that direct the trafficking of allo-activated T cells into 
the graft in response to local production of chemokines, initially by resident cells; chemokines 
attract leucocytes bearing specific chemokine receptors (Stasikowska O et al., 2007). This 
part of the project is important to assess the migration profile of these sub-populations, in 
order to see whether they differ between the groups of patients based on their clinical 
conditions. 
Overall, in addition to the initial 21 liver and 26 kidney transplant recipients already described 
in the above mentioned publication, we enrolled more than 100 additional kidney transplant 
recipients, at the Transplantation Centre at the CHUV in Lausanne as well as at the Divisions 
of Nephrology and Transplantation at the HUG in Geneva. The results of these parts of the 
project have not been published yet but a manuscript is in preparation; they are presented in 
the following sections, after the copy of our initial publication (which follows in the next 
pages). 
4. RESULTS 
68 
BRIEF DEFINITIVE REPORT
JEM © The Rockefeller University Press $15.00
www.jem.org/cgi/doi/10.1084/jem.20062120
Cite by DOI: 10.1084/jem.20062120 1 of 9
The antiallograft immune response remains an 
important cause of acute rejection and late graft 
dysfunction in solid organ transplantation. In 
addition to the clinical and pathological mani-
festations of graft dysfunction, various biologi-
cal markers have been investigated to monitor 
graft rejection over the years. De novo donor-
specifi c anti-HLA antibodies represent a valu-
able marker, as their development is generally 
associated with rejection (1). However, T cell 
immunity plays a pivotal role in graft rejection (2). 
In this regard, a series of biological markers re-
lated to the infl ammatory response, such as cyto-
kines, thromboxane B2, 2 microglobulin (3, 4), 
and other phenotypic and functional markers 
associated with T cell activation such as IL-2R 
(CD25) expression, CD69, HLA-DR (5–8), 
cell prolifera tion, cytokine secretion, and cyto-
toxicity (9–12), have been eva luated to monitor 
cell-mediated immunity. However, these mark-
ers are nei ther sensitive nor specifi c, and their 
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It has been recently shown (Seddiki, N., B. Santner-Nanan, J. Martinson, J. Zaunders, 
S. Sasson, A. Landay, M. Solomon, W. Selby, S.I. Alexander, R. Nanan, et al. 2006. J. Exp. Med. 
203:1693–1700.) that the expression of interleukin (IL) 7 receptor (R)  discriminates 
between two distinct CD4 T cell populations, both characterized by the expression of CD25, 
i.e. CD4 regulatory T (T reg) cells and activated CD4 T cells. T reg cells express low levels of 
IL-7R, whereas activated CD4 T cells are characterized by the expression of IL-7Rhigh. We 
have investigated the distribution of these two CD4 T cell populations in 36 subjects after 
liver and kidney transplantation and in 45 healthy subjects. According to a previous study 
(Demirkiran, A., A. Kok, J. Kwekkeboom, H.J. Metselaar, H.W. Tilanus, and L.J. van der Laan. 
2005. Transplant. Proc. 37:1194–1196.), we observed that the T reg CD25CD45ROIL-
7Rlow cell population was reduced in transplant recipients (P  0.00001). Interestingly, the 
CD4CD25CD45ROIL-7Rhigh cell population was signifi cantly increased in stable trans-
plant recipients compared with healthy subjects (P  0.00001), and the expansion of this cell 
population was even greater in patients with documented humoral chronic rejection com-
pared with stable transplant recipients (P  0.0001). The expanded CD4CD25CD45ROIL-
7Rhigh cell population contained allospecifi c CD4 T cells and secreted effector cytokines such 
as tumor necrosis factor  and interferon , thus potentially contributing to the mechanisms 
of chronic rejection. More importantly, CD4IL-7Rand CD25IL-7R cells were part of 
the T cell population infi ltrating the allograft of patients with a documented diagnosis of 
chronic humoral rejection. These results indicate that the CD4CD25IL-7R cell population 
may represent a valuable, sensitive, and specifi c marker to monitor allospecifi c CD4 T cell 
responses both in blood and in tissues after organ transplantation.
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measurement may be technically complex and time-consum-
ing. For these reasons, none of these markers is routinely used 
in the monitoring of trans plant recipients.
It has been recently reported that regulatory CD4 T cells 
(i.e., T reg cells) express low levels of IL-7R compared with 
other CD4 T cell subsets (13–17), and it has been proposed 
that IL-7R can be used to discriminate between T reg cells 
and activated CD4 T cells within the CD4CD25 cell pop-
ulation (15, 17). The CD4CD25IL-7Rhigh cell popula-
tion contains activated T cells and is poorly represented (	5% 
within CD4CD25 T cells) in healthy subjects. Conversely, 
after transplantation, both activated allospecifi c CD4 T cells 
and T reg cells may play a critical role by either participating 
in allograft rejection or promoting tolerance (18–25).
In this study, we have searched for sensitive and highly 
specifi c cellular markers that may defi ne the population of al-
lospecifi c CD4 T cells to quantify this cell population after 
transplantation, to monitor possible changes, and to determine 
the pattern of the allospecifi c population in chronic graft 
 rejection. We demonstrate that a CD4 T cell population 
 defi ned by the CD25CD45ROIL-7Rhigh phenotype con-
tains allospecifi c cells and is expanded in the blood of stable 
transplant recipients and even further expanded in patients 
with a documented diagnosis of chronic rejection. In these 
latter patients, CD4CD25IL-7R cells were a major com-
ponent of T cells infi ltrating the allograft.
RESULTS AND D I S C U S S I O N 
Distribution of CD4CD25 T cell populations defi ned by 
the expression of IL-7R
 (i.e., IL-7R
low vs. IL-7R
high) in 
stable organ transplant recipients
We have studied the distribution of T reg cells and activated 
CD4 T cells in blood mononuclear cells of 32 stable trans-
plant recipients, 21 liver and 11 kidney transplant recipients, 
and 4 patients with documented chronic kidney rejection, as 
well as 45 healthy subjects.
In accordance with recent studies (15, 17), the majority 
(88.2%) of CD4CD25 T cells were CD45ROFOXP3 
and IL-7Rlow in a representative healthy subject (1 out of 45), 
as shown in Fig. 1 A. This is the typical phenotype of T reg 
cells (26–28). Only a small percentage (3.1% in the example 
shown in Fig. 1 A) of CD4CD25 T cells expressed IL-
7Rhigh, and these cells were FOXP3 negative. We then per-
formed the same analysis in stable transplant recipients. In one 
representative stable liver transplant recipient (1 out of 32), 
the CD4CD25CD45ROFOXP3IL-7Rlow cell popu-
lation was reduced (66.1%; Fig. 1 A) compared with the rep-
resentative healthy subject. Interestingly, we observed a major 
increase (29.1%) in the CD4CD25CD45ROFOXP3IL-
7Rhigh cell population (Fig. 1 A). The diff erences in the 
dis tribution of IL-7Rlow and IL-7Rhigh within the 
CD4CD25CD45RO cell population between healthy 
subjects and stable transplant recipients were confi rmed by the 
analysis of a larger number of subjects.
In agreement with a previous report (25), the percent-
age of total CD4CD25 T cells was signifi cantly reduced 
(P  0.00001) in stable transplant recipients receiving im-
muno suppressive therapy compared with healthy subjects. 
The reduction was in the range of 40%; the mean percentage 
of CD4CD25 T cells was 2.23  0.12% in healthy sub-
jects (n  45) compared with 1.31  0.14% in stable trans-
plant recipients (n  32; Fig. 1 B).
The analysis of IL-7R and FOXP3 expression allowed 
the discrimination between T reg cells (26–28) and activated 
CD4 T cells. This analysis showed that the percentage of 
T reg cells (the IL-7RlowFOXP3 cell population) was signifi -
cantly lower (P  0.00001) in stable transplant recipients 
(mean  62  1.54%) compared with healthy subjects (mean  
29.37  2.33%; Fig. 1 B). Therefore, these results indicate 
that the reduction in T reg cells in stable transplant recipients 
is even greater than that estimated on the basis of the analysis 
of total CD4CD25 T cells. Furthermore, the population 
of activated CD4 T cells (i.e., the CD4CD25CD45ROIL-
7Rhigh cell population) was greatly expanded (mean  18.38  
1.05%) in stable transplant recipients compared with healthy 
donors (mean  6.16  0.76%; Fig. 1 B). These diff erences 
were highly signifi cant (P  0.00001). On the basis of the 
present results and of recent studies (15, 17), we then analyzed 
the correlation between IL-7R and FOXP3 expression 
in CD4CD25 T cells in stable transplant recipients. This 
analysis confi rmed a negative correlation between IL-7R 
and FOXP3 expression in CD4CD25 T cells (Fig. 1 C). 
The IL-7Rlow cells were contained within the FOXP3 pos-
itive cell population, whereas IL-7Rhigh cells were within 
the FOXP3-negative cell population (Fig. 1 C). Collectively, 
these results indicated that IL-7R is a valuable marker to 
discriminate between T reg cells and activated CD4 T cells 
within the CD4CD25 T cell population in stable recipi-
ents of organ transplants.
Next, it was of interest to determine the suppressive ac-
tivity of CD4CD25CD45ROIL-7Rlow and IL-7Rhigh 
cells. For these purposes, sorted purifi ed IL-7Rlow and IL-
7Rhigh cell populations isolated from stable transplant recip-
ients were assessed for their suppressive activity in a mixed 
lymphocyte reaction (MLR). The IL-7Rlow cell population 
(T reg cells) strongly suppressed the MLR (83% inhibition of 
proliferation; P  0.02), whereas the IL-7Rhigh cell popula-
tion did not show any signifi cant suppressive activity (P  
0.2; Fig. 1 D). These results obtained in stable transplant 
recipients are in agreement with those previously shown in 
healthy individuals (15, 17). Furthermore, the CD4CD25
CD45ROIL-7Rhigh cell population was also evaluated for 
the ability to secrete cytokines such as IFN- and TNF- 
 after polyclonal stimulation with anti-CD3 plus anti-CD28 
antibodies. This analysis performed in blood mononuclear 
cells of 29 stable transplant recipients showed that a substan-
tial percentage of CD4CD25CD45ROIL-7Rhigh cells 
secreted infl ammatory cytokines, such as TNF- (	15%) 
and IFN- (	4%), that may be involved in the mechanisms 
of chronic rejection (Fig. S1, http://www.jem.org/cgi/con-
tent/full/jem.20062120/DC1). Collectively, these results 
indicated that the CD4CD25CD45ROIL-7Rhigh cell 
JEM 3 of 9
BRIEF DEFINITIVE REPORT
population does not contain T reg cells and suggested that the 
expansion of this cell population in transplant recipients is as-
sociated with the presence of the allograft.
Larger expansion of the CD4CD25CD45ROIL-7R
high cell 
population in transplant recipients with chronic rejection
To better support this hypothesis, we examined the presence 
of the CD4CD25CD45ROIL-7Rhigh cell population in 
kidney transplant recipients with documented chronic humoral 
rejection. The total CD4CD25 T cell population was not 
signifi cantly diff erent in kidney recipients with documented 
chronic rejection compared with stable transplant recipients 
(P  0.21; Fig. 2 A). The percentage of CD4CD25FOXP3IL-
7Rlow cells (i.e., the T reg cells) within the total CD4CD25 
cell population was slightly reduced in patients with chronic 
rejection (51.07  5.8%) compared with stable transplant re-
cipients (62.02  1.54%; P  0.01; Fig. 2 B). Interestingly, an 
almost doubled percentage of CD4CD25CD45ROIL-
7Rhigh cells within the total CD4CD25 cell population 
was observed in patients with documented chronic rejection as 
compared with stable transplant recipients (mean  33.66  
3.43% vs. 18.38  1.05%; Fig. 2 C). These diff erences were 
highly signifi cant (P  0.0001).
When the CD4CD25CD45ROIL-7Rhigh popula-
tion from patients with chronic rejection was compared with 
the one of stable kidney transplant recipients, the diff erence 
was also signifi cant (P  0.0003; unpublished data). Therefore, 
Figure 1. Expression of CD25, CD45RO, IL-7R
, and FOXP3 on 
blood CD4 T cells of healthy subjects and stable transplant recipients. 
Blood mononuclear cells from 45 healthy subjects and 32 stable organ 
transplant recipients (11 kidney and 21 liver transplant recipients) were 
analyzed for the surface expression of CD4, CD25, CD45RO, and IL-7R 
and for the intracellular expression of FOXP3. (A) Surface expression of 
CD45RO and IL-7R in CD4CD25 T cells. Representative fl ow cytometry 
profi les of one healthy donor (1 out of 45; top) and one stable liver trans-
plant recipient (1 out of 32; bottom). The vast majority of CD4CD25 
T cells are CD45ROIL-7Rlow and FOXP3 in the healthy donor, while a 
substantial percentage of CD4CD25 T cells are CD45ROIL-7Rhigh and 
FOXP3 (green) in the stable transplant recipient. (B) Cumulative data on 
the proportion of CD4CD25 T cells (top left), CD4CD25FOXP3IL-
7Rlow T cells (top right), and CD4CD25CD45ROIL-7Rhigh T cells 
(bottom) in stable transplant recipients and healthy donors. (C) Correlation 
between the expression of FOXP3 and IL-7R within CD4CD25 T cells. 
The percentage of FOXP3 cells correlated with that of IL-7Rlow cells 
within CD4CD25 T cells, and the percentage of FOXP3 cells correlated 
with that of IL-7Rhigh cells within CD4CD25 T cells. The analyses were 
performed in 26 stable transplant recipients. In both cases, these correla-
tions were statistically signifi cant (P  0.05). (D) Suppressive activity 
of IL-7Rhigh and IL-7Rlow CD4CD25CD45RO T cell populations 
in stable transplant recipients. CD4CD25CD45ROIL-7Rhigh and 
CD4CD25CD45ROIL-7Rlow cell populations were sorted from blood 
mononuclear cells of fi ve stable liver transplant recipients, and their sup-
pressive activity was evaluated in a MLR. The extent of cell proliferation in 
a MLR was assessed in the absence (positive control) or in presence of the 
sorted IL-7Rlow and IL-7Rhigh cell populations. Cell proliferation was 
measured by [3H]thymidine incorporation. The data shown are expressed as 
the mean  SE and were obtained from fi ve independent experiments.
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although the expansion of the CD4CD25CD45ROIL-
7Rhigh cell population in patients with chronic rejection was 
associated with a decrease of T reg cells, the reduction of the 
T reg cell population was not suffi  cient to explain the in-
crease of the CD4CD25CD45ROIL-7Rhigh cell popu-
lation, thus indicating an absolute increase in the number of 
this latter population. Indeed, the absolute number of 
CD4CD25CD45ROIL-7Rhigh cells was also signifi -
cantly increased (1.5  0.4  103 cells per 100 l of blood) 
in patients with chronic rejection compared with stable trans-
plant recipients (0.8  0.1  103 cells per 100 l of blood; 
P  0.04). However, the absolute number of T reg cells did 
not signifi cantly change between the stable transplant recipi-
ents (3.8  0.5  103 cells per 100 l of blood) and the pa-
tients with chronic rejection (3  0.5  103 cells per 100 l 
of blood; P  0.3).
Collectively, these results indicate (a) an association between 
the presence of an expanded CD4CD25CD45ROIL-
7Rhigh cell population and the occurrence of chronic al-
lograft rejection, and that (b) the expansion of the activated 
CD4CD25CD45RO cell population defi ned by the ex-
pression of IL-7R cannot be explained only by the result 
of the decrease of the T reg cell population defi ned by the 
expression of FOXP3. Therefore, monitoring IL-7R may 
be a more valuable tool than monitoring FOXP3 to assess the 
patient’s immune status and/or the occurrence of allograft 
chronic rejection.
The CD4CD25CD45ROIL-7R
high cell population 
contains allospecifi c CD4 T cells
To have insights on the possible involvement of the 
CD4CD25CD45ROIL-7Rhigh cell population in the 
allospecifi c response to the graft, we examined the allospecifi c 
response of the transplant recipient to the donor in a MLR. 
Indeed, we had the opportunity to address this issue in a case 
of documented kidney chronic humoral rejection in which 
blood mononuclear cells of the (living) donor were available. 
The CD4CD25CD45ROIL-7Rhigh cell population was 
largely expanded (	40% of the CD4CD25 T cells) at the 
time of the diagnosis of chronic humoral rejection (time point 
1; Fig. 3). The MLR was performed using the transplant 
recipient–sorted CD4CD25CD45ROIL-7Rhigh cells 
mixed with irradiated transplant donor or MHC unrelated 
blood mononuclear cells. Interestingly, we found that the 
proliferation of the CD4CD25CD45ROIL-7Rhigh cell 
population was substantially higher (stimulation index [SI]  66) 
in the presence of irradiated transplant donor blood mononu-
clear cells compared with the proliferation in the presence of 
MHC unrelated blood mononuclear cells (SI  13; Fig. 3). 
Because of the diagnosis of chronic humoral rejection, this 
Figure 2. Expression of CD25, CD45RO, IL-7R
, and FOXP3 on 
blood CD4 T cells of stable transplant recipients and kidney trans-
plant recipients with chronic rejection. Blood mononuclear cells from 
32 stable transplant recipients (11 kidney and 21 liver transplant recipients) 
and 4 kidney transplant recipients with biopsy-proven chronic rejection were 
analyzed for the surface expression of CD4, CD25, CD45RO, and IL-7R 
and for the intracellular expression of FOXP3. (A) Means  SE of cumulative 
data on the proportion of CD4CD25 T cells in stable transplant recipi-
ents and transplant recipients with chronic rejection. The percentage 
of CD4CD25 T cells in total CD4 T cells was slightly increased in 
transplant recipients with chronic rejection compared with stable trans-
plant recipients, but these differences were not signifi cant (P  0.21). 
(B) Means  SE of cumulative data on the proportion of CD4CD25
FOXP3IL-7Rlow T cells in stable transplant recipients and transplant 
recipients with chronic rejection. The proportion of FOXP3IL-7Rlow T cells 
within the CD4CD25 T cell population was slightly reduced in the pa-
tients with chronic rejection compared with stable transplant recipients, 
and these differences were significant (P  0.01).(C) Means  SE of 
cumulative data on the proportion of CD4CD25CD45ROIL-7Rhigh 
T cells in stable transplant recipients and transplant recipients with chronic 
rejection. The proportion of CD45ROIL-7Rhigh T cells within the 
CD4CD25 T cell population was signifi cantly increased in the chronic 
rejection group compared with the stable group (P  0.0001).
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patient was treated with high-dose (2 g/kg) i.v. Ig admin-
istration therapy. We had the opportunity to reassess the 
expansion of the CD4CD25CD45ROIL-7Rhigh cell 
population 15 mo after the fi rst determination (time point 1) 
and 2 mo after treatment with i.v. Ig therapy. At this time 
(time point 2), the IL-7Rhigh cell population had decreased 
to 20% of the CD4CD25 T cells, which corresponded to a 
reduction of 	50% compared with time point 1 (before the 
i.v. Ig therapy). At time point 2, we also analyzed the allospe-
cifi c response mediated by the recipient-sorted CD4CD25
CD45ROIL-7Rhigh cells in a MLR with irradiated donor 
or MHC unrelated blood mononuclear cells. As shown at time 
point 2 in Fig. 3, there was no more evidence of an allospecifi c 
response against the transplant donor–specifi c cells (SI  1.13), 
whereas the proliferative response against the MHC unrelated 
blood mononuclear cells remained unchanged compared with 
time point 1. Therefore, we observed an association between 
the magnitude of the expansion of the IL-7Rhigh–activated 
cell population and the ability to mediate allospecifi c response 
in vitro. Moreover, these results suggested that i.v. Ig admin-
istration may lead to a decrease (in percentage and function) 
in the IL-7Rhigh–activated cell population.
In support of the association between the magnitude of 
the IL-7Rhigh–activated cell population and allospecifi c 
function, we analyzed the allospecifi c response of the IL-
7Rhigh cell population in two additional cases of stable kid-
ney transplant recipients in which blood mononuclear cells of 
the (living) donors were available. The percentage of the IL-
7Rhigh cell population was in the range of 20% (16.8 and 
22.2%) in the two cases, and in agreement with the data 
shown for time point 2 in Fig. 3, allospecifi c responses were 
not detected (unpublished data).
Furthermore, to better characterize the infl uence of im-
munosuppressive therapy on the IL-7Rhigh cell population, 
we studied fi ve additional transplant recipients and seven sub-
jects with various autoimmune diseases receiving immuno-
suppressive therapy. An augmentation of immunosuppressive 
therapy in the transplant recipients was consistently associated 
with a signifi cant subsequent reduction in the percentage of 
the IL-7Rhigh cell population from 31.17  6.33% to 17.33  
4.98% (P  0.002). The percentage of this population in pa-
tients with autoimmune diseases (n  7) receiving various types 
of immunosuppressive therapy was not signifi cantly diff erent 
from the one of healthy subjects (P  0.39; unpublished data).
CD4CD25IL-7R
 cells infi ltrate the allograft
We investigated the phenotype of the cells infi ltrating the 
kidney tissue allograft in fi ve patients with a documented di-
agnosis of chronic humoral rejection. For this purpose, fro-
zen kidney biopsies were simultaneously stained with the 
following antibody combinations: CD4 plus CD25, CD4 
plus IL-7R, CD25 plus IL-7R, CD4 plus FOXP3, IL-
7R plus FOXP3, and CD25 plus FOXP3. Variable num-
bers of cells infi ltrating the allograft were consistently found 
in all of the cases studied. Of interest, with regard to CD4 T 
cells, 	20% were CD25 and 	50% were IL-7R; all 
CD25 cells coexpressed IL-7R (Fig. 4 A). The estimates 
of the percentage of infi ltrating CD4CD25 and CD4 IL-
7R cells have been generated from counting 	80 infi ltrat-
ing CD4 T cells in 18 diff erent microscopic fi elds of the fi ve 
kidney biopsies. We also investigated the expression of 
FOXP3 in the CD4 T cells infi ltrating the allograft, but 
CD4FOXP3 cells were not found in the fi ve kidney biop-
sies examined (Fig. 4 B). However, CD4FOXP3 cells 
were consistently found in the lymph node biopsies used as 
control tissue (Fig. 4 C). It is also worth mentioning that cel-
lular infi ltrates were very scarce in the biopsy of patients with 
a kidney disease such as interstitial nephritis, and in this case, 
infi ltrating CD4 T cells were CD25 and IL-7R (unpub-
lished data). Therefore, these results indicate that the pre-
dominant CD4 T cell population infi ltrating the allograft in 
patients with chronic rejection is composed of CD4CD25 
and CD4IL-7Rcells.
Importance of the analysis of the CD4CD25CD45ROIL-
7R
high cell population in the clinical monitoring 
of transplant recipients
In this study, the results shown in Figs. 1 and 2 demonstrating 
the expansion in blood of the CD4CD25CD45ROIL-
7Rhigh cell population were obtained from a cross-sectional 
analysis performed in 32 (21 liver and 11 kidney) organ trans-
plant recipients. We recently had the opportunity to prospec-
tively monitor the CD4CD25CD45ROIL-7Rhigh cell 
population during the fi rst year after transplantation in 11 
kidney recipients receiving calcineurin-based immunosup-
pression with tacrolimus and mycophenolate mofetil (Fig. 5). 
Figure 3. Analysis of allospecifi c CD4 T cell responses. Sorted puri-
fi ed CD4CD25CD45ROIL-7Rhigh T cells (7  104 cells) from two time 
points of a kidney transplant recipient with biopsy-proven chronic rejection 
were co-cultured with 105 irradiated blood mononuclear cells (40 Gy) either 
from the organ donor or from an MHC unrelated subject. After 7 d of cul-
ture, cell proliferation was measured by [3H]thymidine incorporation. Cell 
cultures containing only irradiated cells were used as negative controls.
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Figure 4. CD4+IL-7R
+ T cells infi ltrate the tissue allograft. Frozen 
kidney biopsies from transplant recipients with chronic rejection were 
stained with IL-7R and CD4 or CD25. (A, top) IL-7R T cells (green) and 
CD4 T cells (red) are indicated by the arrowheads and are present in the 
interstitial compartment. Double-positive CD4IL-7R T cells (yellow 
arrowheads) are colored in orange as a result of the merging of the two 
single-color images. (middle) IL-7R T cells (green) and CD25 T cells 
(red) are also present in the interstitial compartment. Double-positive 
CD25IL-7R T cells (yellow arrowheads) are colored in orange as a 
At study entry (before transplantation), there were no diff er-
ences in the percentage of CD4CD25CD45ROIL-
7Rhigh cells between the transplant recipients and living 
donors. The mean percentage in transplant recipients (5.04  
0.75%) and in living donors (4.65  0.7%) was consistent 
with that observed in the large cohort of healthy subjects 
(n  45; 6.16  0.76%; Fig. 5). Of interest, the 
CD4CD25CD45ROIL-7Rhigh cell population was sig-
nifi cantly increased (up to 	14% of the CD4CD25 
T cells; P  0.005) 1 mo after transplantation as compared 
with study entry, and the activated cell population remained 
expanded during the year of observation (Fig. 5). Interest-
ingly, kidney allograft function in these recipients was stable 
during the study period, and there was no evidence of al-
lograft rejection. These data further support the relationship 
between the expansion of the IL-7Rhigh CD4 T cell popu-
lation and the presence of the allograft and the usefulness of 
implementing the determination of this cellular marker in the 
immunologic monitoring of the transplant recipients.
C O N C L U S I O N S 
We have identifi ed the presence of a CD4 T cell population 
that is selectively expanded in patients after organ transplanta-
tion and is phenotypically defi ned by the expression of CD25, 
CD45RO, and high levels of IL-7R. Of interest, this cell 
population is expanded in stable transplant recipients in the 
absence of measurable circulating anti-HLA antibodies, thus 
indicating that it represents an allospecifi c cellular marker to 
monitor the immune response against the allograft. More im-
portantly, this cell population contains allospecifi c CD4 T 
cells, it is substantially more expanded in patients with docu-
mented chronic humoral rejection, and 	50% of the CD4 T 
cells infi ltrating the allograft (in the case of chronic rejection) 
are IL-7R. Collectively, these results suggest that the 
CD4CD25IL-7R cell population represents a valuable, 
sensitive, and specifi c marker to monitor allospecifi c CD4 T 
cell responses in blood and tissue after organ transplantation. 
The precise contribution of this activated T cell population 
on the induction of eff ector mechanisms of late, chronic al-
lograft rejection (e.g., production of alloantibodies with local 
complement activation) remains to be further studied. The 
clinical usefulness of this novel cellular marker in the moni-
toring of allograft recipients and its relationship with clinical 
outcomes need to be investigated in large prospective cohort 
studies of organ transplant recipients.
MATERIALS AND METHODS
Patients. 21 liver and 15 kidney transplant recipients were studied at the 
Centre Hospitalier Universitaire Vaudois. All patients gave informed written 
consent before participating in the study, which was approved by the local 
institutional review board. 45 healthy volunteers were included as controls.
Peripheral blood was obtained from 21 clinically stable liver transplant 
recipients, all of whom had received a fi rst cadaveric graft and were studied 
for 12 mo after transplantation. This group was composed of 15 males and 
6 females, with a median age of 51.2 yr (range  20–67 yr) at the time of the 
study and a median time from transplantation to the study of 7.6 yr (range  
1–19 yr). Their immunosuppressive therapy was based on cyclosporine or 
tacrolimus with prednisone (n  7) in combination with mycophenolate 
mofetil or azathioprine (n  2) .
Peripheral blood was also obtained from 15 kidney transplant recipients 
divided into two groups: (a) 11 patients with a stable graft function defi ned by 
a stable serum creatinine with values inferior to 150 mol/liter and by a 24-h 
proteinuria inferior to 0.5 g/day, and (b) 4 patients with biopsy-proven chronic 
rejection. The stable kidney group was composed of seven males and four 
 females, with a median age of 48.8 yr (range  24–70 yr) at the time of the study 
and a median time from transplantation to the study of 8.6 yr (range  1–19 yr). 
All patients had received a fi rst graft: eight from a deceased donor, two from a 
Figure 5. Rapid expansion of the CD4CD25CD45ROIL-7R
high 
cell population after transplantation. Means  SE of cumulative data 
on the proportion of the CD4CD25CD45ROIL-7Rhigh T cell population 
in transplant recipients before and up to 1 yr after transplantation. At the 
baseline (before transplantation), recipients and donors have a similar 
proportion of CD4CD25CD45ROIL-7Rhigh T cells. The IL-7Rhigh CD4 T 
cell population is already signifi cantly increased 1 mo after transplanta-
tion in the transplant recipients and remains expanded for up to 1 yr. 
result of the merging of the two single-color images. (bottom) CD25 
T cells (green) and CD4 T cells (red). Double-positive CD4CD25 T cells 
(yellow arrowheads) are colored in orange as a result of the merging of 
the two single-color images. (B, top) CD4 T cells (green) infi ltrating the 
kidney of a patient with documented chronic rejection are FOXP3 nega-
tive (red). (middle and bottom) CD25 T cells (green) and IL-7R T cells 
(green) are also negative for FOXP3 (red). (C) CD4 T cells (yellow) in the 
lymph node are FOXP3 positive (green). Bars, 10 m.
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living/related donor, and one from a living/unrelated donor. No patient in 
this group had circulating anti-HLA antibodies. The chronic rejection group 
was composed of two males and two females, with a median age of 42.8 yr 
(range  26–56 yr) at the time of the study and a median time from transplan-
tation to the study of 9 yr (range  6–16 yr). Also in this group, patients had 
received a fi rst graft: three from a deceased donor and one from a living/ 
related donor (father to daughter). In the four patients with biopsy-proven 
chronic rejection (29, 30), circulating donor-specifi c anti-HLA antibodies 
(DSA) were detected in serum by ELISA (One Lambda, Inc.), and capillary 
C4d deposits were demonstrated in kidney graft biopsies. In three out of four 
biopsies, typical lamination with multilayering of the basement membrane of 
peritubular capillaries was also demonstrated by electron microscopy. In the 
living/donor recipient with chronic rejection, a repeat B cell cross match was 
positive (T and B cell cross matches were negative at the time of transplanta-
tion). In all four patients, circulating DSA were directed against defi ned class II 
antigens (anti–class II DSA). The median serum creatinine at the time of diag-
nosis of chronic rejection was 247 mol/liter (range  184–350 mol/liter), 
whereas the median 24-h proteinuria was 2.1 g/day (range  1–3.5 g/day).
A second group of 11 kidney transplant recipients was monitored pro-
spectively at the Hôpitaux Universitaires de Genève and was composed of 
7 males and 4 females, with a median age of 42.7 yr (range  23–81 yr) at 
the time of the transplantation. The group of kidney donors (living donors) 
was composed of two males and nine females, with a median age of 52.8 yr 
(range  32–73 yr) at the time of the donation. All of these 11 kidney trans-
plant recipients received a 3–4-d thymoglobulin (1.5 mg/kg) course as in-
duction therapy, with a calcineurin-based immunosuppressive regimen.
The group of patients with various autoimmune diseases studied at the 
Centre Hospitalier Universitaire Vaudois was composed of one male and six 
females, with a median age of 37.9 yr (range  21–55 yr) at the time of the 
study. The patients received various regimens of immunosuppressive drugs.
FACS analysis and sorting. Peripheral blood mononuclear cells were iso-
lated using standard Ficoll-Hypaque (GE Healthcare) gradient centrifugation. 
The antibodies used for fl ow cytometric analyses included PerCP, PerCP-
Cy5.5, or PE-conjugated mouse anti–human CD4 (Becton Dickinson); allo-
phycocyanin (APC)-conjugated mouse anti–human CD25 (BD Biosciences), 
FITC (BD Biosciences), or ECD (Beckman Coulter)-conjugated mouse anti–
human CD45RO; and PE (Beckman Coulter)- or APC (R&D Systems)-
 conjugated mouse anti–human IL-7R. For intracellular FOXP3 analysis, cell 
preparations were fi xed and permeabilized with fi xation/permeabilization 
buff ers (eBioscience) after staining of cell surface markers and stained with 
FITC-conjugated rat anti–human FOXP3 (eBioscience). For cell sorting ex-
periments, CD4CD25CD45ROIL-7Rlow, CD4CD25CD45ROIL-
7Rhigh, and CD4CD25 cell populations were isolated from the peripheral 
blood of transplant recipients. The grade of purity in all of the sorting experi-
ments ranged between 92 and 98%. All fl ow cytometric analyses were per-
formed on a FACSCalibur and LSRII, while cell sorting was performed on a 
FACSVantage SE and FACSAria (Becton Dickinson).
Suppressive function assay. The suppressive function of freshly sorted 
CD4CD25CD45ROIL-7Rlow and CD4CD25CD45ROIL-
7Rhigh cells isolated from the peripheral blood of liver transplant recipients 
was assessed in a MLR.
For these purposes, 105 irradiated (40 Gy) allogeneic blood mononuclear 
cells (stimulator cells) and 5  104 CD4CD25 T cells isolated from liver 
transplant recipients (responder cells) were co-cultured either alone (positive 
control) or in the presence of 5  104 freshly sorted CD4CD25CD45ROIL-
7Rlow or CD4CD25CD45ROIL-7Rhigh cells. Proliferation was mea-
sured at day 7 by [3H]thymidine incorporation.
Allospecifi c T cell response. Allospecifi c T cell proliferation of the 
CD4CD25CD45ROIL-7Rhigh cells isolated from one kidney recipient 
with documented chronic rejection was assessed by co-culturing 105 irradi-
ated (40 Gy) donor blood mononuclear cells with 7  104 sorted purifi ed 
recipient CD4CD25CD45ROIL-7Rhigh cells. Cultures were made in 
triplicates, and proliferation was measured at day 7 by [3H]thymidine incor-
poration. As a control, the same sorted purifi ed population was co-cultured 
with irradiated MHC unrelated blood mononuclear cells. The SI was calcu-
lated on the basis of the fold increase in the proliferation observed in the cul-
ture containing CD4CD25CD45ROIL-7Rhigh cells and irradiated 
donor or MHC unrelated cells compared with the negative control, i.e., 
cultures containing irradiated cells alone.
Cytokine production. 2  106 cryopreserved blood mononuclear cells 
from liver and kidney transplant recipients were prestained with anti–IL-
7R PE and mouse anti–human CD25 PE-Cy7 (BD Biosciences) antibod-
ies and stimulated overnight with soluble 1 g/ml anti-CD3 plus 1 g/ml 
anti-CD28 antibodies (BD Biosciences) in 1 ml of complete medium (RPMI 
plus 10% FBS) containing 1 l/ml each of GolgiPlug and GolgiStop (BD 
Biosciences). At the end of the stimulation period, the cells were washed and 
stained with CD4 PerCP-Cy5.5 and CD45RO ECD antibodies. The cells 
were permeabilized with FACS Permeabilizing Solution 2 (BD Biosciences) 
and stained with mouse anti–human IFN- or TNF- FITC and rat anti–
human IL-2 APC (BD Biosciences). Data were acquired on an LSRII and 
analyzed using DiVa software (Becton Dickinson). Unstimulated cells were 
used as negative control for the production of cytokines. The background 
never exceeded 0.02%.
Immunohistochemistry. Frozen tissues from kidney biopsies were incu-
bated at room temperature for 20 min with a blocking solution (5% normal 
goat serum) and immediately stained overnight at 4C with a mix of primary 
antibodies: IgG1 mouse anti–human IL-7R (BD Biosciences) with IgG2a 
mouse anti–human CD4 (Beckman Coulter) or with IgG2b rat anti–human 
CD25 (Serotec) and mouse anti–human CD4 with rat anti–human CD25. 
The tissues were also stained with IgG2a rat anti–human FOXP3 (eBioscience) 
and IgG1 mouse anti–human CD4 (BD Biosciences) or IgG1 mouse anti–
human CD25 (BD Biosciences) or mouse anti–human IL-7R. Secondary 
antibodies (goat IgG specifi c) were added after 16 h (after washing the un-
bound primary antibodies) and incubated for 1 h at room temperature in the 
dark. Goat anti–mouse IgG1 Alexa Fluor 488, goat anti–mouse IgG2a Alexa 
Fluor 594, goat anti–mouse IgG (HL) Alexa Fluor 532, goat anti–rat IgG 
(HL) FITC, biotinylated goat anti–rat IgG (HL), streptavidin Texas red, 
and streptavidin FITC were all obtained from Invitrogen. The tissues were 
mounted with antifade reagent (ProLong Gold; Invitrogen) and observed on 
an imaging microscope (Axioplan 2; Carl Zeiss MicroImaging, Inc.) with 
epifl uorescence using single-band excitation fi lters: Alexa Fluor 488, ex. 
480/40 LP; Alexa Fluor 594, ex. 546/12; and Alexa Fluor 532, ex.535. 
Photos were taken using an AxioCam and AxioVision software (version 4.6; 
Carl Zeiss MicroImaging, Inc.). Each fl uorochrome was imaged separately, 
and the resulting images were automatically pseudocolored and merged by 
the AxioVision software.
Statistical analysis. Statistical signifi cance was calculated by the two-tailed 
t test and linear regression analysis. P  0.05 was considered signifi cant.
Online supplemental material. Fig. S1 shows that CD4CD25CD45RO
IL-7Rhigh cells secrete infl ammatory cytokines. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20062120/DC1.
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4.2.2. Demographic data of the patients 
As mentioned above, we enrolled overall more than 100 new kidney transplant recipients in 
our study, in a retrospective as well as in a prospective way. We decided to classify them in 
different study groups, according to their clinical conditions, and we will use the same 
terminology throughout the following results and discussions. 
For the retrospective part of our study, we could distinguish three different groups of 
patients, with a total of 91 patients: 
(a) stable kidney transplant recipients (n=60): they are defined as patients with a stable 
serum creatinine level, a 24h-proteinuria inferior to 0.5 g/day, no circulating anti-HLA 
antibodies, and a standard immunosuppressive therapy (calcineurin inhibitor (n=54) or 
mTOR inhibitor (n=6) ± mycophenolate mofetil ± steroids); 
(b) kidney transplant recipients with chronic humoral rejection (n=7): they are defined as 
patients with progressive deterioration of their graft function, presence of circulating 
donor-specific anti-HLA antibodies, and a biopsy-proven diagnosis of chronic 
humoral rejection (CHR) based on the criteria of the Banff'07 conference (Solez K et
al., 2008; Appendix I);
(c) kidney transplant recipients on no or minimal immunosuppression (n=24): they are 
defined as patients with a stable serum creatinine level below 150 mol/l, a 
24h-proteinuria inferior to 0.5 g/day, no circulating anti-HLA antibodies, and no (n=1) 
or minimal immunosuppression (n=23; i.e. steroids alone, or mycophenolate mofetil ± 
steroids, or azathioprine ± steroids). 
In addition to the above-described kidney transplant recipients, we also had the unique 
opportunity to analyze four liver transplant recipients on no or minimal immunosuppression: 
they are defined as patients with stable liver tests, and no (n=1) or minimal 
immunosuppression (n=3; i.e., steroids alone, or low-dose tacrolimus alone). All relevant 
demographic data of these patients are summarized in Appendix II.
For the prospective part of our study, patients were enrolled in two clinical protocols, 
differing by the induction and immunosuppressive regimens, with a total of 35 patients: 
(a) group "THYMO" (n=19): induction by thymoglobulin (4 doses, 1.5 mg/kg/day, from 
days 0 to 3) and steroids (tapered in four days unless required), followed by 
maintenance immunosuppression with tacrolimus and mycophenolate mofetil, all 
patients received a first renal graft from a living-donor; 
(b) group "BSX" (n=16): induction by basiliximab (20 mg at days 0 and 4), followed by 
maintenance immunosuppression with tacrolimus, mycophenolate mofetil and 
steroids, all patients received a first renal graft either from a living or from a cadaveric 
donor.  
All relevant demographic data of these patients are summarized in Appendix III.
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4.2.3. Analysis of functionally distinct subsets of CD4+ CD25high T cells 
in solid organ transplant recipients: retrospective part of the study 
Following the results of our initial publication, we performed the same kind of experiments 
(polychromatic flow cytometric phenotyping of peripheral blood mononuclear cells) in the 
above-mentioned 91 kidney transplant recipients and in the 4 liver transplant recipients. We 
used the same gating strategy as the one described in the chapter on healthy individuals 
[Figures 23 and 24]. Overall, our results were consistent with our publication. 
4.2.3.1. Correlation with the clinical status of the kidney transplant recipients 
In order to be able to compare consistently the results between the different study groups, it is 
important to base our conclusions not only on percentages of sub-populations of cells relative 
to their parent or grand-parent population, but also on absolute numbers of cells, expressed as 
number of cells per l) of blood for instance; indeed, the real functional properties of a 
cellular population depends critically on its numerical importance. For this purpose, we 
checked the leucocyte counts in the kidney transplant recipients (3 study groups). Overall, we 
found comparable leucocyte absolute counts in transplant recipients (mean ± standard error of 
the mean: 6.6 ± 0.2 G/L) compared to healthy individuals (6.8 ± 0.4 G/L; P=0.20) 
[Figure 33A]. When looking at the three study groups of kidney transplant recipients, we also 
found no statistical difference with healthy individuals and between each group: stable kidney 
transplant recipients had a mean leucocytes absolute count of 6.2 ± 0.2 G/L (P=0.09 as 
compared to healthy individuals), kidney transplant recipients with CHR 7.3 ± 0.8 G/L 
(P=0.32) and kidney transplant recipients on no or minimal immunosuppression 6.9 ± 0.4 G/L 
(P=0.43) [Figure 33B]. 
Figure 33A. Leucocyte absolute counts in healthy 
individuals and transplant recipients. 
Figure 33B. Leucocyte absolute counts in healthy 
individuals and the three study groups of kidney 
transplant recipients. 
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4.2.3.1.1. CD4+ CD25high T cells 
Then, we were interested in the percentage of CD4+ CD25high T cells, to assess if differences 
between our three study groups were present. Overall, we found that the mean percentage of 
CD25high cells within CD4+ T cells was 1.12% (range: 0.12-4.11%; median: 0.89%), which 
was significantly lower than the mean percentage found in healthy volunteers 
(1.62%; P<0.005) [Figure 34A]; this could be explained by the fact that most 
immunosuppressive treatments target intracellular signals involved in T cell activation after 
antigen presentation, which is, among others, characterized by the transient upregulation of 
the CD25 molecule on the cell surface. When looking at our three study groups, we found the 
lowest percentage of CD4+ CD25high T cells in kidney transplant recipients with CHR 
(0.82 ± 0.15%; P<0.05 as compared to healthy volunteers), followed by stable transplant 
recipients (1.06 ± 0.11%; P<0.005) and kidney transplant recipients on no or minimal 
immunosuppression (1.24 ± 0.15%; P<0.05). These results are in accordance with recent 
publications (Louis S et al., 2006). Interestingly, among stable kidney transplant recipients, 
patients receiving sirolimus as immunosuppressive treatment displayed a CD4+ CD25high T 
cells percentage (1.72 ± 0.46%) similar to the one found in healthy volunteers (P=0.41) 
[Figure 34B], in accordance with recent data (Segundo DS et al. (2006); Ruggenenti P et al.
(2007); Noris M et al. (2007)); interestingly, as demonstrated by in vitro studies, the presence 
of sirolimus in culture experiments induces a selective expansion of murine and human 
regulatory T cells, whereas at the same time it kills effector T cells or at least prevents their 
expansion (Coenen JJ et al., 2007; Battaglia M et al., J Immunol, 2006; Strauss L et al., 2007; 
Keever-Taylor CA et al. 2007; May KF Jr et al., 2007). 
Figure 34A. Percentage of CD4+ CD25high
T cells in 73 healthy individuals and 
91 kidney transplant recipients.  
Figure 34B. Percentage of CD4+ CD25high T cells in kidney 
transplant recipients: 54 stable, 7 with CHR, 24 stable on no or 
minimal immunosuppression and 6 stable on sirolimus. 
However, since CD4+ CD25high T cells contain both regulatory as well as activated T cells, it 
is important to discriminate these sub-populations and assess how they are influenced by the 
clinical status of the kidney transplant recipients. For this purpose, we performed the same 
staining protocol as described in the part on healthy individuals, including anti-CD4, CD25, 
CD45RO, CD127 and FoxP3 monoclonal antibodies, on our three kidney transplant recipients 
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study groups. In accordance with our publication, we found that the respective percentages of 
the activated (CD4+ CD25high CD127high FoxP3-) and regulatory (CD4+ CD25high CD127low
FoxP3+) T cell sub-populations were modified in stable kidney transplant recipients and in 
those with CHR as compared to healthy individuals. In addition, we could also observe 
significant changes in the newly enrolled group of patients on no or minimal 
immunosuppression. 
4.2.3.1.2. Activated T cell sub-population (defined as CD4+ CD25high CD45RO+
CD127high cells) 
Overall, the activated T cell population was expanded in kidney transplant recipients 
(13.51 ± 0.90% of CD45RO+ CD127high cells within CD4+ CD25high T cells) as compared to 
healthy individuals (5.97 ± 0.36%; P<0.001) [Figure 35A]. In stable transplant recipients, the 
percentage was found to be expanded to 14.57 ± 0.97% (P<0.001), and interestingly, an 
almost doubled percentage was observed in kidney transplant recipients with CHR 
(25.32 ± 4.66%; P<0.001). These results are in the range of those of our publication. 
However, it was very interesting to note that stable kidney transplant recipients on no or 
minimal immunosuppression did not exhibit a significant expansion of the activated T cell 
population (7.40 ± 0.72%; P=0.08). Furthermore, among stable transplant recipients, those on 
sirolimus-based immunosuppression exhibited even a lower activated T cell percentage as 
compared to the one found in healthy individuals (3.41 ± 0.74%; P<0.05) [Figure 35B]. In 
addition, in the four liver transplant recipients on no or minimal immunosuppression, the 
activated T cell population was not expanded (9.05 ± 0.93%), and this percentage was 
comparable to the one of their kidney recipients counterparts (P=0.19) [data not shown]. 
Figure 35A. Percentage of the activated 
T cell sub-population in 73 healthy 
individuals and 91 kidney transplant 
recipients. 
Figure 35B. Percentage of the activated T cell sub-population in 
73 healthy individuals, 54 stable kidney transplant recipients on 
CNI-based immunosuppression, 7 kidney transplant recipients 
with CHR, 24 kidney transplant recipients on no or minimal 
immunosuppression and 6 stable kidney transplant recipients on 
sirolimus-based immunosuppression. 
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These results strongly suggest that the assessment of the activated T cell sub-population could 
be useful to help in the clinical evaluation of kidney transplant recipients. For example, it 
could be helpful to detect "(pseudo-)tolerant" patients who could benefit from 
immunosuppression minimization or even withdrawal. At the present time, this is usually 
done under close monitoring for rejection development, including clinical parameters such as 
therapeutic drug monitoring, assessment of serum creatinine and of development of 
circulating alloantibodies, and protocol renal biopsies. However, only prospective studies of 
immunosuppression weaning in a large controlled and randomized setting will enable proof of 
concept of this hypothesis. In this regard, monitoring activated T cells may be very useful. 
We also assessed the mean absolute counts of this activated T cell sub-population; although 
values did not always reach statistical significance, the absolute counts displayed similar 
trends as the above-mentioned percentages. Briefly, the activated T cell population absolute 
count in stable kidney transplant recipients (1.26 ± 0.25 cell per l of blood; P=0.09) as well 
as in transplant recipients with CHR (1.62 ± 0.40 cell/l; P<0.01) tended to be, respectively 
was increased as compared to healthy individuals (0.79 ± 0.13 cell/l); conversely, in kidney 
transplant recipients on no or minimal immunosuppression (0.55 ± 0.11 cell/l; P=0.11) as 
well as in stable kidney transplant recipients on sirolimus (0.33 ± 0.16 cell/l; P=0.08), the 
activated T cell population absolute counts were comparable to the value found in healthy 
individuals [Figure 35C]. 
Figure 35C. Mean absolute counts of the activated T cell sub-population in 73 healthy individuals, 
54 stable kidney transplant recipients on CNI-based immunosuppression, 7 kidney transplant 
recipients with CHR, 24 kidney transplant recipients on no or minimal immunosuppression and 
6 stable kidney transplant recipients on sirolimus-based immunosuppression. 
Thereafter, it was important to look at the changes of the regulatory T cell sub-population, 
defined as CD4+ CD25high CD127low FoxP3+ cells. 
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4.2.3.1.3. Regulatory T cell sub-population (defined as CD4+ CD25high FoxP3+ CD127low
cells) 
Overall, the regulatory T cell sub-population was found to be decreased in kidney transplant 
recipients (50.51 ± 1.98% of CD127low FoxP3+ cells within CD4+ CD25high) as compared to 
healthy individuals (74.05 ± 2.01%; P<0.001) [Figure 36A]. The extent of this decrease was 
close to one third and comparable in the three study groups; in stable transplant recipients, the 
percentage of the regulatory T cell sub-population was decreased to 49.50 ± 2.27% (P<0.001 
as compared to healthy individuals), in kidney transplant recipients with CHR to 
50.50 ± 4.15% (P<0.001), and in kidney transplant recipients on no or minimal 
immunosuppression to 49.40 ± 8.71% (P<0.001). However, the regulatory T cell sub-
population tended to be less decreased in the sub-group of stable kidney transplant recipients 
on sirolimus-based immunosuppression (62.48 ± 4.88%; P<0.05) and was statistically higher 
than in the stable kidney transplant recipients on CNI-based immunosuppression (P<0.05) 
[Figure 36B]. In addition, in the four liver transplant recipients on no or minimal 
immunosuppression, the regulatory T cell sub-population was decreased in the same extent 
(53.64 ± 2.02%; P=0.43) as in their kidney recipients counterparts [data not shown]. 
Figure 36A. Percentage of the regulatory 
T cell sub-population in 73 healthy 
individuals and 91 kidney transplant 
recipients. 
Figure 36B. Percentage of the regulatory T cell sub-population in 
73 healthy individuals, 54 stable kidney transplant recipients on 
CNI-based immunosuppression, 7 kidney transplant recipients 
with CHR, 24 kidney transplant recipients on no or minimal 
immunosuppression and 6 stable kidney transplant recipients on 
sirolimus-based immunosuppression. 
We also assessed the mean absolute count of this regulatory T cell sub-population; as 
compared to healthy individuals (7.54 ± 1.09 cell/l), we found that the absolute number of 
regulatory T cells was significantly decreased in stable kidney transplant recipients 
(3.29 ± 0.50 cell/l; P<0.001), whilst it tended to be decreased in kidney transplant recipients 
with CHR (2.92 ± 0.69 cell/l; P=0.07), as well as in the stable recipients on sirolimus-based 
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immunosuppression (2.75 ± 0.71 cell/l; P=0.06), but not in kidney transplant recipients on 
no or minimal immunosuppression (5.56 ± 0.42 cell/l; P=0.28) [Figure 36C]. 
Figure 36C. Mean absolute counts of the regulatory T cell sub-population in 73 healthy individuals, 
54 stable kidney transplant recipients on CNI-based immunosuppression, 7 kidney transplant 
recipients with CHR, 24 kidney transplant recipients on no or minimal immunosuppression and 
6 stable kidney transplant recipients on sirolimus-based immunosuppression. 
After integration of the results on the whole CD4+ CD25high T cell population, as well as on 
the activated (CD4+ CD25high CD127high FoxP3-) and regulatory (CD4+ CD25high CD127low
FoxP3+) T cell sub-populations, the parameter that showed the better correlation with the 
clinical status of the patients was the percentage of the activated T cell sub-population. This 
conclusion is based on the respective percentages found in the different clinical study groups 
as well as on the results of statistical tests. The results of the Student's t test performed for the 
three parameters and for the clinical study groups are shown in Table 3.
The percentage of CD4+ CD25high T cells was significantly reduced in all kidney transplant 
recipients except in the group on sirolimus-based immunosuppression, as compared to healthy 
individuals; however, the difference between stable kidney transplant recipients and those 
with CHR (P=0.27), between stable and those on no or minimal Immunosuppression 
(P=0.09), as well as between those with CHR and those on no or minimal immunosuppression 
(P=0.08), was not statistically significant. 
Concerning the percentage of the regulatory CD4+ CD25high CD127low FoxP3+ T cell sub-
population, it was significantly reduced in all transplant recipients as compared to healthy 
individuals. However, again, there was no sufficient statistical difference between the clinical 
study groups to permit a clear distinction. 
On the other hand, the percentage of the activated CD4+ CD25high CD45RO+ CD127high T cell 
sub-population displayed a clear and statistically significant differential repartition between 
healthy individuals and the different clinical study groups of kidney transplant recipients, and, 
more importantly, it permitted to discriminate between stable kidney transplant recipients and 
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kidney transplant recipients with CHR. However, the results of some individuals do not fit 
with the "expected" value based on their clinical status. We cannot exclude that other 
parameters play a role and modulate the percentage of the activated T cell sub-population. For 
example, it could be that concurrent infections might increase the percentage of this sub-
population; to prevent this bias, we have carefully checked in all our volunteers before blood 
drawing that they did not have an overt concomitant infection, but the possibility of an occult 
infection still remains. This could explain why some stable kidney transplant recipients 
displayed a high percentage of the activated T cell sub-population. Another explanation could 
be that these patients were at the beginning of an ongoing chronic humoral rejection process 
without having developed clinical signs and symptoms yet. The only way to confirm this 
hypothesis would be to perform a renal biopsy, but most of the patients, as well as clinicians, 
are reluctant to this invasive procedure without any clear clinical justification. On the other 
hand, some stable kidney transplant recipients on standard CNI-based immunosuppression 
displayed lower percentages of the activated T cell sub-population and most of the time 
higher percentages of the regulatory T cell sub-population than expected; this particular blood 
phenotype could be the expression of a more tolerogenic state of these patients towards their 
grafts, and could indicate that they may benefit from a controlled tapering of their 
immunosuppression. Of course, further studies under strict clinical monitoring on selected 
patients are needed to prove this hypothesis. 
Percentage of CD25high cells within CD4+ T cells 
P=
Stable CHR No or  
minimal IS 
Sirolimus All transplant 
recipients 
Healthy 
individuals 
*** <0.001 * <0.05 * <0.05 0.41 ** <0.01 
Stable -- 0.27 0.09 * <0.05 -- 
CHR -- -- 0.08 * <0.05 -- 
No or  
minimal IS 
-- -- -- 0.11 -- 
Percentage of activated CD45RO+ CD127high cells within CD4+ CD25high T cells 
P=
Stable CHR No or  
minimal IS 
Sirolimus All transplant 
recipients 
Healthy 
individuals 
*** <0.001 *** <0.001 0.08 * <0.05 *** <0.001 
Stable -- ** <0.01 *** <0.001 *** <0.001 -- 
CHR -- -- *** <0.001 ** <0.01 -- 
No or  
minimal IS 
-- -- -- ** <0.01 -- 
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Percentage of regulatory FoxP3+ CD127low cells within CD4+ CD25high T cells 
P=
Stable CHR No or  
minimal IS 
Sirolimus All transplant 
recipients 
Healthy 
individuals 
*** <0.001 *** <0.001 *** <0.001 ** <0.01 *** <0.001 
Stable -- 0.45 0.49 0.14 -- 
CHR -- -- 0.46 0.24 -- 
No or  
minimal IS 
-- -- -- 0.26 -- 
Table 3. Results of Student's t tests performed between healthy individuals, stable kidney transplant 
recipients, kidney transplant recipients with CHR, stable kidney transplant recipients on no or minimal 
immunosuppression, and stable kidney transplant recipients on sirolimus-based immunosuppression, for 
the CD4+ CD25high T cell population, the activated CD4+ CD25high CD45RO+ CD127high and regulatory CD4+
CD25high FoxP3+ CD127low T cell sub-populations. 
Statistically significant results are shown in red. 
*: significant; **: highly significant; ***: very highly significant. 
4.2.3.2. Correlation with the immunosuppressive treatments of the kidney transplant 
recipients 
We have already shown that sirolimus seems to have an impact on the repartition of 
CD4+ CD25high T cells sub-populations different from CNIs, and we were interested in 
looking at the effect of other conventional immunosuppressive drugs. As already discussed in 
the Introduction part, most immunosuppressive drugs target the intracellular signals involved 
in T cell activation after antigen presentation. Conventional immunosuppressive drugs used in 
the maintenance phase of transplantation include several compounds, with different 
mechanisms of action: corticosteroids, azathioprine, CNIs, mTOR inhibitors (sirolimus and 
everolimus), and mycophenolate mofetil (MMF). We will briefly review their mechanisms of 
action. 
Corticosteroids (prednisone, prednisolone and methylprednisolone) inhibit transcription 
factors such as NF-B and AP-1, which are involved in transcription of cytokine and 
chemokine genes, including IL-2, TNF and IFN.
Azathioprine was the first immunosuppressive agent to be used extensively in solid organ 
transplantation. It is thought to act by releasing 6-mercaptopurine, which interferes with a 
specific step of the cell cycle, namely DNA synthesis. 
Calcineurin inhibitors (CNIs), including cyclosporine A and tacrolimus, engage respectively 
cyclophilin and FK506-binding protein 12, which in turn inhibit calcineurin, a potent 
phosphatase of the T cell activation transduction pathway. Both drugs limit the production of 
cytokines, including IL-2, by blocking the activation of the transcription factor NFAT. 
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The mTOR inhibitors (sirolimus and everolimus) exert their effect at the level of the 
mammalian target of rapamycin (mTOR), a key protein in the transduction pathway from IL-2 
receptor to cell cycle activation. 
Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid, which inhibits inosine 
monophosphate dehydrogenase, a key enzyme in purine synthesis. T cells in particular are 
dependent on this pathway for cell division. It suppresses the proliferation of antigen-
stimulated T cells. 
To analyze the impact of the immunosuppressive agents, we compared the results of the 
CD4+ CD25high T cells sub-populations among stable transplant recipients with different 
immunosuppressive drugs; we also tested one individual who had his immunosuppressive 
regimen changed, at two different timepoints. 
Overall, among stable kidney transplant recipients on CNI-based immunosuppression, 47 
received tacrolimus (TAC) whilst 11 received cyclosporine A (CsA); the various 
immunosuppressive regimens are shown in Table 4. The sub-group of stable patients on 
sirolimus has already been discussed in the preceding section. 
Immunosuppression N= 
Tacrolimus 47
triple immunosuppression 17
TAC + MMF + pred 
TAC + aza + pred 
16
1
double immunosuppression 30
TAC + MMF 
TAC + aza 
TAC + pred 
27
2
1
Cyclosporine 11
triple immunosuppression 3
CsA + MMF + pred 3 
double immunosuppression 3
CsA + MMF 
CsA + pred 
2
1
single immunosuppression 5
CsA 5 
Table 4. Immunosuppressive regimens of 58 stable 
kidney transplant recipients on CNI-based 
immunosuppression. 
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Concerning the percentage of the activated CD4+ CD25high CD45RO+ CD127high T cell 
sub-population, we did not find any statistical difference between patients receiving TAC 
(15.56 ± 1.01%) and those receiving CsA (12.94 ± 1.65%; P=0.13), regardless of the use of 
other immunosuppressive drugs (e.g. MMF). In patients who did not receive MMF, there was 
no statistical difference between those receiving CsA (15.87 ± 2.03%) and those receiving 
TAC (18.54 ± 1.48%; P=0.32). Looking at the number of immunosuppressive agents that 
were prescribed, we did not find any statistical difference between patients receiving one, 
two, or three immunosuppressants, regardless of the CNI that was used. 
Concerning the percentage of the regulatory CD4+ CD25high CD127low FoxP3+ T cell 
sub-population, there was no significant difference between stable kidney transplant 
recipients receiving CsA (55.48 ± 4.87%) as compared to those receiving TAC 
(46.64 ± 2.68%; P=0.08), regardless of the use of other immunosuppressive drugs. In this 
case, the concomitant administration of MMF did not affect the percentage of the regulatory T 
cell sub-population (CsA: 45.98 ± 7.99%; TAC: 46.08 ± 2.87%; P=0.50). These results are in 
accordance with previously published data showing that MMF-exposed murine regulatory T 
cells maintain expression of FoxP3 and suppressive function in vitro (Zeiser R. et al., 2006). 
We had the opportunity to test a stable kidney transplant recipient (RN25) who had his 
immunosuppressive regimen changed for medical reasons: his treatment consisted of 
mycophenolate mofetil (360 mg/day) and tacrolimus (2x2 mg/day; trough level: 7.7 g/l), and 
was subsequently changed for sirolimus (1 mg/day; trough level: 4.2 g/l) and mycophenolate 
mofetil (180 mg/day). Interestingly, when he was on a CNI-based immunosuppression, the 
percentage of CD45RO+ CD127high T cells among CD4+ CD25high cells was 20.45%; this 
percentage subsequently dropped to 2.34% nine months after tacrolimus to sirolimus switch, 
without any change in his clinical status. This result indicates a striking impact of sirolimus 
on the percentage of activated T cells, at least in stable kidney transplant recipients. 
In conclusion, apart from the significant results of kidney transplant recipients on sirolimus-
based immunosuppression shown in the preceding section, there was no striking effect of the 
other immunosuppressive agents on the percentage of the activated T cell sub-population, or 
on the percentage of the regulatory T cell sub-population. 
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4.2.3.3. Homing properties of CD4+ CD25high T cell sub-populations in kidney 
transplantation 
One aspect that should be taken into account is that immune cells continuously travel through 
different lymphoid compartments (bloodstream, secondary lymphoid organs), and, after 
activation (e.g. rejection in the case of transplantation), through the different tissues they 
serve. The specific migration of immune cells to sites of inflammation is under the control of 
a family of chemoattractant cytokines known as chemokines, which induce directed 
chemotaxis in responsive cells such as leucocytes, monocytes, neutrophils and other effector 
cells. Chemokines can be released by many different types of cells, including monocytes, 
macrophages, neutrophils, mast cells, endothelial cells, platelets, keratinocytes, and 
fibroblasts, among others. They guide cells involved in innate immunity as well as cells 
involved in adaptive immunity, but some chemokines also function in lymphocyte 
development and angiogenesis. Responsive cells bear chemokine receptors on their cell 
surface, allowing them to respond to the recruitment signal provided by the ligation of a 
chemokine to its specific receptor. The panel of chemokine receptors expressed by immune 
cells can provide helpful information on their origin and function: for instance, chemokine 
receptors CCR3, CCR4 and CCR8 are typically expressed by TH2 cells and CCR2, CCR5, 
CxCR3 and CxCR6 by TH1 cells. 
In the literature, it was shown that regulatory T cells are heterogeneous in their expression of 
tissue-specific and inflammatory homing receptors, which allows them to migrate in a wide 
range of tissues and to suppress functionally distinct T cell subsets. The efficient suppression 
of immune responses requires the expression of a diverse array of adhesion and chemokine 
receptors by regulatory T cells; depending on the cytokine milieu in which they are activated, 
they might differentiate to have distinct chemokine receptor expression profiles. Indeed, 
antigen-specific regulatory T cells upregulate their expression of many nonlymphoid 
tissue-homing receptors, that overlap those of follicular TH cells (CxCR5), TH1 cells (CxCR3, 
CCR5, CxCR6), TH2 cells (CCR3, CCR4, CCR8), and TH17 cells (CCR2, CCR4, CCR6, 
CxCR3) (Lee JH et al., 2007; Hirahara K et al., 2006; Lim HW et al., 2008). On the other 
hand, transplantation, and especially allograft rejection, which is characterized by the 
infiltration of mononuclear cells within renal tissue, can be a source of inflammation, 
requiring expression of diverse chemokines by the affected tissue and of diverse chemokine 
receptors by the responsive cells. Experimental studies on human renal tissue in patients with 
renal allograft rejection indicate that MCP-1, MIP-1 (CCL3), MIP-1 (CCL4), RANTES, 
and IL-8 (CxCL8) play a major role in the resolution or progression of the inflammatory 
process; renal cells and inflammatory cells also express chemokine receptors, especially 
CCR5, CCR1, CCR2, and CxCR3 (Stasikowska O et al., 2007). It was shown that during 
acute renal rejection CCR1 mRNA was detectable whilst CCR3 and CCR8 were absent, and 
that leucocytes in diffuse interstitial infiltrates were mainly CCR5 positive, and those in 
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nodular aggregates mainly expressed CxCR4, indicating that renal allograft rejection is 
primarily the result of a TH1-type immune response (Segerer S et al., 2001). As demonstrated 
by Waldmann H et al. (2008), the ability of a graft to recruit regulatory T cells will depend on 
these cells having the right homing and chemokine receptors, and the graft being able to 
generate the appropriate ligands to attract them. 
Receptor Ligand(s) Expression pattern Function(s) 
CCR1 CCL3, CCL4, 
CCL5, CCL6, 
CCL14, CCL15, 
CCL16, CCL23 
TH1 cells  Migration to inflamed tissues 
CCR3 CCL3, CCL8, 
CCL16 
TH2 cells Migration to sites of allergic 
inflammation 
CCR4 CCL3, CCL5, 
CCL17, CCL22 
Skin-tropic CD4+ cells 
TH2 cells  
TH17 cells  
Treg cells 
Migration to normal and inflamed 
skin  
Migration to asthmatic airways  
Migration to sites of inflammation 
CCR5 CCL2, CCL3, 
CCL4, CCL5, 
CCL8, CCL11, 
CCL14, CCL16 
Naïve CD8+ cells  
TH1 cells  
CTLs  
Some Treg cells 
Guided encounters with "helped" 
DCs in lymph nodes  
Migration to inflamed tissues  
Migration to inflamed tissues 
CCR6 CCL20 TH17 cells Migration to inflamed tissues 
CCR7 CCL19, CCL21 Naïve cells  
TCM cells  
Some Treg cells 
Migration to resting lymph nodes  
Interstitial motility in lymph nodes  
Migration to resting lymph nodes 
CCR9 CCL25 Gut-tropic CD4+ and CD8+
cells 
Migration to lamina propria and 
GALT 
CxCR1 CxCL6-CxCL8 CTLs Migration to inflamed tissues 
CxCR2 CxCL1-CxCL8 CTLs Migration to inflamed tissues 
CxCR3 CxCL9, CxCL10, 
CxCL11 
TH1 cells  
CTLs  
TH17 cells  
NK T cells  
Some Treg cells 
Migration to inflamed tissues  
Migration to inflamed lymph nodes 
and tissue  
Migration to inflamed tissues  
Migration to inflamed tissues 
CxCR4 CxCL12 TCM cells  
Naïve cells 
Migration to resting lymph nodes 
CxCR5 CxCL13 Follicular helper CD4+ cells 
Some Treg cells 
Migration to T cell–B cell border and 
GC in lymph nodes 
Table 5. Chemokine receptors on T cell subsets (adapted from Bromley SK et al., 2008). 
TCM: central memory T cells; GC: germinal centre; GALT: gut-associated lymphoid tissue. 
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In the context of our study, it was interesting to analyze the panel of chemokine receptors 
expressed by the activated and regulatory circulating CD4+ CD25high T cell sub-populations, 
to compare them with CD4+ CD25neg T cells, and to try to see if patients with different 
clinical conditions (stable, CHR, minimal immunosuppression) display a differential 
expression of chemokine receptors. The methods used in this part of the study are described in 
the "Materials and methods" chapter. For technical reasons, we could not test all 91 kidney 
transplant recipients of our retrospective study; we decided to select representative subjects 
and controls: we tested 5 stable kidney transplant recipients, 4 kidney transplant recipients 
with CHR, 5 kidney transplant recipients on minimal immunosuppression, and 5 healthy 
individuals. We have also made a selection of the chemokine receptors we wanted to test, on 
the base of the available literature. They are briefly described in Table 5 (adapted from 
Bromley SK et al., 2008). 
4.2.3.3.1. CCR1 / CCR3 
No expression of CCR1 or CCR3 could be detected on circulating T cells in any group of 
patients or in healthy individuals. We can explain these results by the fact that in the absence 
of an acute inflammatory episode, as it was the case in our patients, there is no reason to find 
CCR1 or CCR3 positive T cells in the peripheral blood. On the contrary, it would be 
interesting to test patients with ongoing acute rejection; we can speculate that in this particular 
situation CCR1 and/or CCR3 positive circulating T cells would be detectable, in the 
peripheral blood as well as in renal biopsies. 
4.2.3.3.2. CCR4 / CCR5 / CCR6 
CCR4, CCR5 and CCR6 displayed a comparable expression pattern in our three kidney 
transplant recipients groups and in healthy individuals. In circulating CD3+ CD4+ T cells, only 
approximately 7% of circulating T cells were CCR4 positive, 2% were CCR5 positive, and 
13% were CCR6 positive; these results also apply to CD4+ CD25neg T cells since most 
CD3+ CD4+ T cells are CD25 negative. By contrast, significantly more CD4+ CD25high T cells 
were positive for CCR4 (29.1 ± 3.5%; P<0.001 as compared to CD4+ CD25neg cells), CCR5 
(5.0 ± 1.2%; P<0.05) and CCR6 (24.8 ± 3.0%; P<0.05). When comparing the expression 
profile of the regulatory and activated CD4+ CD25high T cell sub-populations, we found that a 
significantly higher percentage of activated T cells expressed CCR6 (57.8 ± 3.7%; P<0.001) 
as compared to regulatory T cells (29.6 ± 2.9%); on the other hand, regulatory T cells 
expressed significantly more CCR4 (43.8 ± 3.1%; P<0.05) than activated T cells 
(33.9 ± 3.2%). Expression of CCR5 was low and comparable in both sub-populations 
(activated T cells: 5.7 ± 1.2%; regulatory T cells: 4.9 ± 1.1%; P=0.33). Interestingly, naïve 
CD4+ CD25high T cells (defined as CD45RO negative) did virtually not express CCR4, CCR5 
or CCR6. These observations confirm that CCR4, CCR5 and CCR6 are mainly expressed by 
memory T cells, especially memory CD4+ T cells. They also show that these chemokine 
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receptors are up-regulated in CD4+ CD25high T cells, as compared to CD4+ CD25neg T cells, 
which is consistent with their role in organizing the migration of T cells to sites of 
inflammation. Interestingly, we found that a higher percentage of regulatory T cells expressed 
CCR4 as compared to activated T cells, whilst on the contrary a higher percentage of 
activated T cells were found to express CCR6. However, we did not find a significant 
difference between kidney transplant recipients and healthy individuals on one hand, and 
stable kidney transplant recipients and transplant recipients with CHR on the other hand, as 
we could have expected. One explanation could be the same as the one given for CCR1 and 
CCR3, namely that none of our patients was experiencing acute rejection at the time of this 
study. 
4.2.3.3.3. CCR7 
The chemokine receptor CCR7, which typically controls the migration of T cells to secondary 
lymphoid organs such as lymph nodes, was found to be expressed by approximately 70% of 
CD3+ CD4+ T cells. However, there were significant differences between kidney transplant 
recipients and healthy individuals. As compared to healthy individuals (74.1 ± 3.0% of 
CD3+ CD4+ cells were CCR7 positive), the percentage of CCR7 positive cells among 
CD3+ CD4+ cells was significantly decreased in stable kidney transplant recipients 
(48.2 ± 1.7%; P<0.005) and in kidney transplant recipients with CHR (61.2 ± 5.0%; P<0.05); 
by contrast, it was comparable to healthy individuals in kidney transplant recipients on 
minimal immunosuppression (72.7 ± 8.0%; P=0.44). Again, the same observations could be 
applied to CD4+ CD25neg T cells, but not to CD4+ CD25high T cells. In this cell population, a 
smaller proportion of cells expressed CCR7, and percentages found in healthy individuals 
(35.0 ± 5.5%), stable kidney transplant recipients (19.8 ± 0.6%), kidney transplant recipients 
with CHR (41.1 ± 6.0%) and those on minimal immunosuppression (49.3 ± 5.8%) were not 
statistically different. When we compared regulatory and activated CD4+ CD25high T cell 
sub-populations, we found a trend, however not statistically significant, in a higher percentage 
of CCR7 positive cells among activated T cells (approximately 40%) as compared to 
regulatory T cells (approximately 30%). By contrast, a very high proportion of naïve 
CD4+ CD25high T cells (defined as CD45RO negative) expressed CCR7 (approximately 80%). 
These results confirm that CCR7 is mainly expressed by naïve cells, and also by a significant 
proportion of memory T cells, which are called "central memory" (TCM). This subset of 
memory T cells is functionally important, since central memory T cells are in the first line in 
lymph nodes for the presentation of antigens; they have limited effector function, but they 
proliferate and become effector cells upon secondary antigenic stimulation. By contrast, 
another subset of memory T cells, called "effector memory" (TEM), does not express CCR7 
and consequently does not home to lymph nodes but to peripheral tissues, where it can rapidly 
produce effector cytokines (e.g. IFN); however, its proliferative capacity is limited. TCM are 
involved in secondary responses and long-term function, whilst TEM provide immediate 
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function. In our case, the majority of CD4+ CD25neg T cells appear to be TCM, although we 
observed significant differences between kidney transplant recipients and healthy individuals; 
this could be explained by the presence of the antigenic stimulus provided by the allograft, 
promoting the preferential differentiation of TEM over TCM except in transplant recipients on 
minimal immunosuppression who may display a more "tolerogenic" state. In CD4+ CD25high
T cells, the majority of cells were CCR7 negative TEM, and percentages found in healthy 
individuals and kidney transplant recipients were comparable. These results further support 
the idea that both regulatory and activated T cells are functionally heterogeneous populations 
from the point of view of their migratory properties. 
4.2.3.3.4. CCR9 
No CCR9 expression could be detected on CD3+ CD4+ T cells, which could be expected, 
CCR9 being expressed by T cells homing to the gut. 
4.2.3.3.5. CxCR1 / CxCR2 
CxCR1 and CxCR2 were not detected in CD3+ CD4+ T cells, they seem to be specifically 
expressed on cytotoxic CD8+ T lymphocytes. 
4.2.3.3.6. CxCR3 
CxCR3 was found to be expressed by a small proportion of CD3+ CD4+ T cells as well as 
CD4+ CD25neg T cells (5.8 ± 0.7%), but no difference was found between the kidney 
transplant recipients and healthy individuals. However, we observed that significantly more 
activated CD4+ CD25high T cells expressed CxCR3 (9.3 ± 1.8%) as compared to the regulatory 
T cell sub-population (4.8 ± 0.8%; P<0.05), although these percentages remain small. 
Furthermore, naïve CD4+ CD25high T cells expressed virtually no CxCR3. 
4.2.3.3.7. CxCR4 
Almost all CD3+ CD4+ T cells expressed CxCR4 (92.5 ± 1.3%), and no difference was found 
between the different groups of patients and the healthy individuals, or between CD4+
CD25high T cells (91.2 ± 1.3%) and CD4+ CD25neg T cells (92.5 ± 1.3%; P=0.24). As found 
for CCR7, we also observed a trend to a higher percentage of activated T cells expressing 
CxCR4 (90.9 ± 1.4%) as compared to regulatory T cells (87.5 ± 1.6%; P=0.07), and a 
significant increase of CxCR4 positive cells in the naïve population of CD4+ CD25high cells 
(97.4 ± 0.4%; P<0.001). This is in accordance with the fact that CxCR4 is mainly expressed 
by TCM and naïve T cells. 
4.2.3.3.8. CxCR5 
A small percentage of CD3+ CD4+ T cells were found to express CxCR5 (11.7 ± 1.0%), and 
no difference was found between the different groups of patients and the healthy individuals, 
or between CD4+ CD25high T cells (12.2 ± 2.0%) and CD4+ CD25neg T cells (11.2 ± 1.0%; 
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P=0.36). Comparing activated and regulatory T cell sub-populations, we observed a small 
increase in the percentage of activated T cells expressing CxCR5 (14.0 ± 2.8%) as compared 
to regulatory T cells (8.5 ± 1.2%; P=0.04), and naïve CD4+ CD25high T cells expressed even 
more CxCR5 (22.8 ± 5.1%). 
Based on these results, the main conclusion is that T cell populations that seem to share the 
same function are in fact highly heterogeneous from the point of view of their migration and 
homing properties. The overall CD3+ CD4+ T cell population expressed mainly CCR7 and 
CxCR4 (both lymph node homing receptors) and a small percentage also expressed CxCR5 
(homing to lymph nodes) and CCR4, CCR5, CCR6, CxCR3 (homing to inflamed tissues); 
obviously, the same phenotype was found among CD4+ CD25neg T cells. This indicates that 
CD4+ CD25neg T cells mainly contain central memory and naïve cells that have not yet been 
activated, recirculating in the bloodstream between secondary lymphoid organs, such as 
lymph nodes. On the other hand, CD4+ CD25high T cells expressed more or less the same 
chemokine receptors, but in significantly different proportions as compared to CD4+ CD25neg
T cells. We found that CCR7 was less expressed, whilst CCR4 and CCR6 were more 
expressed, suggesting that CD4+ CD25high T cells contained less cells homing to lymph nodes 
and were enriched in cells homing to sites of inflammation. This could be expected since 
CD4+ CD25high T cells contain recently activated T cells, which have upregulated CD25 
expression on their cell surface. When we compared the chemokine receptor expression 
profile of activated and regulatory CD4+ CD25high T cell sub-populations, we found some 
differences, but they were not striking. It is not surprising that these populations studied in the 
peripheral blood are heterogeneous from the point of view of their homing characteristics; 
both must have the capacity to migrate to secondary lymphoid organs as well as to peripheral 
tissues to exert their function where it is required. The picture would have certainly been 
completely different if we had looked into renal biopsies of patients with acute or chronic 
rejection; we would have expected to find cells expressing chemokine receptors specific for 
peripheral tissues and inflammation. Another point that would be interesting to look at is the 
case of transplant recipients with ongoing acute rejection; we can speculate that a majority of 
circulating T cells would express chemokine receptors controlling their migration to the site 
of inflammation. 
4.2.4. Discussion of the retrospective part 
In this retrospective part of our study, we have extended the results of our initial results 
published in The Journal of Experimental Medicine in July 2007. Furthermore, we have 
increased our knowledge of how CD4+ CD25high T cells and the activated, respectively 
regulatory, T cell sub-populations are influenced by the clinical status of the kidney transplant 
recipients as well as by the prescribed immunosuppressive regimens. 
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We have shown that the overall percentage of CD4+ CD25high T cells was significantly 
decreased in all transplant recipients, with the exception of stable transplant recipients 
receiving sirolimus as immunosuppressive therapy. This reduction is probably due to the 
direct inhibitory effect of immunosuppressive drugs on the activation of T cells, limiting 
upregulation of the CD25 molecule at the T cell surface. The extent of the reduction of the 
percentage of CD4+ CD25high T cells was similar in all study groups (except in the already 
mentioned group of stable patients on sirolimus), thus limiting the usefulness of this 
parameter to help in clinical diagnosis. 
The percentage of the sub-population of regulatory T cells, defined as CD4+ CD25high FoxP3+
CD127low cells, was also found to be significantly decreased in all transplant recipients, as 
compared to healthy individuals. The lowest percentage was found in patients receiving a 
CNI, whilst the use of sirolimus seemed to preserve regulatory T cells; the use of MMF did 
not affect the percentage of the sub-population. However, the extent of the reduction of 
regulatory T cells was similar in all study groups, again limiting the practical usefulness of 
this parameter in a clinical setting. 
By contrast, we found that there was a very good correlation between the percentage of the 
activated T cell sub-population, defined as CD4+ CD25high CD45RO+ CD127high cells, and the 
clinical status of the patients. The highest percentage was found in kidney transplant 
recipients suffering from chronic humoral rejection, whilst clinically stable recipients on no or 
minimal immunosuppression displayed a percentage comparable to the one of healthy 
individuals; in clinically stable patients receiving standard CNI-based immunosuppression, 
the percentage of the activated T cell sub-population was intermediate. 
Finally, we have analyzed the chemokine receptor profile of CD3+ CD4+ T cells, of 
CD4+ CD25high T cells and of the activated and regulatory CD4+ CD25high T cell 
sub-populations. We could observe that these populations are very heterogeneous from the 
point of view of their migratory and homing properties, and that the proportion of cells 
expressing secondary lymph node homing or peripheral tissue homing chemokine receptors 
was significantly different between the populations we studied. 
These results could reflect the fact that the level of activation of T cells is different depending 
on the degree of graft acceptance by the transplant recipient. They also indicate that stable 
transplant recipients, despite apparently efficient immunosuppressive therapy, have a 
significant percentage of peripherally circulating activated T cells, which in this situation can 
be named "alloreactive". On the other hand, stable transplant recipients on no or minimal 
immunosuppression seem to be in a more tolerogenic state towards their graft, since the 
percentage of circulating alloreactive T cells is comparable to the one of healthy individuals. 
Of note, the small amount (approximately 5-6%) of "activated T cells" found in healthy 
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individuals is likely due to the continuous challenge of our immune system by foreign 
antigens. 
The quality of this retrospective part of our study could have been improved by considering at 
least two additional points. First, we have been focusing on the phenotype of peripherally 
circulating T lymphocytes subsets; however, it is obvious that the situation observed in the 
peripheral circulating blood may not reflect exactly what happens in the draining lymph nodes 
and/or in the organ targeted by the potentially detrimental immune response, namely the 
allograft. In this regard, it could be interesting to compare the phenotype of T lymphocytes in 
the draining lymph nodes as well as in the allograft in our different study groups; however, as 
already mentioned, this implies the use of invasive techniques that may be not ethically 
acceptable in otherwise healthy individuals. The second important limitation of our study is 
that we did not consider the functional aspect of the CD4+ CD25high T cells sub-populations; it 
would be very interesting to examine the respective functionality of these subsets. On one 
hand, the suppressive capacity of the regulatory T cell subset should be assessed in our study 
groups, and when possible, it should include a specific donor antigens stimulation as 
compared to a third-party antigens stimulation of responder cells. On the other hand, the 
proliferative response of the activated T cell subset (alloimmune response) should also be 
assessed; again, when possible (availability of cells of the organ donor), it should include the 
proliferative response toward donor antigens, the proliferative response toward third-party 
antigens (fully HLA-A, -B, and -DR mismatched with recipient and donor), as well as the 
non-specific proliferative response toward common mitogenic agents. In addition, the 
proliferative response could also be examined with regard to the depletion of regulatory T 
cells. 
To complete our study, we decided to add a prospective view of the evolution of CD4+
CD25high T cells and their sub-populations. This part of the study was implemented to monitor 
the above-mentioned parameters at defined timepoints over the first year after transplantation, 
in close correlation with clinical data. It would allow us to compare two routinely used 
induction regimens, which have distinct mechanisms of action. Preliminary results have been 
described in our publication, in the part "Importance of the analysis of the CD4+ CD25high
CD45RO+ IL-7Rhigh cell population in the clinical monitoring of transplant recipients".
Results of this prospective part of the study are shown in the next section. 
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4.2.5. Analysis of functionally distinct subsets of CD4+ CD25high T cells 
in solid organ transplant recipients: prospective part of the study 
We performed the same kind of immunological experiments (polychromatic flow cytometric 
phenotyping of peripheral blood mononuclear cells), using the same gating strategy as the one 
described in the chapter on healthy individuals [Figures 23 and 24]. 
4.2.5.1. Patient characteristics 
Thirty-five patients were studied prospectively, all of them having received a first kidney 
graft from a cadaveric or living donor. Nineteen of them received thymoglobulin as induction 
regimen, followed by a standard, but steroid-free, maintenance immunosuppressive therapy 
(tacrolimus and mycophenolate mofetil) ("THYMO group"); on the other hand, 16 received 
basiliximab as induction, followed by tacrolimus, mycophenolate mofetil and prednisone 
("BSX group"). Relevant demographic data of these patients are summarized in 
Appendix III. The two study groups did not differ in terms of gender, age at the time of 
transplantation, and HLA mismatches. 
4.2.5.2. Thymoglobulin and basiliximab induction regimens 
The two induction regimens that were compared in this part of the study are individually 
based on different modes of action and thus may exert different effects on various lymphocyte 
sub-populations. They will be discussed hereafter, focusing on CD4+ CD25+ T cells. 
Thymoglobulin (Thymoglobulin®; Genzyme Transplant) has been in use for more than 30 
years. It consists of a purified polyclonal anti-lymphocyte preparation obtained by 
immunization of rabbits with human thymocytes. It contains cytotoxic antibodies directed 
against antigens expressed on human T lymphocytes (such as CD2, CD3, CD4, CD8, CD11a, 
CD18, CD25, CD44, CD45, HLA-DR, HLA class I and 2-microglobulin), and results in 
rapid depletion of T lymphocytes, primarily through complement-dependent cell lysis in the 
blood compartment and apoptotic cell death in lymphoid tissues. Its half-life is about 2-3 
days, but in 80% of patients thymoglobulin can still be detected in the serum 2 months after 
the end of its administration. Besides T cell depletion, possible mechanisms by which 
thymoglobulin may induce immunosuppression in vivo include: T cell clearance from the 
circulation, and modulation of T cell activation, trafficking and cytotoxic activities. Treatment 
with thymoglobulin has been shown to be associated with both short- and long-term changes 
in T cell populations, in particular characterized by expansion of specific T cell subsets 
exhibiting regulatory properties (Mueller TF, 2007). Recent studies suggest that 
thymoglobulin relatively spares CD4+ CD25high regulatory T cells, compared with CD8+ T 
cells, CD4+ naïve T cells and central memory T cells (Lopez M et al., 2006; Pearl JP et al., 
2005), and thus could be beneficial in the optic of transplantation tolerance development. 
4. RESULTS 
99 
Basiliximab (Simulect®; Novartis Pharma) is a chimeric monoclonal antibody (half-life: 7 
days) that specifically binds to and blocks the interleukin-2 receptor  chain (IL-2R, CD25), 
which is expressed on the surface of activated as well as regulatory T cells. The complete and 
constant blockade of the IL-2R is maintained as long as the serum level of basiliximab is 
higher than 0.2 g/ml. This specific high affinity binding to CD25 competitively inhibits 
IL-2-mediated activation of lymphocytes, a critical pathway in the cell-mediated immune 
response involved in allograft rejection. However, IL-2 is also critical for the generation and 
survival of regulatory T cells, which produce only negligible amounts of IL-2 on their own 
and depend on other T cell subsets for IL-2 providing. Therefore, the possible tolerance 
promoting effect of basiliximab, through elimination of alloreactive activated CD4+ CD25+
T cells, could be offset by the prevention of regulatory cell function. Two studies, among 
others, have addressed these concerns. Game DS et al. (2005) showed in in vitro experiments 
that human CD4+ CD25+ cells cultured in presence of basiliximab retained suppressive 
capacity on the proliferation and IFN secretion by CD4+ CD25neg cells responding to 
allogeneic and other polyclonal stimuli. On the other hand, in renal transplant recipients 
receiving basiliximab as induction, Bluestone JA et al. (2008) reported that basiliximab 
caused a profound, but transient, reduction of CD4+ CD25+ FoxP3+ regulatory T cells, within 
7 days of treatment and with a progressive recovery 90 days after treatment, but that their 
function was maintained during the treatment; by contrast, basiliximab did not have a long-
term effect on the percentage or on the functionality of circulating CD4+ CD25+ FoxP3+
regulatory T cells, as compared to pre-transplant levels. However, basiliximab did also lead to 
a dramatic decrease in CD4+ CD25+ FoxP3- activated cells, which contain potential 
alloreactive effector T cells; thus, the authors concluded that the net result was a shift toward 
regulation. 
From a clinical point of view, several studies have compared the effectiveness and safety of 
thymoglobulin versus the anti-IL-2R monoclonal antibodies (among others, Brennan DC et
al., 1999; Al Najjar A et al., 2006). Taken together, these two studies suggest that for the 
lower immunological risk patients basiliximab may be a safer choice (lower incidence of side 
effects) while for the higher immunological risk patients (retransplants, patients with 
panel-reactive antibodies greater than 20%, 6 HLA antigen mismatches, patients of African 
descent) thymoglobulin is likely to be a more effective therapy (lower incidence of 
biopsy-proven acute rejection). 
In our prospective study, all kidney transplant recipients could be classified as low 
immunological risk patients, allowing us to perform consistent comparisons between the two 
study groups. 
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4.2.5.3. Clinical outcome of the patients 
The major concern in the first months after kidney transplantation is the development of a 
rejection episode. Nowadays, the incidence of hyperacute rejection has become insignificant 
thanks to the routine detection of pre-existing anti-donor antibodies. Likewise, acute 
rejections have become rare events (incidence of approximately 10-15%) with the 
improvement of induction regimens and the availability of more potent immunosuppressive 
drugs capable of preventing or treating them. 
In our cohort of patients, as expected no hyperacute rejection occurred; the incidence of acute 
rejection (within the first 6 months after transplantation) was 10.5% (2/19 patients) in the 
THYMO group, and 12.5% (2/16 patients) in the BSX group (not statistically significant). In 
the THYMO group, both acute rejection episodes were cell-mediated and severe, whilst in the 
BSX group there were one humoral and one cellular rejection episodes, both of moderate 
severity. All four rejection episodes resolved successfully with a short course of high-dose 
corticosteroids and the recipients' serum creatinine levels at 6 months after transplantation 
were similar (THYMO group: 129.5 mol/l; BSX group: 125.5 mol/l) and comparable to the 
one of the rejection-free patients. 
The overall serum creatinine levels were not statistically different at any timepoint between 
the two study groups [Table 6]. 
Serum creatinine (mol/l) P value 
THYMO 
group 
BSX 
group 
Before transplantation 654.1 ± 68.3 544.9 ± 57.1 0.13 
3 months post-transplantation 124.9 ± 7.7 114.0 ± 5.5 0.15 
6 months post-transplantation 124.6 ± 7.9 130.6 ± 10.0 0.33 
12 months post-transplantation 126.9 ± 8.2 132.9 ± 11.2 0.34 
Table 6. Respective serum creatinine levels in the THYMO and BSX groups, before 
and 3, 6 and 12 months after kidney transplantation. 
4.2.5.4. Changes in leucocyte and lymphocyte absolute counts during the first year 
after kidney transplantation 
As expected based on the differing modes of action of the two induction regimens studied, the 
leucocyte and lymphocyte counts varied differently in the THYMO and in the BSX groups.  
In both study groups, the pre-transplant leucocyte count (normal range: 4.0-10.0 G/l) was 
comparable to the one of healthy individuals (THYMO group: 7.1 ± 0.5 G/L; BSX group: 
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7.0 ± 0.5 G/L; healthy individuals: 6.8 ± 0.4 G/L). Similarly, the pre-transplant relative 
percentage of lymphocytes among leucocytes (normal range: 25-40%) was also comparable in 
the THYMO group (26.0 ± 2.4%), in the BSX group (22.1 ± 2.3%) and in healthy individuals 
(24.3 ± 1.0%). 
In the THYMO group, the mean absolute leucocyte count dropped of approximately 25% by 
1 month after transplantation (5.3 ± 0.6 G/L), continued to drop at 3 months (4.2 ± 0.6 G/L) 
and 6 months (3.7 ± 0.4 G/L), and then began to recover partially at 12 months 
(4.5 ± 0.4 G/L), but without reaching the pre-transplant count or the count found in healthy 
volunteers [Figure 37]. This long-lasting leucocyte depleting effect of thymoglobulin (in 
patients receiving an immunosuppressive regimen composed of CNIs and MMF) is well 
known and has been shown to persist until at least 2 years after transplantation (Hardinger KL 
et al., 2004; Toso C et al., 2008); moreover, as already mentioned, it is accompanied by a 
redistribution of T cell sub-populations, that will be discussed later. 
On the other hand, basiliximab did not have the depleting effect of thymoglobulin; in the BSX 
group, the mean absolute leucocyte count remained stable and in a normal range throughout 
the 12 months after transplantation (3 months after transplantation: 7.8 ± 0.8 G/l; 6 months: 
7.0 ± 0.6 G/l; 12 months: 7.3 ± 0.8 G/l) [Figure 37]. 
Figure 37. Mean absolute leucocyte count in the THYMO and in the BSX 
groups, before and during the 12 months after transplantation. 
Looking at the lymphocyte population among leucocytes, we found that basiliximab did not 
induce a change in the proportion of the whole lymphocyte population: approximately 
20-25% (1.5-2 G/l) of leucocytes belonged to the lymphocyte lineage, a percentage that 
remained stable throughout the 12 months after transplantation. By contrast, in addition to its 
above-mentioned depleting effect on the total leucocyte population absolute count, 
thymoglobulin preferentially affected lymphocytes; at 1 month after transplantation, the 
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percentage of lymphocytes dropped to 6.35%, and then slowly increased during the next 12 
months. The mean absolute lymphocyte count followed approximately the same kinetic 
[Figures 38A and 38B]. 
Figure 38A. Mean percentage of lymphocytes among 
leucocytes, before and 1, 3, 6 and 12 months after 
transplantation, in the THYMO and BSX groups. 
Figure 38B. Mean lymphocyte absolute count, 
before and 1, 3, 6 and 12 months after 
transplantation, in the THYMO and BSX groups. 
Because of the depleting effect of thymoglobulin, it will be important for us to base our 
results not only on relative percentages of T cell sub-populations, but also on absolute 
numbers. 
4.2.5.5. Changes in T cell sub-populations during the first year after kidney 
transplantation 
In line with the analyses performed in the retrospective part of our study, we were interested 
in studying the evolution of CD4 T cells, and in particular of CD4+ CD25high T cells and their 
sub-populations, during the first year after kidney transplantation, and in comparing the 
respective impact of the two different regimens described above (thymoglobulin and 
basiliximab). 
4.2.5.5.1. CD4+ T cells 
Before transplantation, the mean proportion of CD4+ T cells among the whole lymphocyte 
population in both THYMO and BSX groups was slightly but significantly decreased as 
compared to healthy individuals (THYMO: 41.73 ± 2.75%; BSX group: 39.28 ± 2.26%; 
healthy individuals: 50.04 ± 1.74%; P<0.05 and P<0.005 respectively) [Figure 39A]; this 
result is in accordance with Litjens NHR et al. (2006), who showed that end-stage renal 
disease is associated with lymphocytopenia, especially in the CD4+ T cell and B cell 
compartments.  
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At 1 month after transplantation, the mean percentage of CD4+ T cells among total 
lymphocytes in the THYMO group was found to be decreased by approximately 50% 
(19.99 ± 2.72%; P<0.001) as compared to pre-transplant value. Although we had not access to 
blood samples of the immediate post-operative period, we can speculate that this percentage 
was even more dramatically reduced in the days during and immediately after thymoglobulin 
treatment. A correlate of this observation is that thymoglobulin induces a significant change 
in the CD4/CD8 ratio, which is consistent with previous studies (Mueller TF, 2003). These 
changes stably persisted during the next 12 months of observation (3 months: 23.38 ± 2.10%; 
6 months: 24.16 ± 2.41%; 12 months: 26.58 ± 2.83%) [Figure 39A]. This indicates that 
thymoglobulin induces a profound change in lymphocyte sub-populations, with a preferential 
depletion of CD4+ T cells, as could be expected from its binding properties and its 
regeneration characteristics promoting an earlier homeostatic response of CD8+ T cells.
By contrast, basiliximab did not decrease the CD4/CD8 ratio in the BSX group. By 3 months 
after transplantation, the proportion of CD4+ T cells among lymphocytes had gone back to 
normal values (48.87 ± 2.89%; P=0.34 as compared to healthy individuals), and remained 
stable until the end of the observation period (6 months: 50.36 ± 2.57%, P=0.48; 12 months: 
50.08 ± 3.13%, P=0.44) [Figure 39A]. 
Considering the CD4+ T cell absolute count, the results are consistent with the changes 
observed in CD4+ T cell and lymphocyte percentages. In the THYMO study group, 
thymoglobulin induced a drop in CD4 T cells that persisted during the 12 months of 
observation. On the other hand, basiliximab did not decrease the absolute number of CD4+ T 
cells [Figure 39B]. 
Figure 39A. Mean percentage of CD4+ T cells among 
lymphocytes, before and 1, 3, 6 and 12 months after 
transplantation, in the THYMO and BSX groups. 
Figure 39B. Mean CD4+ T cell absolute count, 
before and 1, 3, 6 and 12 months after 
transplantation, in the THYMO and BSX groups. 
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4.2.5.5.2. CD4+ CD25high T cells 
The mean percentage of CD25high cells within CD4+ T cells before transplantation was 
comparable in the THYMO group (1.48 ± 0.23%; P=0.30), in the BSX group (1.54 ± 0.24%; 
P=0.39) and in healthy individuals (1.62 ± 0.16%) [Figure 40A]. 
In the THYMO group, after transplantation, the proportion of CD25high cells among CD4+
T cells followed a bimodal kinetic: after an initial significant increase at 1 month 
(2.94 ± 0.52%; P<0.01 as compared to pre-transplant value), it slowly decreased at 3 months 
(2.21 ± 0.37%; P=0.06) and was comparable to pre-transplant value at 6 months 
(1.67 ± 0.37%; P=0.40) and 12 months (1.65 ± 0.42%; P=0.36) [Figure 40A]. However, 
when considering the mean absolute count of CD4+ CD25high T cells, the strong depleting 
effect of thymoglobulin on lymphocytes, and especially on CD4+ T cells, has to be taken into 
account. Indeed, a sharp drop in the absolute CD4+ CD25high T cell count was observed as 
soon as 1 month after transplantation (1.51 ± 0.22 cell/l; P<0.001 as compared to pre-
transplant value and healthy individuals), that persisted throughout the next 12 months 
[Figure 40B]. 
In the BSX study group, the evolution of the proportion of CD25high cells among CD4+ T cells 
followed a different kinetic; a progressive decrease could be observed after transplantation 
(3 months: 0.74 ± 0.16%; 6 months: 0.43 ± 0.06%; 12 months: 0.21 ± 0.02%; P<0.01 as 
compared to pre-transplant value, to healthy individuals, and to patients of the THYMO 
group) [Figure 40A]. It would have been interesting to assess the percentage of CD4+
CD25high T cells in the immediate post-operative period (first month), when basiliximab 
exerted its full anti-IL-2R effect, but unfortunately we had not access to blood samples of this 
period; however, based on our observations and on previous publications (Toso C et al., 
2008), we can hypothesize that the expression of CD25 would have been hardly detectable. 
Since basiliximab had almost no effect on lymphocyte and CD4+ T cell absolute counts, it 
was not a surprise to observe that the CD4+ CD25high T cell absolute count also constantly 
decreased after transplantation [Figure 40B]. However, it should be noted that the decrease of 
CD4+ CD25high T cell percentage and absolute count observed in the BSX group after 
transplantation is probably also due to the effect of the maintenance immunosuppressive 
therapy. 
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Figure 40A. Mean percentage of CD25high cells among 
CD4+ T cells, before and 1, 3, 6 and 12 months after 
transplantation, in the THYMO and BSX groups. 
Figure 40B. Mean CD4+ CD25high T cell absolute 
count, before and 1, 3, 6 and 12 months after 
transplantation, in the THYMO and BSX groups. 
Although, as shown above, thymoglobulin and basiliximab had a completely different impact 
on lymphocyte, CD4+, and CD4+ CD25high T cell absolute counts, it was very interesting to 
note that at 12 months after transplantation the absolute count of CD4+ CD25high T cells was 
comparable in the THYMO (2.68 ± 0.51 cell/l) and in the BSX (2.10 ± 0.45 cell/l) study 
groups (P=0.23). We can hypothesize that both induction regimens exert their effect in the 
first one or two months after transplantation, whilst the changes observed afterwards are 
likely due to the maintenance immunosuppressive drugs (e.g. CNIs and MMF). 
As already emphasized in the retrospective part of our study, CD4+ CD25high T cells contain 
two functionally distinct subsets of cells, namely regulatory and activated T cells, which may 
differently impact on the clinical outcome of the transplantation. Their respective evolutions 
during the first year after transplantation and the effect of thymoglobulin versus basiliximab 
will be discussed in the next two parts. 
4.2.5.5.3. Regulatory T cell sub-population (defined as CD4+ CD25high FoxP3+ CD127low
cells) 
Before transplantation, the percentage of the regulatory T cell sub-population (defined as the 
percentage of FoxP3+ CD127low cells within CD4+ CD25high T cells) was found to be 
comparable between the THYMO group (74.29 ± 4.26%) and the BSX group 
(73.48 ± 3.42%), and as compared to healthy individuals (74.05 ± 2.01%; P=0.27 and P=0.21 
respectively). 
In the THYMO study group, the percentage of regulatory T cells tended to slowly decrease 
until 6 months after transplantation (1 month: 62.28 ± 4.41%; 3 months: 48.31 ± 4.43%; 
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6 months: 43.01 ± 3.55%); data at 12 months were not available. These results reached 
statistical significance, as compared to pre-transplant value or healthy individuals, at 3 months 
(P<0.005 and P=0.06 respectively) and 6 months after transplantation (P<0.001 and P<0.05) 
[Figure 41]. 
Figure 41. Evolution of the percentage of the regulatory T cell sub-population, before and 1, 3 
and 6 months after transplantation, in the THYMO and BSX groups. 
The evolution of regulatory T cells in the BSX study group was comparable to the one in the 
THYMO group. This percentage was found to be significantly decreased at 3 months 
(35.06 ± 1.90%) and 6 months (38.45 ± 1.33%) after transplantation, as compared to 
pre-transplant value and healthy individuals [Figure 41]. The respective percentages of 
regulatory T cells found at 3 months and 6 months after transplantation were statistically 
comparable between the THYMO group and the BSX group (P=0.07 and P=0.36). 
Of note, similar to the results found in stable kidney transplant recipients of the retrospective 
part of this study, the percentages of regulatory T cells were found to be decreased in these 
patients, probably as an effect of maintenance immunosuppressive therapy. 
We also calculated the absolute regulatory T cell count, thus taking into account the observed 
depleting effects of thymoglobulin and basiliximab. The long-lasting lymphocyte depleting 
effect of thymoglobulin induced a sharp drop of the regulatory T cell absolute count in the 
THYMO group after transplantation, which persisted during the 6 months of observation 
(before transplantation: 8.96 ± 1.28 cell/l; 1 month: 1.03 ± 0.14 cell/l; 3 months: 
0.94 ± 0.23 cell/l; 6 months: 0.91 ± 0.11 cell/l) [Figure 42]. All these results were 
statistically significant as compared to both pre-transplant value and healthy individuals. 
On the other hand, the specific CD4+ CD25high T cell depleting effect of basiliximab did also 
affect the absolute count of regulatory T cells in the BSX study group; it was found to be 
significantly decreased at 3 months (1.80 ± 0.19 cell/l) and 6 months (2.51 ± 0.11 cell/l)
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after transplantation, as compared to pre-transplant value (6.85 ± 1.05 cell/l) and healthy 
individuals [Figure 42]. 
Figure 42. Evolution of the mean absolute count of the regulatory T cell sub-population, before 
and 1, 3 and 6 months after transplantation, in the THYMO and BSX groups. 
4.2.5.5.4. Activated T cell sub-population (defined as CD4+ CD25high CD45RO+
CD127high cells) 
Before transplantation, the percentage of the activated T cell sub-population (defined as the 
percentage of CD45RO+ CD127high cells within CD4+ CD25high T cells) was comparable in 
the THYMO (5.94 ± 0.79%) and in the BSX (7.66 ± 0.91%) study groups (P=0.10), and both 
were comparable to healthy individuals (5.97 ± 0.36%). 
Thereafter, this population was found to be expanded as soon as 1 month after transplantation 
in the THYMO group (18.72 ± 3.25%; P<0.001 as compared to pre-transplant value). This 
expansion persisted at 3 months after transplantation (15.27 ± 1.51%; P<0.001), at 6 months 
(13.01 ± 1.54%; P<0.001) and 12 months (15.50 ± 1.87%; P<0.001) [Figure 43]. 
Similarly, at 3 months after transplantation, the activated T cell sub-population was found to 
be expanded (19.39 ± 1.70%; P<0.001 as compared to pre-transplant value) in the BSX study 
group, even to a significantly higher percentage as compared to the THYMO group (P<0.05). 
At 6 and 12 months after transplantation, this expansion also persisted (6 months: 
14.41 ± 1.42%, P<0.005 as compared to pre-transplant value; 12 months: 13.69 ± 2.34%, 
P<0.05), but values were not statistically different from the percentages found in the THYMO 
study group (6 months: P=0.20; 12 months: P=0.28) [Figure 43]. 
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Figure 43. Evolution of the percentage of the activated T cell sub-population, before and 1, 3, 6 
and 12 months after transplantation, in the THYMO and BSX groups. 
Of note, activated T cell sub-population percentages found in both THYMO and BSX study 
groups at 12 months after transplantation were comparable to those found in the stable kidney 
transplant recipients (14.57 ± 0.97%) of the retrospective part of this study. These results 
indicate that, despite adequate induction and maintenance immunosuppression, there is a 
rapid expansion of a population of activated CD4+ T cells after kidney transplantation, but 
with no apparent clinical relevance for the patients (no rejection), at least during the limited 
period of observation. However, it was also necessary to take into account the lymphocyte 
depleting effect of thymoglobulin and the CD4+ CD25high T cells depleting effect of 
basiliximab, and to adjust these results to absolute counts. 
As expected on the base of the profound and sustained CD4+ lymphocyte depleting effect of 
thymoglobulin, the mean absolute count of activated T cells dropped after transplantation in 
the THYMO group, remaining significantly below pre-transplant value and control value 
during the 12 months of observation (before transplantation: 0.60 ± 0.10 cell/l; 1 month: 
0.29 ± 0.06 cell/l; 3 months: 0.25 ± 0.07 cell/l; 6 months: 0.27 ± 0.10 cell/l; 12 months: 
0.38 ± 0.07 cell/l) [Figure 44]. 
Conversely, in the BSX study group, the mean absolute count of activated T cells was found 
to remain stable at 3 months after transplantation (0.70 ± 0.11 cell/l), as compared to 
pre-transplant value (0.66 ± 0.11 cell/l; P=0.30) and healthy individuals (0.79 ± 0.13 cell/l; 
P=0.24). However, thereafter, the activated T cells absolute count continuously decreased 
(6 months: 0.43 ± 0.06 cell/l; 12 months: 0.28 ± 0.06 cell/l) to values comparable to the one 
found in the THYMO group at the same timepoints, significantly below pre-transplant and 
control values [Figure 44]. 
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This apparent different evolution of the activated T cells absolute count during the first three 
months after transplantation could reflect the persisting effect of the induction agents, which 
subsequently disappears and is replaced by the effect of the maintenance immunosuppressive 
treatments. 
Figure 44. Evolution of the mean absolute count of the activated T cell sub-population, before 
and 1, 3, 6 and 12 months after transplantation, in the THYMO and BSX groups. 
Of note, in the THYMO group, there was a patient (GER-R13; see Appendix III) who 
experienced a severe and diffuse acute cellular rejection at day 40 after transplantation. 
Interestingly, the percentage of the activated T cell sub-population was highly increased 
(60.18% of CD45RO+ CD127high cells within CD4+ CD25high T cells), as was its absolute 
count (1.02 cell/l) at that timepoint. 
Taken together, both thymoglobulin and basiliximab induction regimens resulted in a 
significant decrease in activated T cells absolute count, what could be considered as a 
potential beneficial effect. However, both led to an even more dramatic decrease in regulatory 
T cells, what definitely cannot be beneficial for the outcome of a graft. As a consequence, the 
net result is the relative selective increase in activated (effector) T cells within the 
CD4+ CD25high T cell population. Another way to analyze the relative evolution of these 
CD4+ CD25high T cell sub-populations and to compare the two study groups could be to 
consider the ratio between the absolute counts of the activated and the regulatory subsets, 
rather than the absolute counts themselves. Applying this strategy, it becomes evident that in 
both study groups there is a relative increase of activated T cells as compared to their 
regulatory counterparts [Figure 45]. However, the kinetic in the THYMO and in the BSX 
study groups seems to be different. In the THYMO group, there is a significant increase of the 
activated/regulatory ratio of approximately four-fold, as soon as 1 month after transplantation, 
lasting until 6 months; at 12 months, the activated/regulatory ratio tended to decrease. In the 
BSX study group, the activated/regulatory ratio was also found to be increased at 3 months 
(approximately four-fold), and drastically decreased at 6 months (approximately two-fold); 
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unfortunately, no blood sample was collected at 1 month after transplantation, but based on 
our knowledge of the depleting effect exerted by basiliximab on CD4+ CD25high T cells 
(which should be stronger at 1 month than at 3 months), we can speculate that the 
activated/regulatory ratio would have been even more increased at 1 month after 
transplantation. Conversely, at 12 months after transplantation, we can hypothesize that the 
activated/regulatory ratio could have returned to "normal" or nearly "normal" values. 
Although it might be tempting to conclude that thymoglobulin is safer in the immediate 
post-transplantation period and that basiliximab is better for the long-term, these conclusions 
have to be taken with caution and be tested in larger studies with more frequent assessment of 
activated and regulatory T cell sub-populations, as well as with longer observation periods. 
Figure 45. Ratio between activated and regulatory T cell sub-populations, before and 1, 3, 6 
and 12 months after transplantation, in the THYMO and BSX groups. 
All values were normalized according to the values found before transplantation. 
4.2.6. Discussion of the prospective part 
In this prospective part of our study, we have analyzed the evolution of CD4+ CD25high T cells 
and their subsets (activated and regulatory) during the first 12 months after kidney 
transplantation, and we have compared the respective impact of two different induction 
regimens (thymoglobulin and basiliximab) on the percentages and absolute counts of the 
above-mentioned cell populations. 
Briefly, we have confirmed that thymoglobulin had a profound and persistent CD4 T cell 
depleting effect, whilst basiliximab induced depletion of CD4+ CD25high T cells, as expected 
based on their respective mechanisms of action. We have observed that in both THYMO and 
BSX study groups there was a significant increase of the percentage of the activated T cell 
sub-population, as soon as 1 month after transplantation, and a concomitant significant 
decrease of the percentage of the regulatory T cell sub-population. However, when looking at 
T cell sub-population absolute counts, the CD4 T lymphocyte depleting effect of 
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thymoglobulin resulted in a net decrease of both activated and regulatory T cell 
sub-populations in the THYMO group. By contrast, basiliximab caused the drop of regulatory 
T cells after transplantation, whilst activated T cells initially remained stable (at 3 months) 
and subsequently decreased. 
To avoid the bias of depletion, we decided to analyze these results by considering the ratio 
between activated and regulatory T cell absolute counts. The net result was an increase of this 
ratio in favor of the activated T cells, in both study groups, especially in the immediate 
post-transplantation period. This observation could explain, at least in part, why the first year 
after transplantation is well-known to be at risk for the development of acute rejection 
episodes. The balance between activated and regulatory T cells is shifted towards activated T 
cells; relatively expanded activated T cells (which contain alloreactive, potentially detrimental 
T cells) may subsequently escape the control of regulatory T cells in decreased numbers, 
although most of the time alloreactive T cells are kept in check thanks to potent 
immunosuppression. After this critical period, and with the disappearance of the negative 
impact of induction treatments on regulatory T cells, accommodation may occur, with the 
possible expansion of a regulatory T cell pool able to regulate anti-donor immune reactivity in 
an antigen-specific way. However, larger studies with a longer observation period are needed, 
looking at these parameters in order to correlate them with the long-term clinical outcome of 
transplant recipients. 
This prospective part of our study confirmed the results obtained in the retrospective part and 
permitted to make the link between the pre-transplant status and the "chronic" stable phase 
after transplantation. 
However, this prospective part of our study suffers from the same limitations as the one that 
have been already discussed in our retrospective part. Briefly, we examined only the 
phenotype of peripherally circulating T lymphocytes subsets, which may not exactly reflect 
the immunological events occurring in the renal allograft or its draining lymph nodes; again, 
there are many controversies among transplantation centers on the usefulness and ethical 
acceptability of performing protocol renal biopsies in otherwise healthy patients. On the other 
hand, as was performed for the phenotype, the functionality of the CD4+ CD25high T cells sub-
populations should also be examined prospectively; in particular, the suppressive capacity of 
the regulatory T cell subset should examined in the THYMO and BSX study groups, at the 
different timepoints during the first year after renal transplantation and for specific regulation 
on donor as well as third party antigens. 
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5. GENERAL CONCLUSIONS AND PERSPECTIVES 
Transplantation is now widely used to replace damaged or failing organs. In recent years, 
major advances have been made in the surgical techniques as well as in the understanding of 
the mechanisms implicated in the acceptance or the rejection of the transplanted organ. In this 
regard, the study of immunology, in particular of the immune responses elicited by a graft, 
represents a major challenge and, in the future, it will allow a better management of the 
transplant recipients. 
A role of CD4+ CD25high T cells in organ transplantation has been established more than ten 
years ago. Since then, the interest for the biology of this particular subset of immune cells has 
been growing steadily, and it has become clear now that the CD4+ CD25high regulatory T cells 
may be used as means for immune intervention strategies aiming at the development of 
transplantation tolerance, or, at least, as an additional tool for the long-term follow-up of 
transplant recipients. 
In this regard, we were interested in dissecting the phenotype and function of CD4+ CD25high
T cells, first in healthy individuals, and second in solid organ transplant recipients. When this 
project started five years ago, there were a lot of controversies on these subjects – and some 
of them still remain today. For example, in humans, there was no established distinctive 
marker to distinguish CD4+ CD25high regulatory T cells from conventional activated T cells; 
moreover, the mechanism of action of regulatory T cells (i.e., the mechanism by which they 
exert their suppressive effect on other immune cells) was still under debate. And the data 
available for transplant recipients were even more controversial. In this context, it was of 
great interest to perform a comprehensive study, in healthy individuals and in solid organ 
transplant recipients. 
Our initial results permitted to demonstrate that: 
• a novel phenotypic surface marker, the  chain of the IL-7 receptor (CD127), allowed 
a clear discrimination between regulatory and activated CD4+ CD25+ T cells, in 
healthy individuals (these results have been confirmed by two publications (Liu W et 
al., 2006; Seddiki N et al., 2006)); 
• this marker could also be used in patients after solid organ transplantation (liver and 
kidney); 
• the regulatory and activated T cell populations, defined on the base of CD127 
expression in CD4+ CD25high T cells, were differentially distributed in healthy 
individuals as compared to transplant recipients. 
This last observation prompted us to also focus our interest on the activated sub-population of 
CD4+ CD25high T cells. We hypothesized that these activated T cells could play an important 
role in the immune response directed towards the graft in the context of transplantation. 
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Our subsequent results, published in the Journal of Experimental Medicine in 2007 (Codarri L 
et al., 2007), showed that: 
• the proportion of the activated T cell sub-population among CD4+ CD25high T cells 
was significantly increased in stable liver and kidney transplant recipients as 
compared to healthy individuals, and even more in kidney transplant recipients with a 
biopsy-proven diagnosis of chronic humoral rejection; 
• cells with the typical activated phenotype were found among the cells infiltrating renal 
allografts of patients with chronic humoral rejection; 
• the activated T cell sub-population contained cells with an antigenic specificity for 
organ donor antigens ("alloreactive T cells"). 
To achieve a better understanding of the role and function of the CD4+ CD25high T cell 
sub-populations, we decided to increase the number of studied kidney transplant recipients, as 
well as the panel of clinical conditions, in terms of immunological status, maintenance 
immunosuppression, and induction regimens (retrospective part of the study, patients already 
being transplanted). 
We could demonstrate that: 
• the proportion of the activated T cell sub-population among CD4+ CD25high T cells 
was significantly increased in the vast majority of stable kidney transplant recipients, 
as compared to healthy individuals, whilst the proportion of the regulatory T cell 
sub-population was found to be decreased; 
• the activated T cell sub-population was significantly more expanded in kidney 
transplant recipients with chronic humoral rejection, whilst the proportion of the 
regulatory T cell sub-population was significantly more decreased. 
In addition, we obtained potentially clinically important data indicating that: 
• stable kidney transplant recipients on minimal immunosuppression ("pseudo-tolerant" 
recipients) were comparable to healthy individuals in terms of distribution of the 
activated and regulatory T cell sub-populations among CD4+ CD25high T cells (i.e., 
"normal" profile); 
• stable kidney transplant recipients on sirolimus-based immunosuppression also 
displayed a CD4+ CD25high T cell sub-populations distribution profile which was 
comparable to healthy individuals; 
• the effect of cyclosporine A, tacrolimus and mycophenolate mofetil on the distribution 
of the activated and regulatory T cell sub-populations among CD4+ CD25high T cells 
was similar; 
• CD4+ CD25high T cell sub-populations expressed different chemokine homing 
receptors as compared to conventional CD4+ CD25neg T cells and CD3+ CD4+ cells. 
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In addition to these retrospective results, we conducted a prospective study, to analyze the 
evolution of CD4+ CD25high T cell subsets during the first year after renal transplantation, and 
the potential influence of two different induction agents (thymoglobulin versus basiliximab). 
This prospective study could demonstrate that: 
• with either induction agent, the proportion of activated T cells increased rapidly after 
transplantation, whilst the proportion of regulatory T cells decreased progressively 
over the first 12 months after transplantation; 
• thymoglobulin had a strong and long-lasting depleting effect on T cells; as a 
consequence, both activated and regulatory T cells absolute counts were decreased 
after transplantation, but in different proportions, with the net result of a relative 
selective increase in activated T cells; 
• basiliximab did not deplete T cells but reduced the proportion of CD25high cells among 
CD4+ T cells; the activated T cells absolute count remained stable for the first three 
months after transplantation and subsequently decreased, whilst the regulatory T cell 
absolute count decreased immediately after transplantation; similar to thymoglobulin, 
the net result was a relative selective increase in activated T cells. 
Our study has allowed to have a better knowledge of CD4+ CD25high T cells in healthy 
individuals, and, more importantly, in solid organ transplant recipients. In particular, we have 
shown that this cell population is heterogeneous in terms of phenotype and function: by 
contrast to what was believed until recently, CD4+ CD25high T cells do not contain only 
regulatory T cells, but they also contain a small, but significant, proportion of activated T 
cells. This observation is perhaps not so important in healthy individuals, where 
approximately 95% of CD4+ CD25high T cells are regulatory T cells; by contrast, it is 
necessary to take this observation into account when studying conditions where the proportion 
of activated T cells can be expected to be increased, e.g. all clinical situations with 
inflammatory syndromes. The fact that researchers used only the CD4 and CD25 markers 
until recently may explain why studies on the role of regulatory T cells in inflammatory 
pathologies, including transplantation and autoimmunity, have led to controversial results. 
Indeed, significant changes in the relative and/or absolute distribution of regulatory and/or 
activated T cells within CD4+ CD25high T cells may have a significant impact on the observed 
frequency of CD4+ CD25high T cells as well as on their suppressive capacity. We have 
overcome this difficulty by using additional markers, namely the  chain of the IL-7 receptor 
(CD127) and FoxP3. However, we must acknowledge that the study of regulatory T cells 
phenotypic markers is probably not at the end: other markers will probably be identified in the 
future, which will further help in the isolation of a purer population of regulatory T cells and 
in the characterization of their properties. 
Our observation of an increased proportion of activated T cells within CD4+ CD25high T cells 
in the blood of solid organ transplant recipients was a completely new finding (Codarri L et
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al., 2007). Furthermore, the fact that this population could also be detected in renal biopsies 
of patients with chronic humoral rejection and that it contained alloreactive cells was a strong 
stimulus for us to continue to study the presence of this population in solid organ transplant 
recipients, besides regulatory T cells. Overall, our retrospective and prospective results 
provide a confirmation of our initial data, but most importantly they provide also new 
evidence on the clinical usefulness of monitoring these activated T cells in transplant 
recipients. Measuring these parameters provides for the first time a direct, and easy to use, 
assessment of the anti-donor immunological activity related to the presence of a renal 
allograft. This may be helpful in the routine follow-up of transplant recipients, as a 
complement to existing diagnostic tools (e.g., serum creatinine measurement, anti-HLA 
antibodies measurement, renal biopsy) for the assessment of graft function as well as for the 
individualization of the immunosuppressive treatment. However, it will be necessary to 
complete our understanding of the implicated mechanisms, e.g. in order to eliminate possible 
confounding factors such as concomitant infections or inflammatory pathologies. This goal 
may be achieved by conducting well-designed prospective clinical protocols, that will
correlate clinical, biological and histopathological findings with the parameters of interest, as 
well as by designing immunosuppression minimization protocols. 
Finally, our results on kidney transplant recipients presented in this work are further 
supported by results obtained by colleagues in our laboratory, who studied activated and 
regulatory T cells in the context of orthotopic liver transplantation, and the impact of hepatitis 
C chronic infection. This study has resulted in a manuscript which is currently submitted to 
the American Journal of Transplantation and which is reproduced in Appendix IV.
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aa .........................amino acid 
ADCC ..................antibody-dependent cell-mediated cytotoxicity 
AICD ...................activation-induced cell death 
AP-1 ....................activator protein 1 
APC .....................antigen-presenting cell 
AR .......................acute rejection 
ATGs ...................antithymocyte globulins 
aTreg ..................."adaptive" regulatory T cells 
aza .......................azathioprine 
BCR .....................B cell receptor 
BSX .....................basiliximab, or basiliximab study group 
cAMP ..................cyclic adenosine monophosphate 
CAN ....................chronic allograft nephropathy 
CHR ....................chronic humoral rejection 
CMV ....................cytomegalovirus 
CNI(s) ..................calcineurin inhibitor(s) 
CR .......................chronic rejection 
CsA ......................cyclosporine A 
CTL .....................cytotoxic T lymphocyte 
CTLA-4 ...............cytotoxic T lymphocyte-associated antigen 4 
CV .......................coefficient of variation 
DC(s) ...................dendritic cell(s) 
DGF .....................delayed-graft function 
DSA(s) .................donor-specific alloantibody(ies) 
DTH ....................delayed-type hypersensitivity 
EBV .....................Epstein-Barr virus 
ELISA .................enzyme-linked immunosorbent assay 
ELISPOT ............enzyme-linked immunospot (assay) 
EMT ....................epithelial-mesenchymal transition 
FKBP12 ...............FK506-binding protein 12 
GITR ...................glucocorticoid-induced tumor necrosis factor receptor 
GVHD .................graft-versus-host disease 
HAR ....................hyperacute rejection 
HCV ....................hepatitis C virus 
HLA ....................human leukocyte antigen
IFN ....................interferon gamma 
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Ig .........................immunoglobulin 
IL .........................interleukin 
IPEX ....................immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome 
IS .........................immunosuppression 
IVIg .....................Intravenous immune globulins 
LAG-3 .................lymphocyte activation gene-3 
LDA .....................limiting dilution assay 
MFI .....................mean fluorescence intensity 
MHC ...................major histocompatibility complex 
MLR ....................mixed leucocyte reaction (assay) 
MMF ...................mycophenolate mofetil 
MPA ....................mycophenolic acid 
mRNA .................messenger ribonucleic acid 
mTOR .................mammalian target of rapamycin 
NFAT ..................nuclear factor for activated T cells 
NF-B ..................nuclear factor- B
NK .......................natural killer (cells) 
Nrp1 ....................neuropilin-1 
nTreg ..................."natural" regulatory T cells 
PBMC .................peripheral blood mononuclear cell(s) 
PD-1 ....................programmed cell death-1 
pred .....................prednisone 
PTLD ..................post-transplantation lymphoproliferative disease 
TAC .....................tacrolimus 
TCR .....................T cell receptor 
TGF ...................transforming growth factor 
TH ........................helper T lymphocyte 
THYMO ..............thymoglobulin, or thymoglobulin study group 
TNF ...................tumor necrosis factor alpha 
TNFR ..................tumor necrosis factor receptor 
Treg .....................regulatory T cells 
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Materials and methods for the retrospective as well as for the prospective parts of our study 
are included in the "Materials and Methods" section of the related publication, and will not be 
reiterated here. 
Additional methods for the retrospective part ("Homing properties of CD4+ CD25high T cell 
sub-populations") are listed below. 
Flow cytometric assessment of chemokine receptors 
Cryopreserved peripheral blood mononuclear cells from kidney transplant recipients were 
thawed according to standard procedure. The monoclonal antibodies included CD3 
PerCP-Cy5.5 (BD Biosciences), CD4 Alexa Fluor® 700 (BioLegend), CD25 FITC (BD 
Biosciences), CD45RO ECD (Beckman Coulter), CD127 APC-Alexa Fluor® 750 
(eBioscience), CCR1 APC-Alexa Fluor® 647 (BD Biosciences), CCR3 PE (BD Biosciences), 
CxCR1 PE (BD Biosciences), CxCR2 APC (BD Biosciences), CxCR4 PE-Cy5 (BD 
Biosciences), CCR9 Alexa Fluor® 647 (BD Biosciences), CxCR5 PE (R&D Systems), 
CxCR3 APC (BD Biosciences), CCR4 PE-Cy7 (BD Biosciences), CCR5 PE-Cy5 (BD 
Biosciences), CCR6 PE (BD Biosciences), and CCR7 FITC (R&D Systems). PBMCs were 
cell surface stained according to the manufacturer's recommendations (30 minutes incubation 
at 4°C), washed and subsequently fixed. 
PBMCs were collected on a LSRII SORP (BD Biosciences), and lymphocytes were gated 
according to their forward and side scatter characteristics. Flow cytometric analyses were 
performed using the FACSDiVa software (BD Biosciences). 
    
146 
9. APPENDICES 
147 
9. APPENDICES 
9. APPENDICES 
148 
9. APPENDICES 
149 
9.1. Appendix I 
Adapted from: Solez K et al. Banff 07 classification of renal allograft pathology: updates and 
future directions. Am J Transplant. 2008; 8: 753-760. 
Banff '97 diagnostic categories for renal allograft biopsies – Banff '07 update 
1. Normal
2. Antibody-mediated changes (may coincide with categories 3, 4 and 5 and 6) 
Due to documentation of circulating antidonor antibody, and C4d or allograft pathology 
C4d deposition without morphologic evidence of active rejection
C4d+, presence of circulating antidonor antibodies, no signs of acute or chronic TCMR or 
ABMR (i.e. g0, cg0, ptc0, no ptc lamination). Cases with simultaneous borderline changes 
or ATN are considered as indeterminate 
Acute antibody-mediated rejection1
C4d+, presence of circulating antidonor antibodies, morphologic evidence of acute tissue 
injury, such as (Type/Grade): 
I. ATN-like minimal inflammation 
II. Capillary and or glomerular inflammation (ptc/g >0) and/or thromboses 
III. Arterial—v3 
Chronic active antibody-mediated rejection1
C4d+, presence of circulating antidonor antibodies, morphologic evidence of chronic tissue 
injury, such as glomerular double contours and/or peritubular capillary basement membrane 
multilayering and/or interstitial fibrosis/tubular atrophy and/or fibrous intimal thickening in 
arteries 
3. Borderline changes: 'Suspicious' for acute T-cell-mediated rejection (may coincide with 
categories 2 and 5 and 6)    
This category is used when no intimal arteritis is present, but there are foci of tubulitis (t1, t2 
or t3) with minor interstitial infiltration (i0 or i1) or interstitial infiltration (i2, i3) with mild 
(t1) tubulitis 
4. T-cell-mediated rejection (TCMR, may coincide with categories 2 and 5 and 6) 
Acute T-cell-mediated rejection (Type/Grade:)
IA. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) 
and foci of moderate tubulitis (t2) 
IB. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) 
and foci of severe tubulitis (t3) 
IIA. Cases with mild-to-moderate intimal arteritis (v1) 
IIB. Cases with severe intimal arteritis comprising >25% of the luminal area (v2) 
III. Cases with 'transmural' arteritis and/or arterial fibrinoid change and necrosis of medial 
smooth muscle cells with accompanying lymphocytic inflammation (v3) 
Chronic active T-cell-mediated rejection
'chronic allograft arteriopathy' (arterial intimal fibrosis with mononuclear cell infiltration in 
fibrosis, formation of neo-intima) 
5. Interstitial fibrosis and tubular atrophy, no evidence of any specific etiology 
(may include nonspecific vascular and glomerular sclerosis, but severity graded by 
tubulointerstitial features) 
Grade: 
I. Mild interstitial fibrosis and tubular atrophy (<25% of cortical area) 
II. Moderate interstitial fibrosis and tubular atrophy (26–50% of cortical area) 
III. Severe interstitial fibrosis and tubular atrophy/loss (>50% of cortical area) 
6. Other: Changes not considered to be due to rejection - acute and/or chronic (may include 
isolated g, cg or cv lesions and coincide with categories 2, 3, 4 and 5) 
1 Suspicious for antibody-mediated rejection if C4d (in the presence of antibody) or alloantibody 
(C4d+) not demonstrated in the presence of morphologic evidence of tissue injury.
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9.4. Appendix IV 
In complement to the above-mentioned studies performed essentially in renal transplant 
recipients, collaborators of our laboratory were also involved in a similar project that studied 
liver transplant recipients. 
In their study, they assessed the frequency of the activated T cell sub-population (defined as 
CD4+ CD25high CD45RO+ CD127high cells, as in our study on kidney transplant recipients) 
and of the regulatory T cell sub-population (defined as CD4+ CD25high CD45RO+ FoxP3+
CD127low cells) in stable patients, more than one year after orthotopic liver transplantation. 
They also analyzed the influence of chronic infection by the hepatitis C virus (HCV) on the 
frequency of these T cell sub-populations, as well as the effect of PEG-interferon and 
ribavirin antiviral treatment. 
In accordance with our results, they found that the frequency of the activated T cell 
sub-population was increased in liver transplant recipients, as compared to healthy 
individuals, whilst the frequency of the regulatory T cell sub-population was decreased. 
Interestingly, in patients with HCV infection, the increase of the activated T cell 
sub-population was lower than in HCV non-infected liver transplant recipients, and regulatory 
T cells were less decreased. Moreover, successful anti-HCV treatment induced a significant 
increase in the percentage of the activated T cell sub-population in responders, whilst after 
unsuccessful treatment this percentage remained unmodified in non-responders. 
These results show that the distribution of CD4+ CD25high T cell subsets was also modified 
after orthotopic liver transplantation, confirming our results obtained after kidney 
transplantation. In addition, HCV infection seems to exert an immunomodulatory effect on T 
cell subsets that have been demonstrated to play a crucial role in the outcome of 
transplantation; again, this observation could modify the therapeutic approach of liver 
transplant recipients, depending on their HCV status. 
My contribution to this study was to perform some of the experiments and to collect some of 
the clinical data concerning the liver transplant recipients. 
The results of this study were recently submitted as a manuscript to the American Journal of 
Transplantation.
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ABSTRACT 
Expression of IL-7R discriminates between activated CD25+CD45RO+CD4+ T cells (IL-7R
high and FoxP3 negative) and regulatory T cells (IL-7R low and FoxP3 positive). The 
IL-7RhighCD25+CD45RO+CD4+FoxP3- T-cell population has been shown to be expanded in 
blood and tissue in patients after kidney transplantation and to contain alloreactive T-cells.  
In the present study, we have analysed the distribution of the 
IL-7RhighCD25+CD45RO+CD4+FoxP3- T-cells in blood of 53 patients after liver 
transplantation. The IL-7RhighCD25+CD45RO+CD4+FoxP3- T-cell population was 
significantly expanded (P<0.0001) in stable transplant recipients as compared to healthy 
donors. However, the magnitude of the expansion was significantly higher (P<0.0001) in liver 
transplant recipients with no HCV infection as compared to those with pre-existing HCV 
infection. Of interest, effective suppression of HCV viremia after antiviral therapy was 
associated with an increase of the IL-7RhighCD25+CD45RO+CD4+FoxP3- T cell population 
to levels comparable to HCV non-infected liver transplant recipients. 
The present results indicate that: a) the IL-7RhighCD25+CD45RO+CD4+FoxP3- T-cell 
population is expanded after liver transplantation, b) it is a valuable immunologic marker to 
monitor activated and potential alloreactive CD4 T-cells in liver transplantation and c) pre-
existing HCV infection negatively influences the expansion of this population in liver 
transplant recipients. 
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INTRODUCTION 
End stage liver disease related to hepatitis C virus infection (HCV) is currently the leading 
indication for orthotopic liver transplantation (OLT) (1). Recurrence of HCV infection is 
almost universal after liver transplantation (2) leading to cirrhosis in approximately 20% of 
patients within 5 years or in 50% of patients within 10 years after transplantation (3). 
Immunosuppressive therapy is likely responsible for a more severe and accelerated course of 
HCV hepatitis post-transplantation as compared to the non-transplanted setting (3, 4). In 
particular high doses of steroids, multi-drug combinations, powerful induction treatments and 
treatment of acute rejection can lead to worse outcomes (5).Whether HCV-infected liver 
transplant recipients have a different risk for liver allograft rejection, compared to non-HCV 
infected recipients remains unclear. Rosen et al. prognosed that HCV re-infection of the liver 
allograft can precipitate an anti-donor response as suggested by the identification of HCV-
specific cytotoxic T lymphocytes (CTLs) restricted by donor alleles (6). Other some studies 
have however shown no difference in the incidence of acute cellular rejection in HCV-
infected liver recipients (7). Recently, it has been shown that patients with chronic HCV 
infection have a down-regulated expression of the IL-7R on CD4+ and CD8+ T lymphocytes 
when compared to individuals who have cleared HCV infection (8). IL-7 receptor is 
expressed differently in different stages of T-cell differentiation. It is expressed on cells that 
have not differentiated into effectors (9, 10). Furthermore, recent data have indicated that the 
IL-7R expression is lower on CD8+ T cells specific in viral chronic infections (11). The 
previous reported evidence that downregulation of IL-7R is associated with HCV viral 
persistence provides new insights which stimulate the study of HCV as a virus potentially 
influencing activated and/or regulatory T cells. 
IL-7R (CD127) is a surface marker able to discriminate between two distinct CD4+ T cells 
populations: CD4+ T regulatory cells (Tregs) and CD4+ activated T cells. Tregs express low 
levels of IL-7R, whereas activated CD4+ T cells have been shown to express high levels 
(12,13). Recent data indicate that a subset of CD4+CD25+ T cells (Foxp3 negative) 
expressing CD45RO and IL-7Rhigh is significantly increased in solid organ transplant 
recipients as compared to healthy subjects, particularly in patients with documented chronic 
allograft humoral rejection. This T cell population (CD4+CD25+CD45RO+IL-7Rhigh)
appears to be donor-specific and it increases in the circulation within a few weeks after 
transplantation (14).  
Analysis of these CD4+ T cell subsets has not been reported in HCV-infected liver transplant 
recipients. We hypothesized that chronic HCV infection may downregulate expression of IL-
7R after liver transplantation, thus possibly decreasing the frequency of 
CD4+CD25+CD45RO+IL-7Rhigh T cells. In this perspective, we analyzed CD4+ T cell 
subsets in the blood of stable liver transplant recipients, either infected or non-infected by 
HCV.  
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PATIENTS AND METHODS 
Patients 
A total of 53 liver transplant recipients, 29 patients with pre-existing HCV-infection (end-
stage liver disease, ESLD, was HCV-related) and 24 with no HCV-infection (their etiologies 
for ESLD were alcoholic cirrhosis (n=16), autoimmune hepatitis (n=2), sclerosing cholangitis 
(n=2), primary biliary cirrhosis (n=1), haemangioma (n=1), HBV related ESLD (n=1) and 
alpha1 antitripsine deficiency (n=1)) were studied at the Centre Hospitalier Universitaire 
Vaudois (CHUV) in Lausanne and at the University Hospital Geneva (HUG) 
As control groups, 38 healthy subjects and 53 non-transplanted HCV-chronically infected 
patients were studied.  
All patients gave informed written consent to participate to the study which had been 
approved by the local Institutional Review Boards (IRB). 
All patients had received liver transplants from deceased donors and they were studied at 
more than one year after transplantation. 
FACS analysis  
Peripheral blood mononuclear cells were isolated using standard Ficoll-Hypaque (Amersham 
Pharmacia Biotech, Piscataway, NJ) gradients centrifugation. The antibodies used for flow 
cytometric analyses included PerCP, PerCP-Cy5.5 or PE conjugated mouse anti-human CD4 
(Becton Dickinson, Franklin, NJ), APC-conjugated mouse anti-human CD25 (BD 
Pharmingen, San Diego, CA), FITC (BD Pharmingen, San Diego, CA) or ECD (Immunotech, 
Beckman-Coulter, Marseille, France) conjugated mouse anti-human CD45RO, and PE 
(Immunotech, Beckman-Coulter, Marseille, France) or APC (R&D Systems, Minneapolis, 
MN) conjugated mouse anti-human IL-7R. For intracellular FoxP3 analysis, cell 
preparations were fixed and permeabilized with fixation/permeabilization buffers 
(eBioscience, San Diego, CA) after staining of cell surface markers, and stained with FITC-
conjugated rat anti-human FoxP3 (eBioscience, San Diego, CA). All flow cytometric analyses 
were performed on a FACSCalibur and LSRII (Becton Dickinson Systems, Franklin, NJ). 
Statistical analysis 
Statistical significance was calculated by two tailed t student test. P values <0.05 were 
considered significant. 
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RESULTS 
Baseline patient characteristics and post-transplant course 
The 29 HCV-infected liver recipients (22 males and 7 females) had a median age at time of 
the study of 54 years (range 41-70 years) and a medium time after transplantation of 5.5 years 
(range 1-14 years). The 24 non-HCV-infected liver recipients (17 males and 7 females) had a 
median age at time of the study of 52 years (range 20-70 years) and a medium time after 
transplantation of 6.6 years (range 1-13 years). Immunosuppressive therapy consisted of 
cyclosporine or tacrolimus (FK) alone (n=15 in HCV-infected, n=8 in non-HCV- infected) 
combined with prednisone (n=4 in HCV-infected, n=3 in non-HCV-infected), or with 
mycophenolate mofetil (MMF) (n=8 in HCV-infected, n=8 in non-HCV-infected) and 
combined with both (n=2 in HCV-infected, n=5 in non-HCV-infected). 
The diagnosis of acute rejection (AR, according to the biopsy) within the first year post 
transplant was made in 8 out 29 HCV-infected patients  and in 12 out 24 non HCV-infected 
patients (p=0.057).  
The 38 healthy subjects (17 males and 21 females) had a median age at time of the study of 
50 years (20-74) and the 53 non-transplanted HCV-chronically infected patients (32 males, 21 
females) had a median age at time of the study of 40 years (28-59). 
During the study, 10 HCV-infected liver transplant recipients were treated with a lower dose 
combined antiviral therapy of pegylated interferon alpha 2a (PEG-IFN-alpha2a, Pegasys, 
Hoffmann La- Roche; Switzerland) 135 mg/week, together with ribavirin (RBV, Copegus, 
Hoffmann La- Roche; Switzerland) 200-400 mg/day, as previously described (15). The 
antiviral therapy was planned for 12 months depending on genotype (i.e. 6 months in patients 
with genotype 2 and 3) and tolerability. Reasons for treatment discontinuation were: bacterial 
pneumonia, persistent bronchitis, cerebral hemorrhagic stroke and retinal haemorrhage. Six 
out 10 patients achieved a sustained viral response with serum HCV-RNA levels not 
detectable at 6 months after treatment interruption. During antiviral therapy patients were 
studied for CD4 T cell subpopulations profile at 4 weeks, 3, 6 and 12 months of therapy and 6 
months after treatment discontinuation. Sustained viral response to antiviral therapy was 
defined by suppression of HCV viremia below the limit of detection of PCR HCV RNA assay 
at 6 months after treatment interruption. 
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Analysis of CD4+CD25+ T cells 
The distribution of CD4+CD25+ T cells was analysed in blood mononuclear cells of 53 liver 
transplant recipients (24 HCV negative and 29 HCV-chronically infected) and of 90 non-
transplanted subjects (52 HCV-chronically infected patients and 38 healthy donors). 
In non-transplanted HCV-infected subjects the percentage of CD4+CD25+ T cells was not 
significantly different from healthy subjects (2.5+/-0.3% versus 2.2+/-0.1%, p>0.05) (Fig. 
1A). 
However, the percentage of CD4+CD25+ T cells was significantly lower (P<0.05) in the total 
cohort (n=53) of liver transplant recipients (Fig 1A). 
Figure 1A 
Expression of CD4+CD25+ T cells. The distribution of CD4+CD25+ T cells was analysed in blood 
mononuclear cells of 53 liver transplant recipients, 52 non-transplanted HCV-infected subjects and 38 
healthy subjects. In non-transplanted HCV-infected subjects, the percentage of CD4+CD25+ T cells was not 
significantly different from healthy subjects. The percentage of CD4+CD25+ T cells was significantly lower 
in the total cohort of transplant recipients compared both to non-transplanted HCV-infected subjects and to 
healthy subjects.
We then analysed the proportion of CD4+CD25+ T cells in the liver transplant recipients 
stratified on the basis of pre-existing HCV infection. CD4+CD25+ T cells were significantly 
lower (p<0.0005) in HCV-negative liver transplant recipients (1.5+/-0.1%) compared to 
healthy subjects (2.2+/-0.1%), while the percentage of CD4+CD25+ T cells was not 
significantly different (p>0.05) in HCV-infected liver transplant recipients (1.9+/-0.2%) and 
healthy subjects (2.2+/-0.1%). 
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In HCV-infected liver transplant recipients the percentage of CD4+CD25+T cells (1.9+/-0.2%) 
was significantly lower (p<0.05) compared to non-transplanted HCV-infected (2.5+/-0.3%) 
(Fig 1B). 
Figure 1B 
Expression of CD4+CD25+ T cells in liver transplant recipients stratified on the basis of the presence 
of HCV infection. The distribution of CD4+CD25+ T cells was not statistically different between HCV-
infected transplant recipients and HCV-negative transplant recipients. CD4+CD25+ T cells were 
significantly lower in HCV-negative liver transplant recipients compared to healthy subjects but not 
significantly different in HCV-infected transplant recipients and healthy sujects. In HCV-infected liver 
transplant recipients the percentage of CD4+CD25+ T cells was significantly lower compared to non-
transplanted HCV-infected.
CD4+CD25+CD45RO+FoxP3+IL-7Rlow T cells, i.e. T regulatory cells (Tregs) in liver 
transplant subjects  
Since CD4+CD25+ T cell population is heterogeneous we analysed allospecific and T 
regulatory cells based on the expression of IL-7R and FoxP3. 
In healthy subjects, a majority of CD4+CD25+ T cells (79.3+/-2.3%) were FoxP3+ and IL-
7Rlow i.e., Tregs. In HCV-infected non-transplanted patients the proportion of Tregs was not 
significantly different than in healthy donors (Fig 2). In HCV-negative liver transplant 
recipients, the population of Tregs was significantly decreased (59.3+/-2.9%) compared to 
healthy subjects and non-transplanted HCV-infected patients (P<0.0005) (Fig 2). In HCV-
infected liver transplant recipients, the population of Tregs was significantly lower compared 
to healthy subjects (p<0.05) and non-transplanted HCV-infected patients (p<0.005) while was 
significantly increased compared to HCV-negative liver transplant recipients (p=0.009) 
(Fig 2). 
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Figure 2 
Expression of CD25, CD45RO, FoxP3 and IL-7Rlow on CD4 T cells, i.e. T regulatory cells, in liver 
transplant recipients, non-transplanted HCV-infected subjects and healthy subjects. 
In healthy subjects, majority of CD4+CD25+ T cells were FoxP3+ and IL-7Rlow i.e. T regulatory cells. In 
HCV-infected non-transplanted patients the proportion of T regs was not significantly different than in 
healthy subjects. In HCV-negative liver transplant recipients the population of T regs was significantly 
decreased compared to healthy subjects and non-transplanted HCV-infected patients. In HCV-infected 
transplant recipients, the population of Tregs was significantly lower compared to healthy subjects and non-
transplanted HCV-infected patients, while it was significantly increased compared to HCV-negative liver 
transplant recipients. 
Expansion of activated CD4+CD25+CD45RO+FoxP3-IL-7Rhigh T cells in liver transplant 
recipients  
Expression of CD45RO and IL-7Rhigh on CD4+CD25+FoxP3- T-cells defines the population 
of activated alloreactive CD4 T-cells as previously described (14). This CD4 T-cell 
population ranged about 6.1+/-0.7% in healthy subjects (Fig 3A). In non-transplanted HCV-
infected patients, the population of activated T cells was not different from healthy subjects 
(6.6+/-0.9%, p=0.26) (Fig 3A). However, this CD4 T-cell population was significantly 
increased in transplant recipients, both in HCV-negative or HCV-infected recipients (17.6+/-
1.4% and 10.5+/-0.9%, respectively, p<0.001), as compared to healthy subjects or non-
transplanted HCV-infected patients (Fig 3A). Of interest, this activated CD4 T-cell 
population was significantly lower in HCV-infected compared to HCV negative recipients 
(P<0.0001) (Fig 3A). 
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Figure 3A 
Expression of CD25, CD45RO, and IL-7Rhigh on CD4 T cells, i.e., activated T cells, in liver transplant 
recipients, non-transplanted HCV-infected subjects and healthy subjects.  
In non-transplanted HCV-infected patients, the percentage of activated CD4 T cells, defined by the expression 
of CD25, CD45RO, and IL-7Rhigh, was not different compared to healthy subjects; in contrast, this population 
was significantly increased in transplant recipients both HCV-negative and HCV-infected recipients compared 
to healthy subjects and non-transplanted HCV-infected patients. The population of activated CD4 T cells was 
significantly lower in HCV-infected transplant recipients, compared to HCV-negative recipients. 
A representative flow cytometry profile of the CD4+CD25+CD45RO+FoxP3-IL-7Rhigh
activated T-cell population in HCV-negative and HCV-infected liver transplant recipient is 
shown in Figure 3B.
Figure 3B. 
Representative flow cytometry profile of CD4+CD25+CD45RO+IL-7Rhigh activated T cell population in 
HCV-negative and HCV-infected transplant recipients.  
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Increase of CD4+CD25+CD45RO+IL-7Rhigh T-cell population in HCV-infected 
transplant recipients after antiviral therapy 
To further analyze the impact of HCV infection on the CD4+CD25+CD45RO+IL-7Rhigh T 
cell population, we analysed potential changes in this population in HCV-infected transplant 
recipients before and after antiviral therapy with PEG-IFN and ribavirin. In patients who 
responded to antiviral therapy, as defined by sustained viral suppression of HCV viremia 
below the limit of detection of the PCR HCV RNA assay, the CD4+CD25+CD45RO+IL-
7Rhigh T-cell population increased from 10.73+/-2.63% (prior therapy) to 21.7+/-6.3% (after 
suppression of HCV viremia) (p<0.05), to levels similar to those measured in HCV negative 
liver transplant recipients. In HCV-infected non-responder to antiviral therapy recipients, 
CD4+CD25+CD45RO+IL-7Rhigh T-cells remained unchanged prior and after therapy (11.8+/-
3.3% and 11.3+/-3.3%, respectively) (Fig. 4A and 4B). 
Figure 4A. 
We analysed the changes of CD4+CD25+CD45RO+IL-7Rhigh T cell population in six HCV-infected 
transplant recipients who responded to treatment by PEG-IFN and ribavirin and showed viral clearance. 
The figure shows the changes before and after therapy when HCV viremia was negative. After viral 
clearance, the CD4+CD25+CD45RO+IL-7Rhigh T cell population significantly increased. 
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Figure 4B. 
In six HCV-infected transplant recipients who did not respond to antiviral therapy and showed persistent 
HCV-viremia, the CD4+CD25+CD45RO+IL-7Rhigh T cell population did not change over time, neither 
during nor after antiviral therapy. 
DISCUSSION
In this study, we analyzed the expression of a CD4+ alloreactive T cell population, 
phenotypically defined by expression of CD25, CD45RO and high levels of IL-7R, in stable 
liver transplant recipients more than one year after transplantation. Both HCV-infected and 
HCV negative liver transplant recipients were studied and compared to non-transplanted 
HCV-infected patients and to healthy subjects. 
First, we analysed overall CD4+CD25high T cells and the results indicated a trend towards 
higher level of these T cells in non-transplanted HCV-infected patients, but the difference did 
not achieve statistical significance compared to healthy subjects. In contrast, we found a 
significant decrease of these cells in HCV negative transplant recipients compared to healthy 
subjects. This decrease in transplant recipients is most likely due to the immunosuppressive 
therapy. We observed no difference between HCV-infected and negative liver transplant 
recipients. 
To better define the type of cells included in the CD4+CD25+ T cell population, we analysed 
the expression of IL-7R (absence/low expression) and FoxP3 (presence) as markers of 
regulatory T cells. In healthy subjects, the majority of CD4+CD25+ T cells were IL-7R low 
(i.e., regulatory T cells) as previously described (12,13). In contrast, these cells were 
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decreased in liver transplant recipients, but there was a significant difference between HCV-
infected and non-infected transplant recipients, with higher levels of T regs in HCV-infected 
transplant recipients. This result in HCV-infected liver transplant recipients was in accordance 
with the observed increase of T regs in non-transplanted HCV-infected patients, as compared 
to healthy individuals (16,17). The analysis of IL-7R expression allows identification of 
regulatory T cells (i.e., IL7-R low and FoxP3 positive) versus activated CD4 T cells (i.e., IL-
7R high and FoxP3 negative).  We measured an important increase of activated 
CD4+CD25+CD45RO+IL-7R+ T cells in liver transplant recipients compared to healthy 
subjects. Interestingly, this increase of activated T cells in transplant recipient group was 
significantly lower in HCV-infected recipients when compared to HCV negative recipients. 
As such the presence of HCV infection in liver transplant recipients resulted in a significant 
increase of regulatory T cells and a decrease of alloreactive T cells, when compared to HCV-
non infected liver transplant recipients.  
These two findings indicated a potentially important effect of HCV on the immune system 
after transplantation by increasing the suppressive role of T regs and or decreasing 
alloreactive T cells. To further study the impact of HCV infection after liver transplantation 
we analysed the levels of CD4+CD25+CD45RO+IL-7Rhigh T cells before and after antiviral 
therapy both in responders (i.e., who became HCV-RNA negative) and in non-responders 
(i.e., HCV-RNA persistently positive despite antiviral therapy). All recipients were treated 
according to a protocol previously described with PEG-IFN and ribavirin (15). 
In responders, we observed a significant increase of CD4+CD25+CD45RO+IL-7Rhigh T cells 
when compared to non-responders, in whom levels of CD4+CD25+CD45RO+IL-7Rhigh T
cells remained unmodified. The observed changes in levels of 
CD4+CD25+CD45RO+IL-7Rhigh T cells were associated only with viral clearance and not to 
decrease of HCV-RNA levels. We observed an increase of the T cell population only after the 
virus was cleared and not after starting antiviral therapy.  
Overall, these results further suggest that HCV infection has some immune modulation 
properties. This immune modulation may have importance in the transplant setting and it is 
possible that stable HCV-infected transplant recipients greater than one year post-
transplantation, may be at lower risk for graft rejection compared to HCV negative recipients. 
This may have implications for the long term administration of IS therapy. 
Recipients with low levels of activated T cells might represent a group of patients who need 
lower levels of immunosuppressive therapy. If confirmed, our results may also be relevant for 
the design of “tolerogenic” or minimisation protocols, as HCV-infected may actually be ideal 
candidates for such strategies. Furthermore lower levels of immunosuppressive therapy for 
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HCV-infected transplant recipients could be positive for a less severe and a better outcome of 
HCV hepatitis post-transplantation. Finally, the precise mechanism by which HCV might 
interfere with the allospecific immune response is not understood and it remains to be further 
investigated. Future studies investigating the immune status of liver transplant recipients 
should take into account the presence or not of chronic HCV infection, as this may alter the 
interpretation or the conclusion of these studies. 
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